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SUMMARY 
This thesis examined the possible role of the microfilaments and 
microtubules in controlling the activity of the granulocyte plasma membrane 
oxidase. There - have not been any detailed investigations of this topic 
published to date. 
The conflicting literature on the nucleotide specificity and 
location of the oxidase within the granulocyte was examined. In vitro 
techniques for isolating granulocytes from human peripheral blood and for 
quantitating the initial rate of plasma membrane oxidase activity were de-
veloped and used for these investigations. The involvement of microfilaments 
and microtubules in oxidase activity was studied by using pharmacological 
agents known to disrupt these structures in vitro (cytochalasin B, and 
colchicine, vinblastine and vincristine, respectively). Control experiments 
were also performed to ensure that microfilament and microtubule disruption 
by these agents provided the best explanation for the results presented here-
in. Correlative experiments were conducted to determine if a change in 
hexose monophosphate shunt activity was associated with the observed 
changes in plasma membrane oxidase activity brought about by the drug 
treatments. 
Experiments on non-phagocytic granulocytes showed that microfilament 
disruption led to enhanced oxidase activity, while microtubule disruption pro-
duced a dual effect : a paradoxical enhancement (with low doses or brief 
exposures to the agents) and an impairment in oxidase activity. These 
results suggested that microfilaments act as a constraint against, while 
microtubules are required for plasma membrane oxidase activity. The re-
quirement for microtubules was highlighted in experiments where the usual 
enhancement in oxidase activity with cytochalasin B was ablated when the 
vii 
viii 
granulocytes were concomitantly incubated with a microtubule-disrupting 
agent. (With phagocytic granulocytes qualitatively similar results were 
observed. However, those experiments were not suitable for studying cell 
surface oxidase activity because the presence of ingestable. Particles made 
it impossible to determine whether plasma membrane and/or granule oxidase 
activity was being measured.) 
Based on the spectrophotometric and electron microscopic results 
presented and the relevant findings from other investigators, a scheme 
concerning the participation of the cytoskeletal elements in granulocyte 
plasma membrane oxidase activity was devised. In this scheme the micro-
filaments physically constrain the oxidase within the plasma membrane, 
and thereby hold the activity of the oxidase in check. Thus, microfilament 
disruption is envisaged to result in enhanced oxidase activity by freeing the 
enzyme. However, the oxidase is viewed as optimally active only as long as 
the microtubules are present to maintain the plasma membrane topography 
suitable for the enzyme's activity. 
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SECTION 1 
INTRODUCTION 
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1.1 
	Introductory remarks  
This thesis is concerned with the human granulocyte 
plasma membrane oxidase responsible for superoxide production. 
Specifically it sets out to examine the possible role Of the 
cytOskeletal elements (the microfilaments and microtUbules) in 
the control of the activity of this enzyme. 
1.2 	The Granulocyte  
The neutrophilic polymorphonuclear leucocyte (granulocyte) 
is able to engulf and subsequently kill ingested macro-organisms 
and for this reason these cells have been called "professional 
phagocytes" (Rabinovitch, 1968) and recognized as an important 
first line of defence against infection. The role played by 
phagocytic cells in higher organisms was first recognized by 
the Russian zoologist, Metchnikoff, in 1883 (cited by Stossel, 
1974; Murphy, 1976). Phagocytosis by unicellular organisms had 
been understood as a process whereby single cells obtained food, 
but it was Metchnikoff who postulated that the same process in 
eukaryotes could protect the higher organism from invasion by 
pathogens. 
Intense study of the granulocyte since Metchnikoff's 
work has shown that the cell is capable of directed movement 
towards a target, called chemotaxis (McCutcheon, 1946; Harris, 
1954) and that phagocytosis begins as soon as the cell touches an 
attractive particle. 
It has also been shown that the granulocyte exhibits 
discretion when it comes to ingestion: foreign but not autologous 
cells are eaten, and encapsulated micro-organisms are not touched 
2 
while others are vigorously attacked (Mudd et al , 1934; Foley 
and Wood, 1959; Rabinovitch, 1968; Maruta and Mizuno, 1971; 
Richardson and Sadoff, 1977). 
The target is identified as ingestable by (the 
granulocyte's) recognition of a host-derived coating of immuno-
globulin and complement molecules, known as opsonin l . The role 
of these proteins as molecules which interact with the surface 
receptors on the granulocyte to promote ingestion has recently 
been reviewed by Stossel, in 1975. 
To engulf the micro-organism, the migrating granulocyte 
extends hyaline ectoplasm to form pseudopodia on either side of 
the particle and then the pesudopodia simply surround the particle 
and fuse at its distal side. The micro-organism is then contained 
within a phagocytic vacuole or phagosome, the boundary of which 
is inverted plasma membrane. The phagosome pinches off from the 
parent plasma membrane and moves towards the cell centre (Mudd 
et al, 1934; Hirsch and Cohn, 1960). 
At about this time, the cytoplasmic granules within the 
vicinity of the phagosome move towards and fuse with the vacuole 
membrane, discharging their cytotoxic contents into the phago-
some (Hirsch and Cohn, 1960). There is evidence that the smaller 
specific granules discharge their contents first followed by the 
azurophilic granules (Bainton, 1973). The act of degranulation 
and lysosomal enzyme release from the cytoplasmic granules, in 
1. This term was coined by Wright and Douglas in 1903 and comes 
from the Greek opsono: I prepare for eating (cited by Koch, 
1978). 
3 
concert with an increase in metabolic activity in the phagocytos-
ing cell serves to kill the micro-organism. 
	
1.3 	Phagocytosis-associated metabolic events 
The increased metabolic activity ("respiratory burst") 
following contact and phagocytosis is characterized by an 
increased consumption of oxygen, an increase in glucose oxidation 
via the hexose monophosphate shunt, and an increase in the 
production of hydrogen peroxide and superoxide radical (Sbarra 
and Karnovsky, 1959; Iyer, Islam and Quastel, 1961; Rossi and 
Zatti, 1964; Selvaraj and Sbarra, 1966; Baehner and Nathan, 
1968; Babior, Kipnes and Curnutte, 1973). It was found that 
the increased uptake of oxygen during phagocytosis and 
phagocytosis itself were insensitive to inhibitors of mitochondrial 
oxidative metabolism (Sbarra and Karnovsky, 1959) and that the 
energy for phagocytosis was derived from anaerobic glycolysis 
(McKinney et al, 1953; Beck, 1958; Marchand, Leroux and 
Cartier, 1972). The oxygen taken up by the cells during 
phagocytosis was shown, at least in part, to be reduced to 
hydrogen peroxide (Iyer, Islam and Quastel, 1961). Iyer et a/ 
were also the first to suggest that the H 202 generated by 
phagocytosing cells was used as a microbicidal agent. The 
cellular pathway for the reduction of molecular oxygen to hydrogen 
peroxide has been the subject of considerable debate for many 
years. 
1.4 	The oxidase responsible for superoxide production  
Three flavoproteins (NADH oxidase, NADPH oxidase and 
D-amino acid oxidase) as well as myeloperoxidase have been 
suggested as the enzyme responsible for the generation of H202 
4 
(reviewed by Gee and Cross, 1973). It is now accepted that the 
enzyme involved is a reduced pyridine nucleotide oxidase (Babior, 
1978) but whether the hydrogen donor for the oxidase is NADPH or 
NADH has not been resolved (See Appendix I). 
The oxidase catalyzes the reduction.of oxygen by a 
one-electron transfer step and therefore the unstable and highly 
reactive intermediate, superoxide radical, is formed (Babior et al, 
1973; Babior et al, 1976). The stoichiometry for this reaction, 
with NADPH - for example, is: 
202 	NADPH 
(Babior, 1978) 
 
+ H+ 202 	+ 	NADP 
 
Using methods which allowed precise quantitation of the 
fate of the oxygen taken up during the metabolic burst, Root and 
Metcalf (1977) demonstrated that all of the oxygen taken up was 
- converted to 0 2 and then 80 percent of this superoxide was 
converted to H202 by dismutation. They showed as well that the 
dismutation of two molecules of superoxide was the only important 
source of the H2 02 generated by the granulocyte. H 202 is formed 
from the superoxide radical intermediate in the following 
reaction: 
2H+ 02 2 
(Fridovich, 1972) 
This dismutation reaction can occur spontaneously or it can be 
catalyzed by the enzyme superoxide dismutase. Interestingly, the 
enzyme catalyzes the reaction at a faster rate than the spontaneous 
dismutation (Fridovich, 1978). 
5 
The microbicidal potential of the superoxide radical 
was first suggested by McCord, Keele and Fridovich in 1971 because 
of the presence and distribution of superoxide dismutase in 
certain microbes. Anaerobic microbes are relatively deficient 
in superoxide dismutase compared to aerobes, and thus anaerobes 
are more sensitive to the cytotoxic effects of superoxide. The 
granulocyte's oxygen-dependent mechanisms for killing micro-
organisms involving H2 02 , superoxide radical, and other metabol-
ites of oxygen such as hydroxyl radicals and singlet oxygen 
have been reviewed by Klebanoff (1975), Koch (1978) and Babior 
(1978). 
	
1.5 	The plasma Membrane oxidase  
The oxidase responsible for catalyzing the formation 
of superoxide has been found in the cytoplasmic granules (see 
Appendix I). Recent evidence indicates that in addition to 
the granular location of the oxidase, a plasma membrane location 
also exists (Briggs et al, 1975; Segal and Peters, 1976; Tsan 
et a/, 1976b; Goldstein et a/, 1977). Teleologically, it is 
sensible to have the enzyme located in the plasma membrane be-
cause with ingestion the plasma membrane containing this oxidase 
(Briggs et al, 1975) is internalized around the particle and 
forms the limiting intracellular boundary of the phagosome. It 
is self-evident that maintenance of close contact between this 
enzyme in the membrane and the ingested particle would contribute 
to the efficiency of superoxide and hydrogen peroxide delivery 
to the phagosome (see Appendix I). 
1.6 	The fluid mosaic model of the membrane 
In the light of the recent reports describing a plasma 
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membrane location for the oxidase, it seemed an opportune time to 
study this enzyme. To begin this study of the plasma membrane 
oxidase it was necessary to review the structure of the cell 
membrane. The accepted model for plasma membrane organisation is 
the fluid mosaic model of Singer and Nicolson (1972). In this 
model of the membrane, proteins are situated in a bilayer mixture 
of lipids, and the non-polar portions of both the lipids and 
proteins are found within the hydrophobic interior of the bilayer. 
The hydrophobic interior is sandwiched between an outer and inner 
layer of hydrophilic molecules - the polar head groups of the 
phospholipid molecules and the polar groups of proteins. The 
proteins can extend into the membrane to different depths depend-
ing upon the distribution of the polar and non-polar groups 
within the particular protein (Figure 1.1). Thus proteins are 
classed as integral (embedded) or peripheral (surface-associated). 
The integral proteins can be further sub-divided into ecto- and 
endoproteins. Ectoproteins have a large mass projecting outside 
the membrane, beyond the cell surface, while endoproteins project 
away from the membrane on its cytoplasmic surface. Examples of 
ectoproteins are the glycoproteins, histocompatibility antigens, 
immunoglobulin molecules, and drug and hormone receptors 
(Rothman and Lenard, 1977; Smith, 1978). An example of an 
endoprotein is the erythrocyte membrane protein, spectrin (Smith, 
1978). 
The fluid mosaic model for membrane organisation 
proposed that proteins would be mobile within the lipid matrix 
of the membrane, and therefore with such movements the topographi-
cal organisation of membranes would be random (Singer and 
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Nicolson, 1972). It has often been found, however, that the 
associations (lipid-lipid, lipid-protein, and protein-protein) 
between components rendei. most if not all membranes non-random, 
or heterogeneous, in short-range topography (Nicholson, 1977). 
Nevertheless, many membrane proteins are free to move within 
the plane of the membrane and assume a homogeneous or random 
distribution. Definitive evidence for the mobility of proteins 
within the membrane came from the experiments of Frye and 
Edidin (1970). In their experiments they labelled the surface 
antigens of mouse and human cells with different fluorescent dyes, 
and then fused the cells with Sendai virus to form a hybrid. 
They found that with time the human and mouse antigens, made 
visible by fluorescence microscopy, had spread over the surface 
of most of the hybrid cells. Their work validated the Singer-
Nicolson model for membranes by showing that these proteins were 
able to translocate within the plane of the membrane. 
1.7 	Movement of proteins within the membrane  
It is certain that free diffusion alone cannot 
explain the ordering of cell-surface topography, especially the 
long-range movements of proteins in the membrane (Nicolson, 1976). 
Major factors affecting the movement of proteins within the plane 
of the membrane include:- 
1) the binding of a ligand to its cell membrane receptor. Such 
binding can induce movement, or redistribution, of the ligand-
receptor complex within the membrane. The ligands most extensive-
ly studied are the lectins (plant proteins which bind to specific 
carbohydrates on the cell surface) and antibodies to leucocyte 
surface immunoglobulins (Schreiner and Unanue, 1976). 
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Redistribution of leucocyte surface immunoglobulin has been 
envisaged to be of some importance in vivo in that it could be a 
mechanism whereby leucocytes (especially lymphocytes) redistribute 
immunoglobulins to present a dense cluster of these molecules to 
other immuno-competent cells, thereby facilitating cell signalling, 
recognition and contact phenomena (Taylor et a/, 1971; 
Nicolson, 1977). 
2) the cytoskeletal elements of the cell, in particular the 
microtubules and microfilaments. It is now established that 
cells can maintain a degree of topographic order within their - 
fluid membranes by virtue of trans-membrane associations 
between proteins in the membrane and cytoplasmic cytoskeletal 
elements (Berlin et al, 1974; Edelman, 1976; Nicolson, 1976). 
These elements are located underneath the plasma membrane and 
include microtubules, microfilaments, intermediate filaments 
and possibly other filament-like structures, as illustrated in 
Figure 1.2. The interaction between the plasma membrane 
proteins and the cytoskeletal elements has been studied by 
exposing cells to drugs known to impair the function of 
microtubules or microfilaments, and observing the effect such 
treatment has upon the movement of.anti-immunoglobulin antibody 
or lectin-binding proteins within the plane of the membrane. 
These drugs can inhibit or stimulate to various degrees, and 
sometimes even reverse the redistribution of such surface 
receptors (Schreiner and Unanue, 1976). 
Similar studies with such drugs have shown that during 
ingestion granulocytes can, through the cytoskeletal elements, 
confer a topographical heterogeneity upon the plasma membrane. 
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This then allows the granulocyte to determine phagocytosable 
(internalizable) and transport (non-internalizable) sites 
(Ukena and Berlin, 1972; Berlin, 1975). 
The work to be discussed in this thesis was prompted 
by the discovery of a plasma membrane location for the oxidase 
involved in the metabolic burst of granulocytes. In the light 
of reports of a role for the cytoskeletal elements in the control 
of plasma membrane phenomena, it seemed an opportune time to 
study their possible role in the control of plasma membrane 
oxidase activity. This thesis describes those studies. 
1.8 	Outline of the Thesis  
As explained above, the aim of this work was to 
examine the possible role of the cytoskeletal elements in the 
control of granulocyte plasma membrane oxidase activity. To 
begin these studies it was first necessary to devise an 
improved method for the isolation of granulocytes from peripheral 
blood. This method is described in Section 2. Similarly, 
in vitro techniques for quantitating the activity of the plasma 
membrane oxidase in intact cells had to be devised and standar-
dized (Section 3). To prevent interference from the cytoplasmic 
(granule-associated) oxidases in these experiments, the cells 
were not provided with phagocytosable material. In Section 4 
the techniques described in Sections 2 and 3 were used to examine 
the effects of microtubule and/or microfilament disruption on 
the activity of the plasma membrane oxidase. Similar experiments 
were conducted with phagocytosing granulocytes, and the effects 
of microtubule and/or microfilament disruption on the enzyme 
activity under these circumstances are outlined in Section 5. 
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The effects of microtubule or microfilament disruption on phagocy-
tosis itself are also described in that section. In Section 6, the 
effects of microtubule disruption on concanavalin A receptor re-
distribution were examined. Studies with the fluorescent membrane 
probe, 1-anilino-8-naphthalene sulphonate, are detailed in Section 
7. HMPS activity in resting (non-phagocytic) granulocytes after 
exposure to agents disrupting microtubules or microfilaments was 
examined and is described in Section 8. Electron microscopy was 
used to study the location of the plasma membrane oxidase after 
microtubule or microfilament disruption (Section 9). Finally, 
in Section 10 the results and conclusions from these experiments 
are discussed in relation to the published literature from 
other investigators. 
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FIG. 1.1. The arrangement of ectoproteins and endoproteins 
within the membrane (adapted from Rothman and 
Lenard, 1976). All of the proteins shown are 
integral (embedded). The circles represent the 
polar head groups of the phospholipid molecules. 
FIG. 1.2 A model depicting opposite but coordinated roles 
for the microfilaments (contractile) and micro-
tubules (structural) in controlling cell surface 
topography (taken from Nicolson, 1977). Bridging 
molecules (such as myosin and a-actinin, see 
text) between the microfilaments (MF) and micro- 
tubules (MT) and between the cytoskeletal elements 
and the plasma membrane (PM) components allow for 
indirect interactions. Myosin (my) is shown 
existing both as small bundles and as larger 
filaments. 
SECTION 2 
SEPARATION OF GRANULOCYTES FROM 
PERIPHERAL BLOOD 
2.1 	INTRODUCTION 
Granulocytes are the most difficult of the leucocytes 
to separate from peripheral blood. Their density is the greatest 
of the leucocytes and it increases with the degree of maturation 
of the cell (Zipursky et al, 1976). The density of the more 
mature segmented granulocytes is similar to that of the erythro-
cyte (Tullis, 1952), making separation of the granulocytes from 
the erythrocytes the most difficult step in their isolation 
from peripheral blood. 
Relatively good yields of granulocytes can be obtained 
from peripheral blood by simple sedimentation of whole blood 
admixed with dextran or methylcellulose to aggregate the 
erythrocytes (Skoog and Beck, 1956). The sedimentation rate of 
the erythrocytes is increased by their aggregation but the 
sedimentation of leucocytes is largely unaffected, and the 
leucocytes can be harvested from the upper part of the tube after 
erythrocyte sedimentation is complete. However, the gain in 
yield using this method is outweighed by the impurity of the 
final leucocyte preparation. 
In 1964 Boyum employed, in a different way, the concept 
of sedimenting erythrocyte aggregates to isolate the leucocytes. 
In his modification the erythrocyte-aggregating agent was 
mixed with a non-toxic compound of high density, sodium 
metrizoate. The blood was then carefully layered on top of this 
mixture, causing the erythrocytes to aggregate at the interface 
and sediment to the bottom of the tube. The leucocytes remained 
in the plasma layer above the interface because of the density 
barrier. The high density, non-toxicity and pH near neutrality 
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were the properties which made sodium metrizoate particularly suit-
Able forthis purpose (Day, 1970). 
This work led into the best method to date for separat-
ing granulocytes from peripheral blood; a technique which was 
also devised by Boyum. In this method the mononuclear leucocytes 
were first removed from the blood by one centrifugation of diluted 
blood layered onto a mixture of sodium metrizoate and a sucrose 
polymer (Ficoll). Ficoll was chosen for this purpose because of 
its relatively low viscosity and high solubility. The density of 
the sodium metrizoate-Ficoll gradient was 1.077 g/ml, which allowed 
the granulocytes to sediment to the bottom of the tube under one 
centrifugation. In a second step the granulocytes were separated 
from the erythrocytes by sedimentation employing dextran as an 
erythrocyte-aggregating agent. The disadvantages of this tech-
nique are its relatively low yields of granulocytes, especially 
in blood anticoagulated with heparin, and the erythrocyte 
contamination of the final granulocyte preparation. This 
feature (as discussed in section 2.4) makes the granulocyte 
preparation unsuitable for functional studies. The aim of the 
experiments described in this section was to devise an improved 
method of isolating granulocytes from peripheral blood. In 
addition the functional capacity of the isolated granulocytes 
was examined with phagocytic, candidacidal and NBT-dye reduction 
assays (see Dewar, 1978). 
2.2 	METHODS  
2.2.1 	Blood 
Venous blood anticoagulated with heparin (10 IU/ml) 
was collected from 16 healthy adults for these studies. 
2.2.2 	Plasma 
AB-Rh-negative plasma was obtained from the Red Cross 
Blood Transfusion Service, Hobart, Tasmania. It was divided into 
5 ml aliquots and stored at -20°C. 
	
2.2.3 	Isopaque-Ficoll density gradients (IFGs)  
IFGs were prepared by mixing 30 ml Isopaque with 70 ml 
Ficoll 0.09 g/ml, giving a gradient with a final density of 
1.077 g/ml at 200C. 
2.2.4 	Dextran solution  
Dextran was prepared as a 0.040 g/ml solution in 
0.15 M sodium chloride. 
2.2.5 	HEPES-buffered physiologic saline solutions  
A HEPES-buffered physiologic saline solution 
containing Ca +2 and Mg+2 (HSS) was prepared for these experiments. 
In addition, Ca+2 free (CFH) and Ca+2 and Mg+2  free (CMFH) 
solutions were prepared and used where indicated (Appendix II). 
2.2.6 	Erythrocyte lysis  
In preliminary experiments the technique of Craddock et a/ 
(1974) was used to lyse the contaminating erythrocytes in the 
final step of granulocyte isolation. However this method 
resulted in too much stroma from incompletely lysed erythrocytes, 
and the stroma was impossible to separate from the granulocytes. 
Therefore the erythrocyte lysing solution (ELS) of Goyle 
(1968) was adopted and proved satisfactory. The ELS consisted 
of isotonic NH 4C1 in Tris buffer, pH 7.4. 
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2.2.7 	Total and differential leucocyte counts  
Counts were performed according to the methods out-
lined in Dacie and Lewis (1968). At least 200 cells were counted 
for total and 500 cells for differential leucocyte counts. In 
addition, differential leucocyte counts of the final granulocyte 
preparations, using slides prepared according to Hirsch and Cohn 
(1960), were performed. 
2.2.8 	Buffy coat leucocytes  
Buffy coat leucocytes were prepared by centrifuging 
whole blood at 1000 x g for 15 min, collecting the buffy coat 
and lysing the erythrocytes in ELS (Goyle, 1968). The granulocytes 
were then washed in CFH once and resuspended in HSS to 25 x 10 6 
cells/ml. 
2.2.9 	Phagocytic assay  
Phagocytosis of polystyrene latex beads was measured 
in a system consisting of 1.25 x 106  cells, 10% plasma, 
and 50 x 106 polystyrene latex beads in a total volume of 500 pl 
HSS. Phagocytosis was initiated by the addition of the beads and 
promoted by end-over-end rotation (30 rpm) at 37 °C for 20 min. 
It was terminated by adding 100 pl of 0.009 g/ml EDTA in 0.15 M 
sodium chloride at 4°C and centrifuging at 100 x g x 4°C for 
5 min to separate the uningested beads from the cells. The cell 
pellet was used to prepare slides which were used to calculate 
the number of cells containing 0, 1-5, 6-10, or >10 beads per 
cell. At least 200 cells were counted from each slide. 
2.2.10 	Candidacidal assay  
The candidacidal assay developed by Lehrer and Cline 
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(1969), employing methylene blue to distinguish between viable 
and nonviable intracellular yeast was used. The strain of 
C. albicans used was originally obtained from the vaginal swab 
of a patient. During the incubation the ratio of granulocytes: 
Candida was 1:1, the volume 1.0 ml, and the final concentration 
of added AB-Rh-negative plasma 25% v/v. Incubations were done 
in triplicate using sterile technique. The reaction was stopped 
after 60 min by the addition of 0.25 ml of sodium deoxycholate 
(2.5%) which lysed the granulocytes without disturbing the 
Candida. Methylene blue was added to facilitate the haemocyto- 
meter counts of the number of viable and non-viable (blue-stained) 
micro-organisms. At least 200 Candida were counted from each 
sample tested and the percentage of stained micro-organisms was 
determined. In addition, the ingestion and killing of the 
Candida was monitored by electron microscopy (section 9.2.6.3). 
2.2.11 	NBT dye reduction test 
A modification of Baehner and Nathan's technique (1968) 
was used to quantitate NBT dye reduction as a measure of 
cyanide-insensitive oxidative metabolism (Fridovich, 1974). 
In this test all solutions were Millipore-filtered (0.45 pm) to 
ensure a 'spontaneous' dye reduction test (Baehner and Nathan, 
1968). The final test system contained between 6.25 x 10 5 and 
1.25 x 106 cells in a solution of 0.49 mM NBT, 1 mM KCN, 6.0 mM 
glucose, 0.06 mM Ca2+ and Mg2+  in HSS to a final volume of 
200 pl with a pH of 7.2. 
2.2.12 	Calculating the recoveries of isolated granulocytes  
2.2.12.1 Recoveries using the quotient G 1/G0 
The recoveries were calculated by dividing the number 
of granulocytes isolated from the gradients (G 1 ) by the number 
of granulocytes applied to the gradients (G 0) and multiplying 
by 100. 
G0  was determined from the total and differential 
leucocyte counts and the volume of blood applied to the gradients. 
At least 200 cells were counted in each half of the haemocytometer 
chamber in calculating recoveries. 
2.2.12.2 Recoveries calculated using Boyum's method  
Boyum expressed his yield of granulocytes as 
the number of granulocytes in the erythrocyte/granulocyte pellet 
as a percentage of the total number of granulocytes found in the 
tubes after separation (Boyum, 1968). The formula was not given 
in his paper, but the formula for similarly calculating the yield 
of mononuclear cells was supplied, and using the latter as a 
guide the following formula was devised to express Boyum's method 
of estimating yields: 
100 x g, x mo - m2 
go 	ml m2 
where g2 = percent granulocytes in the bottom fraction 
g0  = percent granulocytes in whole blood 
ml = percent mononuclear cells in the top fraction 
mo = percent mononuclear cells in whole blood 
and m2 = percent mononuclear cells in the bottom fraction 
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2.2.13 	Isolation of granulocytes  
• Using Boyum's method (1968) as a starting point, a 
three-step procedure was devised for the isolation of granulocytes 
from peripheral blood. In the first step, 2 ml of blood was mixed 
with 4 ml of isotonic saline in siliconized test tubes (tubes 
'A'). This blood plus 1 ml of saline washings from 'A' was layered 
onto each 3 ml IFG at 20oC in siliconized polycarbonate test tubes 
('B'). The loaded gradients were then centrifuged for 30 min at 
20oC with a force of 400 x g at the blood - IFG interface. 
The supernatant, containing plasma diluted with saline, 
mononuclear cells, and IFG, was removed to within 1-2 mm of the 
pellet (Fig. 2.1). The pellets containing the granulocytes and 
erythrocytes were washed in 5 ml of CFH twice, and then mixed 
with 2 ml AB-Rh-negative plasma. Dextran solution (3.0 ml) at 
4oC was then added and the tubes gently mixed with a 5 ml 
pipette, sealed, and allowed to sediment for 50 min at 4 °C. After 
this time, the granulocyte-rich upper layer (Fig. 2.2) was removed 
and the cells harvested by centrifugation in tubes 'C'. The cells 
were washed once in CFH, and the erythrocytes lysed in ELS 
(Goyle, 1968). The granulocytes were then collected by 
centrifugation, washed in CFH, and resuspended in HSS at 25 x 10 6 
cells/ml. The method is shown diagrammatically in Figure 2.3. 
2.3 	RESULTS 
Sections 2.3.1 - 2.3.5 inclusive outline the results 
of experiments preliminary to the adoption of the separation 
procedure outlined in section 2.2.13. 
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	2.3.1 	Yield after 30 min or 40 min centrifugation  
Pt 
In Boyum's procedure the diluted blood was centrifuged 
for 40 min on the IFGs, but it was suggested by Boyum that 30 min 
may be sufficient if the procedure were to be used for granulocyte 
isolation. Boyum also suggested however, that the change from 
40 to 30 min would cause some erythrocyte and granulocyte 
contamination of the mononuclear layer, and thus a slight drop 
in the yield of granulocytes from the lower layer. In two 
experiments where this was examined it was found that 30 min was 
just as efficient in sedimenting the granulocytes as 40 min. 
[Exp't 1: 2.5±0.2 x 10 6 granulocytes (40 min) versus 2.4±0.3 
x 106 granulocytes (30 min) per IFG (3 IFGs). Exp't 2:• 
3.2±0.1 x 106 granulocytes (40 min) versus 3.2±0.2 x 106 
granulocytes (30 min) per IFG (3 IFGs)]. Therefore in 
subsequent work a 30 min centrifugation of blood on IFGs was 
adopted as the standard procedure. 
2.3.2 	Volume of plasma used in the dextran sedimentation step  
Boyum used 1 ml of the heparinized, autologous plasma 
found at the top of the tube after the centrifugation step as the 
source of plasma for the dextran sedimentation (Fig. 2.1). When 
1 ml of this diluted plasma was compared with 1 ml of AB-Rh-
negative plasma, it was found that the latter provided a more 
efficient separation of granulocytes. Furthermore, 2 ml of 
AB-Rh-negative plasma gave an improved yield over 1 ml (Table 2.1). 
Increasing the volume of AB-Rh-negative plasma to 3 ml was of 
no benefit (Table 2.1), therefore 2 ml of plasma was routinely 
used. 
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2.3.3 	Autologous versus AB-.Rh-negative plasma  
On finding that whole AB-Rh-negative plasma provided 
a better separation of granulocytes than diluted autologous plasma 
(section 2.3.2) it was reasoned that whole autologous plasma 
might be more efficient than AB-Rh-negative plasma. Centrifuging 
the blood (as in section 2.2.8) to obtain the undiluted autologous 
plasma necessitated replacing the plasma with heparinized isotonic 
saline (10 IU/ml) to dilute the blood before separation on IFGs. 
This caused clumping of the reconstituted blood which interfered 
with the efficiency of the centrifugation (Table 2.2), as 
measured by the numbers of granulocytes isolated. Therefore 
AB-Rh-negative plasma was used in all subsequent work. 
2.3.4 	Dexttan 
2.3.4.1 	Volume of dextran in the sedimentation step  
8 In Boyum's procedure 0.4 ml of dextran, 0.045 g/ml 
in isotonic saline, is used with 1 ml of diluted autologous 
plasma in the sedimentation step. In two experiments where the 
volume of dextran was altered, it was found that the optimal 
volume for the dextran was 3.0 ml (Table 2.3). 
2.3.4.2 Concentration of dextran  
It was found that 0.040 g/ml and 0.045 g/ml were 
equally effective while 0.035 g/m1 dextran was not as 
efficient in aggregation and sedimentation of the erythrocytes 
(Table 2.4). Therefore, 0.040 g/ml dextran was used in 
subsequent experiments. 
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2.3.4.3 Erythrocyte contamination of the granulocytes in the sedimentation  
step  
fi 
Following Boyum's procedure, 0.4 ml dextran was used 
in the sedimentation step and the erythrocyte contamination of 
the upper granulocyte-rich layer varied from 32:1 to 66:1. When 
3.0 ml dextran was used however, the erythrocyte contamination 
was reduced to between 10 and 13 erythrocytes per granulocyte 
(Table 2.5). 
2.3.5 	Inner diameter of the sedimentation step tube  
fi 
Boyum suggested that performing the dextran sedimentation 
in an 8.5 mm versus 13 mm inner diameter tube increased the yield 
of granulocytes. In two experiments with 9 mm versus 15 mm inner 
diameter tubes, no difference was found in the yield of 
granulocytes [3.6±0.1 x 106 granulocytes (15 mm) versus 3.5±0.1 
x 106 granulocytes (9 mm) per IFG]. 
2.3.6 	Viability  
Viability of the isolated granulocytes as assessed by 
Trypan Blue or Eosin Y dye exclusion was always > 98%. 
2.3.7 	Granulocyte functional tests  
2.3.7.1 	Phagocytic assay  
The percentage of granulocytes which had ingested 0, 
1-5, 6-10 or >10 polystyrene latex beads after 20 minutes was 
the same whether the granulocytes had been isolated by the 
procedure described in section 2.2.13 or as buffy coat (2.2.8) 
leucocytes (Table 2.6). 
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2.3.7.2 	Candidacidal assay  
Buffy coat and isolated granulocytes were identical 
in their ability to kill ingested C. albicans after 60 minutes 
incubation (Table 2.7). Electron microscopical studies of the 
assay confirmed that ingested Candida were being killed (Figure 
2.4). 
2.3.7.3 	NBT dye reduction assay  
The NBT dye reduction capacity of isolated granulocytes 
was compared to that of buffy coat leucocytes from 4 samples. Re-
duction was identical in all cases except at 90 min, where the O.D. 
of reduced dye from the buffy coat of sample 3 (Fig. 2.5) was 
significantly different from that of the isolated granulocytes 
from the same sample. When this test was repeated with cells 
from the same individual 3 weeks later (3+, Figure 2.5), no 
significant difference between granulocytes obtained from either 
method could be found. 
2.3.8 	Differential counts of whole blood and isolated granulocytes  
Differential counts of the peripheral blood (Table 
2.8) showed that the granulocytes were mainly composed of 
neutrophils (95.5±0.7%) with only 4.3±0.7% and 0.2±0.1% eosinophils 
and basophils respectively. The isolated granulocytes showed 
94.9±0.7% neutrophils which was not significantly less than in 
the peripheral blood. Similarly the percentage of eosinophils 
in the final preparation (3.8±0.6%) was not significantly less 
than in the peripheral blood. However the percentage of basophils 
in the preparation (1.1±0.3%) was significantly greater than in 
peripheral blood ( p <0.01). 
2.3.9 	Recoveries of isolated granulocytes  
2.3.9.1 Recoveries using the quotient G 1/G0 x 100 
A mean of 70.9% of granulocytes applied to 8 gradients 
was recovered using the technique in section 2.2.13 (Table 2.8). 
2.3.9.2 Recoveries calculated using BOyum's method  
Using the formula G 1/G0 x 100 (section 2.2.12.1) a 
mean of 69.5±2.4% of the granulocytes applied to 6 (of the original 
8) IFGs was recovered. For these 6 samples full data was 
obtained and therefore the formula 
100 x g 2 x mo m2 (section 2.2.12.2) 
    
g0 	ml - m2 
was also used to calculate the recovery of granulocytes. 
With this formula the recovery rose to 79.1 -110.4% (Table 2.9). 
2.3.10 	Isolated granulocytes  
The final granulocyte preparation is shown in 
Figure 2.6 
2.4 	DISCUSSION 
Using the two-step procedure Boyum was able to isolate 
48.7% of the granulocytes from peripheral blood anticoagulated 
with heparin (BOyum, 1968). He estimated the yield of granulocytes 
by taking the number of granulocytes in the erythrocyte/granulocyte 
fraction as a percentage of the total number of granulocytes 
found in all fractions after separation. Using his method to esti-
mate the yield (section 2.2.12.2), and the improved separation 
procedure described in section 2.2.13, a mean of 79.1 -110.4% of the 
granulocytes was isolated from 6 peripheral blood samples. Employ-
ing the alternative formula G1/G0 x 100 (section 2.2.12.1) to 
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calculate the recovery of granulocytes from the same 6 samples, 
the yield was 69.5±2.4%. 	The discrepancy in recoveries is most 
likely due to Boyum's inaccuracy of assuming that the total number 
of granulocytes found in the tubes after separation is equal to 
the number applied to the gradients. This assumption does not 
take into account losses of granulocytes other than to the mono-
nuclear layer, for example, losses to glassware. Therefore 
with Boyum's formula the yields can exceed 100% (Table 2.9). It 
can be seen that Boyum's formula describes the efficiency of the 
separation more accurately than it reflects the yield. Neverthe-
less, with the isolation procedure described in Section 2.2.13 
a significant improvement in yields of granulocytes has been 
achieved. 
Several modifications of Boyum's technique were made 
which may have contributed to the increased yields of granulo-
cytes. Firstly, collecting the saline washings from the tubes 
used for dilution of whole blood ('A') minimized losses of cells 
to glassware at that point. Secondly, washing the pellet from 
hypertonic IFGs restored the density of the granulocytes and 
may have made the sedimentation step more efficient. Thirdly, the 
use of whole AB-Rh-negative plasma rather than diluted autologous 
plasma (collected after separation on IFGs) was clearly advantage-
ous in the second step. The major losses of granulocytes occurred 
during this step, when sedimenting aggregates of erythrocytes 
trapped the granulocytes and prevented them from moving upward 
into the plasma layer (Boyum, 1968). As the yields obtained with 
whole plasma (70.9%) were similar to those obtained from separat-
ing unfractionated leucocytes from whole blood-dextran mixtures 
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(Skoog and Beck, 1956), it was reasoned that undiluted plasma may 
somehow have prevented the majority of granulocytes from being 
sedimented with the erythrocytes. An attempt to further increase 
the yield of granulocytes by using autologous plasma (saved from 
centrifuging the blood) met with failure, however. The reason for 
this is not clear, but it may be due to the observed clotting of 
the centrifuged and then reconstituted blood. It can therefore 
be concluded, in agreement with Boyum, that the separation is 
hampered by using blood altered in any way other than by dilution. 
In the second step, the increased volume, decreased 
density and lowered temperature (4 °C) of dextran had a net effect 
of slowing the sedimentation by 10 min and decreasing the 
erythrocyte contamination. The lower erythrocyte contamination 
was much easier to remove by lysis. Finally, allowing sediment-
ation to occur in the same tubes that were used for the IFGs 
rather than transferring to new tubes had the effect of 
eliminating another source of cell loss to glassware. 
Examination of the final granulocyte preparation 
showed the proportion of basophils therein to be significantly 
greater than in peripheral blood. This discrepancy may be due 
to the inaccuracy of determining the true percentage of the 
small numbers of basophils in the blood films as opposed to the 
concentrated final cell preparation. Alternatively, the 
procedure may effectively isolate basophils, resulting in a 
higher percentage of basophils in the final granulocyte 
preparation. 
The erythrocytes were lysed in the final step of 
25 
this procedure because in early tests of granulocyte function the 
erythrocytes were found to interfere. Granulocytes tended to clump 
around crenated erythrocytes during extended incubations, and this 
introduced inaccuracies in phagocytic and candidacidal assays where 
granulocyte contact with beads or yeast, respectively, was required. 
Analysis of the results of granulocyte function testing 
showed the NBT dye reduction activity of buffy coat granulocytes 
in sample 3 was significantly greater than that of isolated 
granulocytes at 90 min. At the time of testing, monocytes com-
prised >15% of the buffy coat leucocytes in sample 3 and it was 
assumed that the difference in dye reduction was due to the mono-
cytes which have been shown able to reduce the dye (Humbert et 
al, 1973). This was confirmed when a repeat of the test 3 weeks 
later showed no significant difference between buffy coat and 
isolated granulocytes. The monocyte count at retesting was <4%. 
2.5 	SUMMARY 
In this section, a method is described by which granulo-
cytes may be isolated from human peripheral blood. The yield of 
granulocytes using this technique (70.9%) is considerably greater 
than that obtained by alternative methods. The isolated cells are 
mainly composed of neutrophils, but the ratio of eosinophils to 
neutrophils is not significantly different from that of the 
peripheral blood. The isolated cells are comparable to buffy 
coat granulocytes with respect to phagocytic, candidacidal and 
NBT dye reduction capacity and are representative of the 
granulocyte population of whole blood. The purity of the final 
cell preparation makes it suitable for critical work. 
FIG. 2.1 Blood which has been separated by centrifugation on 
(top) 	an IFG. The fractions shown contain:- 
(1) diluted autologous plasma 
(2) mononuclear cells (lymphocytes, monocytes) 
(3) IFG 
(4) the pellet of granulocytes and erythrocytes 
FIG. 2.2 The appearance of the blood after the erythrocyte- 
(bottom) granulocyte pellet has sediminted for 50 minutes 
in a mixture of AB-Rh-negative plasma and dextran. 
The layers shown contain:- 
(1) granulocyte-rich plasma/dextran with moderate 
erythrocyte contamination 
(2) erythrocytes 

Diluted blood and washings from tubes 'A' 
layered onto IFGs in tubes 'B' 
/STEP 1 	centrifugation 400g x 30 min x 20 °C 
Pellets washed twice, then plasma and dextran 
added and tubes mixed by vortex 
/STEP 2 	sedimentation lg x 50 min x 4 oC 
Plasma removed into tubes 'C', then cells 
washed once and pelleted 
/STEP 3 	lysis of erythrocytes 10 min x 4 oC 
Final pellet washed once and resuspended 
to 25 x 106 granulocytes/ml 
Fig. 2.3 The three step procedure for the isolation 
of granulocytes from peripheral blood, as 
described in detail in section 2.2.13, 
and in Dewar (1978). 
FIG. 2.4 Electron micrographs of ingested Candida athicans 
within the phagocytic vacuoles of isolated granulo-
cytes. Fusion of the granules with the membrane 
of the vacuole is visible in the uppermost 
micrograph (asterisks). The thick cell wall 
surrounding the microorganism is evident in the 
top and middle views (arrows). The bottom micro-
graph shows the remnants of a partially digested 
microorganism, identifiable again by the thick 
cell wall (arrow). Magnifications : top, 
19,300x, middle 11,400x, bottom 14,300x. 

2 
12, 
•10, 
ul .08 
it) 
.06 
.04 0 
•02 
ISOLATED GRANULOCYTES 
.12 
-10 
.08 
t • 06 
ci 
cs .04 
.02 
0 20 40 60 80 
BUFFY COAT LEUCOCYTES 
0 20 40 60 80 
TIME (min) 
FIG. 2.5. The NBT dye reduction capacity of isolated (top) 
versus buffy coat (bottom) leucocytes. Sample 3 t 
was a repeat (3 weeks later) of sample 3. Each 
point represents the X ± SEM of 3 determinations. 
FIG. 2.6 The final isolated granulocyte preparation (two 
views). Magnification top 1,250x, bottom 
2,100x. 
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TABLE 2.1 	Volume of plasma used in the dextran sedimentation step  
Volume (ml) Number of granulocytes (x10
6 ) 
recovered from IFGs ± SEM 
   
Experiment 1 	Experiment 2 
1.0 a) 
	
2.4 	2.3 	2.4 	2.0 	2.3 t 0.1 
1.0 b) 2.8 	2.5 	2.1 	2.6 	2.5 ± 0.1 
2.0 b) 
	
3.5 	3.1 	3.0 	3.6 	3.3 ± 0.1 
3.0 b) 3.7 	3.6 	3.0 	3.1 	3.4 ± 0.2 
a) 1.0 ml diluted autologous plasma 
b) 1.0, 2.0, or 3.0 ml AB-Rh-negative plasma 
TABLE 2.2 	Autologous versus AB-Rh-negative plasma  
Autologous 	AB-Rh-negative 
Expt. 1 Expt. 2 Expt. 1 Expt. 2 
Granulocytes 2.9 2.2 3.4 3.2 
isolated (x 
per IFG 
106 ) 2.6 2.4 3.5 3.6 
± SEM 2.5 ± 0.1 3.4 ± 0.1* 
* The difference between the two means is statistically significant 
Op < 0.01) 
TABLE 2.3 	Volume of dextran used in step 2  
Volume (ml) 
• Number of granulocytes (x106  ) Isolated per IFG ± sEm 
   
Experiment 1 	Experiment 2 
	
0.4 	 0.2 	0.9 1.5 	1.2 	1.0 -±0.3a) 
1.0 3.4 	4.5 	2.0 	1.5 	2.9  
3.0 	 3.5 	3.9 2.5 	2.3 	3.1±0.4c) 
4.0 3.6 	3.4 	2.3 	2.8 	3.0 -±0.3d) 
Values b), c), d) are significantly greater than a), with p < 0.01. However, values 
c) and d) are not significantly different from each other. 
TABLE 2.4 	Concentration of dextran used in step 2 
Concentration 
(g/ml) 
Number of granulocytes (x10 6 ) isolated per IFG 
± SEM Experiment 1 	Experiment 2 
0.035 2.4 	2.7 	2.3 2.1 2.5 2.4 ± 0.1 a) 
0.040 2.7 	2.8 	2.5 2.3 2.6 2.6 ± 0.1 
0.045 2.8 	2.7 	2.8 2.5 2.3 2.6 ± 0.1 
a) 
Not significantly lower than the value 2.6 ± 0.1. 
TABLE 2.5 	Erythrocyte contamination of the granulocyte fraction  
(after step 2) with 0.4 or 3.0 ml dextran  
Volume 
	Cells x 106 per IFG 	 Ratio 
(ml) Erythrocytes 	Granulocytes 	Erythrocytes: 
granulocytes 
0.4 a)  
0.4 b) 
3.0 a) 
3.0 
175.0 
680.0 
155.0 
280.0 
5.4 
10.2 
14.9 
21.6 
32:1 
66:1 
10:1 
13:1 
a) Experiment 1 
	
b) Experiment 2 
TABLE 2.6 	Phagocytic assay. Percent granulocytes containing 0, 1 to 5, 6 to 10 or >10 
beads per cell after 20 minutes  
Number of latex beads per granulocyte 
Sample 0 	 1 - 5 	 6-10 	 10 
 
Buffy coat Isolated 	Buffy coat 	Isolated 	Buffy coat 	Isolated 	Buffy coat 	Isolated 
cells cells cells cells 
N.S 	 N.S 
1 
2 
3 
4 
± SEM 
P value 
32.2 
22.6 
29.8 
20.4 
26.3±2.8 
	
23.4 	2.9 
19.8 	4.4 
28.5 	4.5 
27.6 	5.2 
24.8±2.0 	4.3±0.5 
N.S 	 N.S 
5.3 
4.9 
5.9 
4.3 
5.1±0.3 
5.1 
7.3 
4.7 
5.2 
5.6±0.6 
15.0 
6.3 
5.7 
5.9 
8.2±2.3 
59.8 
65.7 
61.0 
69.2 
63.9±2.2 
56.3 
69.0 
59.9 
62.2 
61.9±2.7 
Symbols  
P value = probability value for each pair of means 
N.S. 	= the difference between the two means is not statistically significant 
TABLE 2.7 Candidacidal assay. 	Percent Candida organisms 
  
killed after 60 minutes 
Sample Buffy coat leucocytes 
Isolated 
granulocytes 
5 27.5 29.4 
6 19.7 16.5 
7 31.2 38.2 
8 45.4 42.4 
± SEM 31.0±5.4 31.6±5.7 
P value 	 N.S. 
Symbols  
P value = probability value between the means 
N.S. 	= the difference between the means is not 
statistically significant. 
TABLE 2.8 	Differential counts of whole blood and isolated granulocytes  
and percent recoveries of granulocytes  
	
Sample % Granulocytes % Neutrophils % Neutrophils % Eosinophils % Eosinophils % Basophils % Basophils 	% Recovery of 
in whole blood 	in A 	in isolated 	in A 	in isolated 	in A 	in isolated 	Granulocytes 
(A) granulocytes granulocytes granulocytes 
1 48.8 98.1 97.8 1.9 1.5 0 0.4 66.1 
2 55.8 94.4 94.9 5.6 4.2 0 0.9 70.2 
3 32.0 95.5 93.9 4.4 3.2 0.1 2.7 63.0 
4 41.6 94.0 93.0 6.0 5.1 0 1.9 70.3 
5 47.2 93.4 94.4 6.5 5.2 0.1 0.4 80.2 
6 41.1 94.5 93.4 5.2 6.0 0.3 0.5 67.2 
7 52.3 95.0 93.5 4.1 4.3 0.9 1.8 77.9 
8 35.3 99.1 98.3 0.7 1.2 0.2 0.5 72.2 
C ± SEM 	44.3±2.9 	95.5±0.7 	94.9±0.7 	4.3±0.7 	3.8±0.6 	0.2±0.1 	1.1±0.3 	70.9±2.0 
) value 0.10<P<0.20 0.10<P<0.20 P<0.01 
Symbols for Table 2.8  
P value = probability value between the two means. Only the basophils are significantly 
elevated in the final preparation compared to whole blood. 
Symbols for Table 2.9  
0 • total number of granulocytes (x10 6 ) in the blood 
G
1 
• total number of granulocytes (x10 6 )  
g2 • percent granulocytes in the bottom fraction 
g0 
 • 
percent granulocytes in whole blood 
• percent mononuclear cells in whole blood 0 
m2 • percent mononuclear cells in the bottom fraction 
1 • percent mononuclear cells in the top fraction 
a) using the quotient G1/G0 x 100 (section 2.2.12.1) 
b) using the formula from section 2.2.12.2:- 
	
100 x g 2 	
m0 - m2  
g0 	- m2 
TABLE 2.9 	Calculating recoveries of granulocytes using the formulae  
given in sections 2.2.12.1 and 2.2.12.2  
Sample 0 G1 g2 o mo m2 m1 percent
a) 
recovery 
percentb) 
recovery 
1 36.9 24.4 98.8 48.8 40.0 1.2 95.0 66.1 83.0 
2 97.4 68.4 99.0 55.8 33.6 1.0 97.0 70.2 60.3 
28.4 17.9 99.6 32.0 40.3 0.4 98.0 63.0 127.6 
4 60.7 42.7 99.3 41.6 25.7 0.7 92.0 70.3 64.4 
5 43.0 34.5 98.4 47.2 35.6 1.6 93.0 80.2 77.1 
6 25.9 17.4 98.1 41.1 26.8 1.9 98.0 67.2 62.1 
X ± sEm 69.5 ± 2.4 79.1 ± 10.4 
SECTION 3 
ASSAY OF PLASMA MEMBRANE OXIDASE 
ACTIVITY 
26 
3.1 	INTRODUCTION  
The aim of these experiments was to devise a method for 
studying the plasma membrane oxidase of isolated granulocytes. NBT 
dye reduction was chosen as a suitable method for examining the 
activity of the oxidase via the production of superoxide radical 
(Baehner et al, 1976 ; see also Babior, Curnutte and Kipnes, 1975). 
NBT (nitroblue tetrazolium) is a yellow, water soluble 
quaternary ammonium salt (Rust, 1955) which is transformed to a 
highly coloured (dark blue) water-insoluble dinitroformazan once 
reduced. Its structure and the structure of the dinitroformazan 
are shown in Figure 3.1. The low redox potential of -0.05 volts 
for NBT (Hooper, 1969) makes it a useful indicator for biological 
work (Rust, 1955). There have been several reviews of the chemical 
nature and use of the tetrazolium salts, including NBT, as biologi-
cal redox indicators (Rust, 1955; Hooper, 1969; Eadie et al, 
1970). 
Baehner and Nathan (1967) first described the reduction 
of NBT by isolated granulocytes and pointed out that the reduction 
was enhanced during phagocytosis. In addition, they noticed that 
the granulocytes from patients with chronic granulomatous disease 
(CGD) reduced dye very slowly, even when phagocytosing. They took 
advantage of this fact in designing a qualitative screening test 
for CGD, and later, a quantitative test which was sensitive enough 
to pick up the carrier state (Baehner and Nathan, 1968). About this 
time also, Park et al (1968) suggested that because phagocytosis 
enhanced NBT reduction, the presence of infection should be detect-
able with the NBT test if the granulocytes were ingesting pyogenic 
bacteria. However, intense study of the possible clinical useful- 
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ness of the NBT test as an indicator of infection showed that 
there were many false positives and false negatives with the 
test, and therefore this application of the NBT test has fallen 
into disrepute. The pitfalls of using the NBT test in this 
way have been reviewed by Segal (1974) and Lace et al (1975). 
Fortunately the controversy regarding the use of 
NBT reduction as a guage of the presence of infection has not 
detracted from the well-established value of the test in 
diagnosing CGD, and in studying the oxidase responsible for 
superoxide production. Among the many workers who have used NBT 
reduction to study the function of the granulocyte are Johnston 
et a/, 1969; Nathan et al, 1969; Gifford and Malawista, 1970; 
Segal and Levi, 1973; Stossel, 1973; McCall et al, 1974; 
Baehner et a/, 1975 and 1976; Briggs et al, 1975; Segal and 
Peters, 1976 and 1977. 
For these studies of the plasma membrane oxidase, 
non-phagocytic granulocytes have been used because in the 
absence of phagocytosis NBT dye cannot enter the granulocytes 
(Nathan et al, 1969; Segal and Levi, 1973; Briggs et al, 
1975) 1 . Therefore dye reduction will occur at the plasma membrane 
in non-phagocytic granulocytes, as Briggs et a/ (1975) have shown. 
1 
In phagocytosing granulocytes, NBT dye enters the cell along 
with the particles being ingested and reduction occurs intra-
cellularly as well, in the phagocytic vacuoles. The superoxide 
source in this case can be the granule or plasma membrane 
oxidase (see Nathan et al, 1969; Johnston et al, 1969; Segal 
and Levi, 1973; and Appendix I). 
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With this in mind, an assay designed to measure the 
initial rate of superoxide production (NBT reduction) from 
the plasma membrane oxidase of isolated granulocytes was developed, 
and is detailed in this section. 
3.2 	METHODS  
3.2.1 	Physiological saline solutions  
3.2.1.1 	HEPES physiological saline (HSS)  
HSS was prepared daily for experiments, as described 
previously (Dewar et a/, 1976, Appendix II). The final compo-
sition of HSS was 136.9 mM Na + , 6.0 mM K+ , 1.2 mM Mg+2 , 2.4 mM 
- Ca+2 , 150.1 mM Cl , 11.9 mM glucose and 9.0 mM HEPES, with a 
pH of 7.4 • 
3.2.1.2 	Ca+2 and Mg+2 free HEPES physiological saline (CMFH)  
CMFH was also prepared daily as before (Dewar et al, 
1976, Appendix II). The final composition of CMFH was 142.9 
- mM Na , 6.0 mM K , 148.9 mM Cl , 11.9 mM glucose and 9.0 mM 
HEPES with a pH of 7.4. 
3.2.2 	Granulocyte monolayer preparations 
Granulocytes were isolated as described in section 
2.2.13 and kept at 4°C 	 2 	CMFH at 25 x 10 6/ml until used . 
2 The cells used in these and all other experiments described 
in this thesis were as fresh as possible, that is, they were 
used on the same day as they were isolated from the blood. 
In no experiments were the granulocytes aged more than 6 (and 
in most cases they were 1-2) hours post-isolation. Viability 
as assessed by Trypan Blue or Eosin Y dye exclusion was always 
> 98%, even in granulocytes at 6 hours post-isolation. 
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To prepare the monolayers 200 pl of HSS was placed onto a 22 mm 
square glass coverslip seated in a round plastic Petri dish or 
its lid. Then 50 pl of the granulocyte suspension (1.3 x 10 6 
cells) was injected into the HSS and gently mixed with the 
microlitre pipette (Fig. 3.2). The dishes were then incubated 
10 min at 37oC in an humidified incubator (Clemco, Australia) 
to form the monolayers. 
	
3.2.3 	Nitroblue tetrazolium solution (NBT)  
NBT was prepared as a saturated solution by adding 
100 mg of NBT to 50 ml of HSS. [The actual concentration of 
NBT in solution was 1.05 mg/ml, as determined by Stossel's 
procedure (Stossel, 1973a)]. The NBT solution was prepared at 
least 24 hours in advance of an experiment to ensure that 
dissolution was complete. Before use the NBT solution was 
centrifuged and then filtered (Millipore, 0.45 pm) to ensure 
clarity. •For tests, 2 volumes of this solution was mixed with 1 
volume of KCN, 0.010 M in HSS, giving a final KCN concentration 
at testing of 1.5 mM. 
3.2.4 	Experiments to establish the initial rate of NBT reduction  
3.2.4.1 Time course of NBT reduction by monolayers  
Granulocyte monolayers were prepared as described in 
section 3.2.2. To the cells in HSS was added 200 pl of NBT 
test solution (section 3.2.3). The monolayers were then incubated 
at 37oC for fixed time periods between 1 and 60 min. At the 
allotted time the reduction of NBT was terminated by immersing 
the monolayers rapidly several times in a beaker of CHIFH at 4 °C. 
The last drop of liquid was removed and the monolayers dried in 
air. The NBT reduced by each monolayer was quantitated by 
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extracting each monolayer into 0.8 ml pyridine (10 min x 100 °C), 
and then reading the OD of reduced dye at 515 nm (Baehner and 
Nathan, 1968). 
3.2.4.2 Effects of granulocyte concentration on NBT reduction  
Monolayers of granulocytes were prepared which con-
tained 0.25 - 3.8 x 106 cells per dish of 200 pl. Then by using 
the assay described in section 3.2.4.1 with a 30 min incubation 
period, the effect of cell concentration on NBT dye reduction 
was determined. 
3.2.4.3 Effect of NBT concentration on reduction  
Solutions of varying NBT concentration were prepared 
by diluting the NBT solution (section 3.2.3) with HSS. The NBT 
concentrations tested were 0.08, 0.15, 0.23, 0.30, and 0.38 mM. 
The assay of NBT reduction as described in section 3.2.4.1 was 
performed with these solutions and a fixed time period of 5 min 
incubation to determine the effect of NBT concentration on NBT 
reduction. The data from these experiments was plotted as 
the rate of NBT reduction versus the concentration of NBT. 
3.2.4.4 The kinetics of the initial rate of NBT reduction  
The data from the experiments on the effect of NET 
concentration (section 3.2.4.3) was used to construct double 
reciprocal plots (1/rate of reduction versus 1/NBT concentration). 
From these plots an 'apparent Km ' and V x for the initial rate 
of NBT reduction by intact granulocytes was determined 
(Appendix III). 
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3.3 	RESULTS  
3.3.1 	NET dye reduction by granulocyte monolayers  
Light microscopical examination of unstained monolayer 
preparationswhich had been exposed to NBT dye for 5 min (as in 
section 3.2.4.1) showed a ring-like appearance of reduced dye at 
the edges of the cells (Fig. 3.3). 
3.3.2 	Experiments to establish the initial rate of NBT reduction  
3.3.2.1 Time course of NBT reduction  
From the plot of the reduction of NET with tithe (Fig. 
3.4), it was apparent that the rate of reduction was maximal, and 
linear (with respect to time) for the first 5 min at least. 
After the initial 5 min, the reduction of NBT showed a slower 
increase with time until the capacity for reduction was complete, 
at approximately 30 min. 
3.3.2.2 The effect of granulocyte concentration on NBT reduction  
As shown in Fig. 3.5, the reduction of NBT was 
directly proportional to the number of granulocytes (= the cell 
concentration) on the monolayer. 
3.3.2.3 The effect of NBT concentration on reduction  
Sixteen plots of the rate of reduction of NBT dye 
versus the concentration of NBT were hyperbolic. Two of the 
16 plots are shown in Fig. 3.6. These curves showed that the 
rate of reduction of NBT dye was proportional to the dye concen-
tration, and that the rate of reduction reached a maximum at the 
highest concentrations of NBT tested. With all 16 plots it 
was apparent that there was very little difference in the rate 
of reduction with the two highest concentrations of NBT tested 
(0.30 and 0.38 mM NBT). 
3.3.2.4 The kinetics of the initial rate of NBT dye reduction  
The 16 hyperbolic plots of the rate of reduction 
versus the NBT concentration (section 3.3.2.3) were transformed 
into straight lines, or Lineweaver-Burk plots, by plotting 
1/reduction rate against 1/NBT concentration (Appendix III). 
Two of these plots are illustrated in Fig. 3.7. For each 
Lineweaver-Burk plot, the y-intercept (I/Vmax ) and x-intercept 
(1/apparent Km) values were used to determine the Vmax and 
apparent Km , respectively, for NBT reduction by intact 
granulocytes (Appendix III). As indicated in Table 3.1, the 
X ± SEM values for these two kinetic parameters were:- 
0.102 ± 0.011 (apparent Km, in units of mM NBT) 
0.081 ± 0.903 (V 	, in units of OD515/1.3 x 106 max 
granulocytes/5 min) 
3.4 	DISCUSSION 
In this section a method for studying the plasma 
membrane oxidase of isolated granulocytes has been presented. 
To ensure that plasma membrane superoxide production was being 
detected, non-phagocytic granulocytes were used, and superoxide 
production was quantitated by NBT reduction (Baehner et al, 1976). 
NBT cannot cross the granulocyte plasma membrane (Nathan et al, 
1969; Segal and Levi, 1973; Briggs et al, 1975) and therefore 
dye reduction occurs at the plasma membrane in non-phagocytic 
granulocytes l . Once reduced to formazan, NBT is lipid-insoluble 
and therefore remains in situ at the site of reduction (Nachlas 
et al, 1957). Briggs et al (1975) were able to exploit this 
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property of NBT to demonstrate with electron microscopy that NBT 
is reduced at the plasma membrane of non-phagocytic granulocytes. 
The light microscopical studies presented in this section (and the 
electron microscopical studies of section 9.3) confirm that dye 
reduction occurs at the plasma membrane of these cells. It is 
extremely unlikely that the NBT reduced at the cell surface of non-
phagocytic granulocytes is reduced by granule-produced superoxide 
which has diffused throughout the cytoplasm because superoxide is 
a highly reactive radical which would be consumed within the 
cytoplasm3 very near to its site of production (Fridovich, 
1978; see also Goldstein et al, 1977). 
Thus with NBT dye reduction as an index of plasma 
membrane oxidase activity, the necessary conditions for measuring 
the initial rate of superoxide production (NBT reduction) could 
be established. There was a need to develop such an assay of NBT 
reduction by non-phagocytic granulocytes. In almost all previous 
studies, quantitation of granulocyte NBT reduction was performed 
using a modification of the original method of Baehner and Nathan 
(1968). Unfortunately, there were two problems with this assay. 
Firstly, it was not firmly established that the concentration of 
NBT used for the test was saturating, and secondly a relatively 
long incubation period (15 min) with the NBT was used. This meant 
that towards the end of the incubation period, the supply of NBT 
dye was becoming exhausted, and therefore there was a concomitant 
decrease in the rate of reduction. Hence with such an assay, only 
3 For example, by dismutation via cytoplasmic superoxide 
dismutase to produce H 2 02 and 02 (see section 1.4). 
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the granulocyte's capacity for reduction was being measured and 
the assay could not distinguish between variations in reduction 
rate, or capacity, or both. Thus if a particular drug treatment 
were to alter the rate (but not the capacity) of reduction, then 
only at high doses of this drug might a significant effect on NBT 
reduction have been detected by the assay of Baehner and Nathan. 
In developing a more sensitive assay of NBT reduction 
by intact, non-phagocytic granulocytes, the papers of Weisman and 
Korn (1967) and Michell et al (1969) were consulted. These 
authors developed sensitive assays of the optimum (or initial) 
rate of ingestion by intact phagocytes. Following their methods, 
the reduction of NBT by intact granulocytes was treated as if it 
were a single enzymatic reaction (see Appendix III). It was 
found that (i) the initial rate of reduction was independent of 
the concentration of NBT used. That is, the reduction of dye 
exhibited first order and saturation kinetics with respect to the 
NBT concentrati9n (Fig. 3.6), and therefore it was valid to 
consider the granulocyte as containing a finite number of enzyme 
(oxidase) molecules capable of being saturated by substrate 
(NBT). As well, (ii) the initial rate of reduction was constant 
with time as long as the incubation period with dye was S. 5 min 
(Fig. 3.4). Finally, (iii) reduction was found to be a linear 
function of the granulocyte (= enzyme) concentration (Fig. 3.5). 
To confirm that this was a suitable assay of the 
initial rate of NBT reduction, irrespective of the granulocyte 
donor, the data from 16 individual plots of the rate of 
reduction versus the NBT concentration was analyzed. As these 
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particular plots yielded curved lines (Fig. 3.6), the data was hard 
to compare between donors. Therefore the same data was plotted as 
Lineweaver-Burk (or double reciprocal) plots (Appendix III). With 
these plots of 1/rate of reduction versus 1/NBT concentration, 
straight lines were obtained. This facilitated comparisons between 
the donors as to the values for the 'apparent Km' (the concentra-
tion of NBT at which reduction proceeded half maximally) and Vmax 
(the maximal velocity) of NBT reduction (Appendix III). There was 
good agreement in these values from the 16 normal donors (Table 
3.1) indicating that this assay of the initial rate of NBT reduc-
tion was reproducible with human granulocytes collected from 
different donors. 
SUMMARY 
In this section, an assay designed to measure the 
initial rate of NBT reduction (0-2  production) from the plasma 
membrane oxidase of isolated granulcoytes has been presented. 
The two kinetic parameters, apparent Km and V, were max 
determined for the reduction of dye by granulocytes isolated from 
16 individuals. As these values showed good agreement in the 16 
samples, it was concluded that this assay of the initial rate of 
NBT reduction was reproducible with human granulocytes collected 
from different donors. The assay procedure is shown diagrammati-
cally in Figure 3.8. 
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FIG. 3.1. The structures of NBT (top) and its dinitroformazan 
(bottom), taken from Nachlas et al (1957). Since 
tautomerism can occur, the structure of the tetrazole 
(the numbered ring, above left) is tautomeric with a 
form having double bonds between N-2 and N-1, and 
between C-5 and N-4, and with a positive charge at 
N-2 rather than N-3. 
FIG. 3.2 	Injecting the granulocyte suspension into HSS 
on the glass coverslips. (For the purposes of 
this photograph the granulocytes were at a much 
higher concentration than the standard 
25 x 106 cells/mi.) 
Magnification - 1.4 

FIG. 3.3 NBT dye reduction at the cell surface of isolated 
granulocytes. Granulocyte monolayers were incubated 
with NBT dye for 5 min, using the procedure outlined 
in Fig. 3.8. These granulocytes were then fixed in 
methanol, stained briefly with May-Grunwald (2 min) 
and Giemsa (4 min) stains, and mounted with Depex 
(Dade and Lewis, 1968, p58). Dye reduction is evident 
as a ring at the periphery of the cells and as a 
heavy deposit where two granulocytes touch (top and 
middle photographs). The eosinophil granules are 
prominent in the middle photograph. The pictures 
were taken with a Leitz Orthoplan light microscope 
using Kodak Plus-X film and a yellow and green filter 
combination. May-Grunwald/Giemsa stain did not stain 
the plasma membrane of these cells (cf. Fig. 2.6). 
Magnification 2,800 x. 
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FIG. 3.4. The plot of the reduction of NBT with time (top). 
Points shown are the R ± SEM of 3 determinations. 
FIG. 3.5. The reduction of NBT dye as a function of the number 
of granulocytes (bottom). Each point gives the 
± SEM of 3 determinations. 
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FIG. 3.6. Two plots (from 2 of 16 experiments) of the rate of 
NBT reduction versus the concentration of NBT dye 
(top). Each point is the R ± SEM of 3 determinations. 
FIG. 3.7. Replotting the data from FIG. 3.6 (above) as Line-
weaver-Burk plots ( 1/reduction rate versus 1/NBT 
concentration) to obtain straight lines. Line A 
corresponds to sample 8, and line B to sample 3 in 
Table 3.1 (see also Appendix III). 
granulocyte monolayers prepared 
on glass coverslips (section 3.2.2) 
NBT test solution added (section 3.2.3) 
dye reduction allowed to proceed for 5 min 
reduction terminated by repeated immersion 
of monolayers in cold CMFH 
monolayers allowed to dry 
reduced dye on each monolayer extracted into 
pyridine at 1000C 
OD of reduced dye on each monolayer determined 
at 515 nm 
Fig. 3.8 The assay of the initial rate of 
NBT reduction by intact, non-phagocytic 
granulocytes. 
TABLE 3.1 	Kinetic parameters for the reduction of  
NBT by intact granulocytes*  
Sample 
Km
a) V
max
b) 
1 .083 .078 .99 
2 .054 .075 .99 
3
c) .094 .063 .99 
4 .068 .052 .93 
5 .071 .075 .91 
6 .050 .085 .90 
7 .118 .093 .94 
8
d) .054 .086 .99 
9 .103 .083 .94 
10 .185 .102 .99 
11 .105 .087 .92 
12 .192 .069 .91 
13 .102 .081 .95 
14 .146 .093 .93 
15 .127 .089 .92 
16 .087 .090 .81 
± SEM 	.102 -1.011 	.081-1.003 	.94-1.01 
a) apparent Km for NET, in mM concentration units 
b) V
max 
in units of 0D515/1.3 x 106 granulocytes/5 min 
c) corresponds to line B in Fig. 3.7 
d) corresponds to line A in Fig. 3.7 
* See Appendix III 
r = correlation coefficient 
SECTION 	4 
MICROFILAMENT AND MICROTUBULE DISRUPTION 
AND OXIDASE ACTIVITY 
(NON - PHAGOCYTIC GRANULOCYTES) 
4.1 	INTRODUCTION 
In this section, the possible role of cytoplasmic 
microtubules and microfilaments in the control of the activity 
of the plasma membrane oxidase was examined. For these studies, 
the granulocytes were incubated with drugs at doses known to dis-
rupt microtubules or microfilaments (VBL, VCR, colchicine, and 
cytochalasin B, respectively; see Appendix IV). Drug 
incubations were followed by measurement of Plasma membrane oxidase 
activity, using the procedure outlined in Section 3 and illustrated 
in Figure 3.8. 
4.2 	METHODS 
4.2.1 	Preparation of the drugs in HSS  
The drugs (VBL, VCR, colch) were prepared as stock 
solutions of 1 mM in water and then dilutions of these stock 
solutions were used in the preparation of HSS. The only exception 
was cyto B, which was prepared as a stock solution in DMSO. 
However all subsequent dilutions of the drugs (including cyto 
B)were made with water. 
Successive dilutions as outlined below were made to 
obtain concentrations of the drugs which, when used to prepare 
HSS, would result in a final drug concentration at testing of 
1, 0.1, 0.01, or 0.001 W. These doses have been shown to dis-
rupt microfilaments (cyto B) or microtubules (colch, VBL, VCR) 
in vitro (see Appendix IV). 
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stock solution (1 mM) = 1000 pM (a) 
0.1 ml (a) + 2.9 ml water = 33 pM (b) 
0.1 ml (b) + 0.9 ml water = 3 pM (c) 
0.1 ml (c) + 0.9 ml water = 0.3 pM (d) 
0.1 ml (d) + 0.9 ml water = 0.03 pM (e) 
To obtain HSS with 1 pM drug, 1 volume of dilution (b) 
was used to replace 1 volume of the water used in preparing HSS 
(Appendix II). HSS containing drug at 0.1 pM, 0.01 pM, or 0.001 
gM was prepared in the same way, using drug dilutions (c), (d), 
and (e) respectively. 
4.2.2 	DMSO control for cyto B-treated granulocytes  
Cytochalasin B was dissolved in DMSO at 1 mM to give 
stock solution (a), in section 4.2.1. Therefore in those experi-
ments where the effects of cytochalasin B were being studied, 
control HSS containing DMSO at the appropriate concentration had 
to be prepared. DMSO was used as the control stock solution, and 
using the dilution format outlined in section 4.2.1, the DMSO 
concentrations were 
100 % 	v/v = (a) 
(a) x 1/30 = 3.3 % 	v/v = (b) 
(b) x 1/10 = 0.33 % 	v/v = (c) 
(c) x 1/10 = 0.03 % 	v/v = (d) 
(d) x 1/10 = 0.003 % v/v = (e) 
Dilutions (b), (c), 	(d) and (e) were then used in 
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the preparation of control HSS for the cytochalasin B experiments. 
Following tpe method discussed in section 4.2.1, the final DMSO 
content (% v/v) during incubation of the granulocytes was 
therefore:- 
for 1 pM cytochalasin B or its control ... 0.25 	% v/v DMSO 
for 0.1 pM 	ii 	n 	n • • • 0.03 	% v/v DMSO 
for 0.01 pM 	is 	ii 	it 	... 	0.003 	% v/v DMSO 
for 0.001 OM 	is 	ii 	is 	... 	0.0003 % v/v DMSO 
4.2.3 	The initial rate of NBT reduction by drug-treated granulocytes  
4.2.3.1 The effect of drug dose on reduction  
Monolayers of granulocytes were prepared as described 
in section 3.2.2. Drug-treated granulocytes were exposed to the 
drugs on the monolayers, while control cells were incubated in 
water or DMSO. After a 10 min exposure to the agents or controls, 
the granulocyte monolayers were assayed for the initial rate of 
plasma membrane NBT reduction (Section 3, Figure 3.7). During 
the 5 min reduction of dye, the drugs were present at a concen-
tration of 1 pM, 0.1 pM, 0.01 pM, or 0.001 pM. Dye reduc-
tion was terminated and quantitated spectrophotometrically as 
described in section 3.2.4.1. As before, the initial rate of 
NBT reduction was expressed as 0D515/1.3 x 106 granulocytes/5 
min. 
4.2.3.2 The effect of incubation time with the agents  
Granulocyte monolayers were exposed to each of the 
different drugs (VaL, VCR, colch, or cyto B) or controls for 
5, 10, 15, or 30 min. These monolayers were then assayed for 
the initial rate of NBT reduction. The drug concentration 
tested (and present) during dye reduction was 1 pm for each 
agent. Reduction was quantitated as described in section 3.2.4.1. 
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4.2.3.3 Simultaneous cyto B and colch (or VBL) incubations  
Granulocyte monolayers were incubated with cyto B and 
colch (or VBL) simultaneously and at the same dose, for 10 min 
prior to assaying the initial rate of NBT reduction. The drugs 
were present at three different concentrations (0.1, 0.01, and 
0.001 pM) during these experiments. Control experiments were 
conducted in parallel with granulocyte monolayers exposed to 
either agent alone, or no drugs (water, DMSO). 
4.2.3.4 Colch (or VBL) pre-incubation followed by cyto B  
Granulocytes were pre-incubated with colch (or VBL) 
for 5 min followed by a 5 min incubation with cyto B at the 
same dose and in addition to the colch (or VBL). These granulo-
cytes were then assayed for the initial rate of NBT reduCtion. 
At the time of reduction, the drugs were present either singly 
or together, at 0.001, 0.01, 0.1, or 1 pM. Control experiments 
were conducted in parallel with granulocyte monolayers exposed to 
either agent alone, or no drugs (water, DMSO). 
4.2.3.5 Cyto B pre-incubation followed by colch (or VBL)  
Granulocytes were pre-incubated with cyto B for 5 min, 
followed by a 5 min incubation with colch (or VBL), at the same 
dose and in addition to the cyto B. These granulocytes were then 
assayed for the initial rate of NBT reduction. At the time of 
reduction of dye, the drugs were present at 0.001, 0.01, 0.1, or 
1.0 pM. Control experiments were conducted in parallel with 
granulocyte monolayers exposed to either agent alone, or no drugs 
(water, DMSO). 
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4.2.4 	Incubation of  NBT dye with the drugs  
The complete medium for assaying the initial rate of 
NBT dye reduction, except for the granulocytes, was placed into 
test tubes. To these tubes was then added cyto B, colch, VBL or 
VCR at a final concentration of 1 4M. The tubes were then incu-
bated at 37oC for 30 min, centrifuged and the supernatant removed. 
The contents of the tube were then extracted with pyridine and 
NBT reduction quantitated (section 3.2.4.1). 
4.2.5 	Generation of  lumicolchicine  
The suggestions of Wilson and Friedkin (1966) were 
followed in preparing lumicolchicine from colchicine by ultra-
violet (UV) irradiation. Colchicine was prepared as a solution 
of - 0.025 M in 95% ethanol. This stock solution was then diluted 
1000-fold (three serial 10-fold dilutions), to give a solution of 
- 2.5 x 10-5 M. Matched quartz spectrophotometer cuvettes of 
4 ml capacity and 10 mm path length were used to hold the 
dilution of colchicine, which was then irradiated with long-wave 
UV light having a peak at 360 run. The cuvettes were situated 
10 cm from the source during irradiation. The absorbance of the 
irradiated solution at 350.5 nm was checked periodically to 
monitor the progress of the reaction. Irradiation was continued 
until the OD at 350.5 nut had reached a low value and was no 
longer decreasing. 
The irradiated sample and a control sample of 
colchicine which had not been exposed to UV light were compared 
(by performing a wavelength scan between 220 and 400 run) to ensure 
that lumicolchicine had been generated. The lumicolchicine solution 
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thus prepared was used for experiments after evaporating off the 
ethanol and resuspending the drug in water. 
	
4.2.6 	The reduction of NBT by lumicolchicine-treated granulocytes  
Granulocyte monolayers were exposed to colchicine 
or lumicolchicine for 10 min prior to NBT reduction. Dye 
reduction was allowed to proceed for 5, 20, or 30 min in the 
presence of either agent at 2 pM. Control monolayers reduced dye 
for 5, 20, or 30 min in the absence of either drug. Reduction 
was terminated and then quantitated spectrophotometrically 
as described in section 3.2.4.1. 
4.2.7 	Protein measurements of granulocyte monolayers  
Protein measurements of drug-treated and control 
monolayers were determined by the method of Lowry et al (1951) 
All measurements were carried out in duplicate, using the 
following procedure:- 
Standard solutions of bovine albumin fraction V, 
containing - 2.5 - 50 pg protein/ml were prepared. The exact 
protein content of these reference solutions was calculated by 
using the conversion factor provided by Peters and Blumenstock 
(1967). That is, a 10 mg/ml solution of bovine albumin fraction 
V has an OD of 6.61 at 278.5 nm. To 0.5 ml of each standard 
solution was added 0.5 ml of 4% NaOH. Blanks were prepared by 
mixing 0.5 ml of water with 0.5 ml of 4% NaOH. The granulocyte 
monolayers were dissolved in 0.5 ml of 20% NaOH, and then 
diluted to 5.0 ml with water. 
To 0.5 ml of the above solutions in NaOH (standard 
solutions, blanks or granulocyte monolayers in solution) was 
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added 2.5 ml of fresh copper reagent (section 4.2.7.1). The 
tubes were then incubated 30 min at 37°C. 
After this time the tubes were agitated with a vortex 
mixer while 0.25 ml of dilute F-C reagent (section 4.2.7.2) was 
added. The colour was then allowed to develop for exactly 30 min 
at room temperature before the OD at 540 nm of the granulocyte 
and reference protein solutions was read against the blank. A 
standard curve of 0D540 versus pg protein/ml was constructed from 
the data obtained. 
The OD values at 540 nm for the granulocyte monolayers 
were then converted to pg protein/ml values with the aid of the 
standard curve. 
4.2.7.1 Copper reagent  
The copper reagent was prepared by mixing 20 ml of 
10% Na2CO3 (anhydrous) with 1 ml of 2% sodium potassium tartrate 
(NaKC4H406 x 4H2 0), and then adding sufficient water for 100 ml 
of solution. To this solution was then added 2 ml of 0.5% 
CuSO4 x 5H2 0. The copper reagent was prepared fresh daily for 
protein determinations. 
4.2.7.2 	Dilute Folin-Ciocalteu (F-C) reagent  
By the method of Oyama and Eagle (1956) it was 
determined that 5 ml of the purchased 2 M F-C phenol reagent 
should be diluted with 11 ml water to prepare a dilute F-C 
reagent suitable for protein determinations by the method 
outlined above. The F-C reagent was therefore prepared fresh 
daily in this manner. 
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4.3 	RESULTS  
4.3.1 	The initial rate of NBT reduction by drug-treated granulocytes  
4.3.1.1 The effect of drug dose upon reduction  
As indicated in Fig. 4.1, cytochalasin B produced 
a dose-dependent stimulation in the initial rate of dye reduction 
from the plasma membrane. The stimulation with reference to 
the control varied from 22% (with a dose of 0.001 pM) to 83% 
(with 1 pM cyto B), and was statistically significant (Fig. 4.1). 
The DMSO used to dissolve the cyto B had no effect on dye 
reduction, even at the highest concentration tested (0.25% 
v/v DMSO, the control for 1 OM cyto B incubations). 
A dual effect on NBT reduction was seen with the 
microtubule-disrupting agents colch, VBL or VCR. At the lowest 
dose tested (0.001 pM), a slight but statistically significant 
stimulation above the control value was seen. This stimulation 
varied between 13% (colch) and 45% (VCR) above the control 
(Fig. 4.1). With the other three doses tested, a trend towards 
a dose-dependent inhibition of the initial rate of dye reduction 
by VBL, VCR or colch was observed. The maximal inhibition was 
produced with the highest dose (1 pM), and varied between 15% 
(colch) and 18% (VBL, VCR) of the control value. As indicated 
in Fig. 4.1, the inhibition of dye reductionwith higher doses was 
statistically significant with reference to the control. 
4.3.1.2 The effect of incubation time with the agents  
As illustrated in Fig. 4.2, granulocytes incubated 
for varying periods of time with cyto B showed a time-dependent 
stimulation of the initial rate of dye reduction. The 
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stimulation with reference to the control was 50% after 5 min, 
and rose to a high of 99% after 30 min incubation with the drug. 
When granulocytes were incubated with the microtubule-
disrupting agents (colch, VBL or VCR) for varying periods of time, 
an initial (slight) stimulation of reduction after 5 min was 
followed by a time-dependent decrease in the rate of dye reduction 
(Fig. 4.2). There was very little difference between the three 
agents in these experiments. The stimulations seen with very short 
incubation times were - 12% above the control value. In contrast, 
the inhibition of the initial rate of dye reduction was as great 
as 38% with colchicine. 
4.3.1.3 	Simultaneous cyto B and colch (or VBL) incubations  
The effects of incubating granulocytes with cyto B 
and colch (or VBL) simultaneously for 5 min before measuring 
the initial rate of dye reduction are illustrated in Fig. 4.3. 
A dose-dependent stimulation of the initial rate of dye reduction 
was observed, but the maximal stimulation seen (when the two 
agents were at a dose of 0.1 pM) was far less than the maximal 
stimulation seen with cyto B alone, at 0.1 pM. At 0.1 pM as 
well as 0.001 WI, the magnitude of the stimulation observed fell 
between that seen with cyto B or colch alone at the same dose. 
At 0.01 pM however, the stimulation with both agents together 
was greater than the stimulation seen with either agent alone. 
As indicated in Fig. 4.3, not all of these stimulations were 
statistically significant. 
4.3.1.4 Colch (or VBL) pre-incubation followed by cyto B  
When granulocytes were pre-incubated with colch 
(or VBL) for 5 min followed by a 5 min incubation with cyto B 
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(at the same dose and in addition to the colch or VBL), a marked 
depression in the initial rate of NBT reduction was observed. 
That is, the dye reduction curve seen with cyto B-treated 
granulocytes was replaced by a curve which ran parallel but 
showed a significant drop in the rate of dye reduction (Fig. 4.4). 
4.3.1.5 Cyto B pre-incubation followed by colch (or VBL)  
When granulocytes were pre-incubated with cyto B for 
5 min followed by a 5 min incubation with colch (or VBL) in 
addition to the cyto B, the usual dose-dependent stimulation 
observed with cyto B treatment was lost. Instead the dye 
reduction curve seen with the doubly-incubated granulocytes 
was virtually parallel to the curve for cyto B, but with a 
significant drop in the rate of dye reduction (Fig. 4.5). 
	
4.3.2 	Incubation of NBT dye with the drugs  
When the medium for assaying NBT reduction was 
incubated (in the absence of granulocytes) with either VBL, VCR, 
colch or cyto B, no dye reduction was observed visually. Further-
more, no dye reduction could be detected spectrophotometrically 
at 515 run. The OD 515 values were between 0.000 and 0.003 in 
each case. 
4.3.3 	Generation of lumicolchicine 
The OD at 350.5 nm of the colchicine dilution 
(- 2.5 x 10-5 M) was found to be 0.464. After 165 min 
irradiation with long-wave UV light, the 0D 350 	fallen to 
a value of 0.015 and was not decreasing any further with continued 
irradiation. 
When the irradiated sample and a control (not 
irradiated) sample of colchicine were compared by performing a 
wavelength scan between 220 and 400 nm, it was found that (i) 
the 0D
350.5 
of the irradiated sample was minimal (0.015), and 
(ii) two isosbestic points were apparent, at 255 and 305 rim 
(Fig. 4.6). These findings confirmed that lumicolchicine had 
been generated from colchicine (Wilson and Friedkin, 1966). 
As the OD, or absorbance, of the irradiated 
colchicine at 350.5 nm was 0.464, the true concentration of the 
colchicine (and lumicolchicine) solution could be calculated, as 
shown:- 
log E = 4.22 for colchicine in ethanol at 350.5 nm 
(The Merck Index, 1958, p.278) 
then E = 16,600 
and as E = A/bc (Beer's Law, see Meloan, 1968) 
where E = molar absorptivity 
A = OD (or absorbance) at 350.5 nm 
b = path length (= 1 cm) 
and c = molar concentration of colchicine 
then 16,600 = 0.464/1 x c 
and c = 2.8 x 10 -5M 
Thus the true concentration of the irradiated 
colchicine sample was 2.8 x 10 -5 M. As 1 mole of colchicine 
breaks down under UV irradiation to yield 1 mole of lumicolchicine 
(Wilson and Friedkin, 1966 ) it was concluded that the 
lumicolchicine solution thus generated was also 2.8 x 10 -5 M. 
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4.3.4 	The reduction of NBT by lumicolchicine-treated granulocytes  
As indicated in Figure 4.7, incubation of granulocytes 
for 5, 20 or 30 min with lumicolchicine at 2 PM had no effect on 
NBT reduction. In parallel experiments with colchicine, at the 
same dose, however, a significant depression in NBT reduction 
was seen with incubations longer than 5 min. After 30 min 
incubation with colchicine, for example, there was a 23% drop 
in the rate of NBT reduction compared with the control. 
4.3.5 	Protein measurements of granulocyte monolayers  
As detected by measuring the OD at 540 nm, there 
were no differences in the protein content of drug-treated or 
control granulocyte monolayers (Table 4.1). The 
0D540 
values 
of drug-treated and control monolayers were all approximately 
0.035, representing a protein content of - 35 pg/ml (Figure 
4.8) per monolayer. 
4.4 	DISCUSSION 
Cytochalasin B produced a time and dose-dependent 
stimulation of the initial rate of NBT dye reduction from the 
plasma membrane oxidase of non-phagocytic granulocytes. The 
marked stimulation in dye reduction was seen with incubation 
periods as brief as 5 min, and doses as low as 0.001 uM cyto B. 
The greatest stimulation seen was 99% above the control value, 
and this occurred after a 30 min incubation with 1 pM cyto B 
(Fig. 4.2). 
Three other groups of workers also found that treat-
ment of non-phagocytic granulocytes with the cytochalasins 
stimulated the production of superoxide. Using cytochalasin E, 
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Nakagawara et a/ (1975, 1976a) demonstrated a stimulation 
in superoxide production with both NBT and cytochrome C 
reduction. In addition they showed that this stimulation could 
be enhanced if the granulocytes were incubated with concanavalin 
A along with the cytochalasin (Nakagawara, Nabi and Minakami, 
1977). Interestingly, they found that neither the cytochalasin 
or cytochalasin/concanavalin A - induced stimulation in 
superoxide production could be elicited from the granulocytes 
of chronic granulomatous disease (CGD) patients (Nakagawara et al 
1976a; Nakagawara, Nabi and Minakami, 1977). It is known that 
binding of concanavalin A to the cell surface (even in the 
absence of phagocytosis) is sufficient to stimulate the oxidative 
metabolism of the granulocyte by perturbing the plasma membrane 
(see for example, Goldstein et a/, 1977). Thus it is not 
unreasonable to conclude that the experiments of Nakagawara and 
his associates suggest that the activity of a plasma membrane 
oxidase is defective in CGD granulocytes (see also Appendix I). 
The other two groups of investigators to find a 
cytochalasin-induced enhancement in oxidase activity from non-
phagocytic granulocytes were Okuda et al (1976) and Zabucchi 
et al (1978). The report from Okuda et a/ described a 
dramatic increase in the number of granulocytes reducing NBT 
dye (histochemically) when cytochalasin B was present. 
contrast, Zabucchi et al (1978) used the uptake of oxygen as a 
guage of oxidase activity, and described a very slight stimulation 
of this activity by cytochalasin B. 
It must be mentioned that the cytochalasin-induced 
stimulation of oxidase activity was not observed by Curnutte and 
Babior (1975), Johnston and Lehmeyer (1976) and Roos and his 
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colleagues (Goldstein, Roos et al, 1975; Roos, Homan-Miller 
and Weening, 1976; Roos et al, 1976). In fact, Curnutte and 
Babior (1975) and Johnston and Lehmeyer (1976) found that 
cytochalasin B inhibited the production of superoxide from non-
phagocytic granulocytes. In contrast, Roos et al found that 
cytochalasin B was without effect. These discrepancies 
cannot easily be explained, but initially it was thought that 
adherent granulocytes may respond differently to cytochalasin B 
than granulocytes in suspension. However, a closer examination 
of the techniques employed by the various investigators revealed 
that technical differences in measuring oxidase activity do not 
provide the explanation. For example, adherent granulocytes may 
(Okuda et a/, 1976; and this thesis) or may not (Johnston 
and Lehmeyer, 1976) show the enhancement in oxidase activity. 
Similarly, even when the same method for quantitating oxidase 
activity was used (cytochrome C reduction), it was found that 
cytochalasin-treated granulocytes did or did not show increased 
activity (Nakagawara et al, 1976a; Curnutte and Babior, 1975; 
respectively). As many of these investigators were also 
conducting experiments on cytochalasin-treated phagocytic 
granulocytes, their work will also be discussed in section 5.4 of 
this thesis. 
In addition to the experiments with cyto B, the 
results of studies with the microtubule-disrupting agents 
(colch, VBL, VCR) were also presented in this section. As shown 
in Figs. 4.1 and 4.2, a dual effect of these agents on plasma 
membrane NBT dye reduction was observed. At low doses of, 
or brief incubation periods with these agents, a slight but 
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statistically significant stimulation in the initial rate of 
dye reduction was seen. Longer incubations (> 5 min) or higher 
doses (>0.001 pM) with any one of these agents resulted in a 
trend towards a dose-dependent inhibition of the initial rate of 
dye reduction. The latter finding is in agreement with the results 
of experiments conducted by Malawista and Bodel (1967) and Curnutte 
and Babior (1975). By measuring the superoxide-dependent reduction 
of cytochrome C, Curnutte and Babior found that colchicine or 
vinblastine produced an inhibition in superoxide production from 
non-phagocytic granulocytes. The rate of cytochrome C reduction 
was 45% below that produced by untreated granulocytes when a 
dose of 2.5 pM colchicine was employed. In contrast to the 
studies of Curnutte and Babior, Malawista and Bodel (1967) and 
Lehrer (1973) quantitated oxidase activity by measuring oxygen 
consumption. Malawista and Bodel reported a 25% drop in 
oxygen uptake in 8 experiments with colchicine-treated 
granulocytes, but stated that the fall was not consistently 
observed. Lehrer, on the other hand, and in a similarly brief 
account maintained that the oxygen consumption of non-phagocytic 
granulocytes was not affected by colchicine. These workers have 
also studied the oxidase activity of colchicine-treated 
phagocytic granulocytes, and therefore those studies are 
discussed in section 5.4. 
Some interesting results were seen when granulocytes 
were (i) incubated with the two agents simultaneously (cyto B 
with colch, or VBL), or (ii) pre-incubated with one agent 
followed by an incubation with both agents together. In both of 
these situations the overall effect was an inhibition of the 
51 
usual response seen with cyto B. That is, the usual stimulatory 
response with cyto B was largely ablated when the granulocytes 
were incubated with colch (or VBL) prior to, during, or after 
cyto B incubation. Assuming that microfilaments and microtubules 
were disrupted by the drugs, these results suggest that the 
stimulatory response seen with cyto B was bi-phasic, consisting 
of an initial disruption of the microfilaments by cyto B 
followed by a phase (characterized by the stimulation) which was 
dependent upon the presence of intact microtubules. 
Several control experiments were conducted and 
must be discussed. In the absence of granulocytes, no dye 
reduction occurred even when NBT was incubated at 37 °C for 30 
min with any particular agent. Thus any stimulations in dye 
reduction observed were not due to a direct effect of the agents 
on NBT dye. As well, the inhibition of dye reduction seen after 
colch, VBL, or VCR incubations (for longer than 5 min or at 
doses above 0.001 pM) was not an artefact of cell losses from 
the monolayer preparations, as the protein content of drug-
treated and control granulocyte preparations was virtually 
identical. 
Control experiments with lumicolchicine were 
conducted also. (Lumicolchicine is a photoproduct of 
colchicine which is unable to bind to tubulin and disrupt 
microtubules, and is therefore used as a control for experiments 
with colchicine, as discussed in Appendix IV). As lumicolchicine 
was without effect in experiments where an inhibitory response 
was observed with colchicine, it can be assumed that the inhibition 
in NBT reduction was mediated by colchicine's binding to tubulin 
and disruption of microtubules. This conclusion is strengthened 
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by the finding that NBT reduction showed a similar sensitivity 
to all three microtubule-disrupting agents tested (VBL, VCR and 
colch, see Appendix IV). Furthermore it appears as though 
microfilament and microtubule disruption have nearly opposite 
effects on plasma membrane oxidase activity, as measured by NBT 
reduction. That is, microfilaments provide a constraint against 
plasma membrane oxidase activity and thus cyto B-treated granulo-
cytes show enhanced reduction; while microtubules are required 
for activity and therefore colch, VBL or VCR treatment produces 
an inhibition of dye reduction. 
It is reasonably certain that the agents used in 
these experiments were mediating their effects through micro-
filament (cytochalasin B) or microtubule (colchicine, VBL, VCR) 
disruption (see Appendix IV). However, to make certain that 
the cytoskeletal elements were indeed disrupted by the respective 
treatments, the additional control experiments described in 
Sections 5 - 9 of this thesis were performed. 
4.5 	SUMMARY 
The possible role of cytoplasmic microtubules and 
microfilaments in the control of granulocyte plasma membrane 
oxidase activity has been studied. The experiments were 
designed to record changes in the initial rate of oxidase 
activity (NBT reduction) brought about by treatment of the 
granulocytes with appropriate doses of pharmacological agents 
known to disrupt microtubules (colchicine, VBL or VCR) or 
microfilaments (cytochalasin B). 
It was observed that treatment of granulocytes 
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with cyto B led to a time and dose-dependent enhancement of plasma 
membrane oxidase activity. A similar stimulation was also reported 
by Nakagawara et al (1976a), Okuda et a/ (1976) and Zabucchi et a/ 
(1978). On the other hand, incubation of granulocytes with a 
microtubule-disrupting agent (VBL, VCR or colch) resulted in a 
dual response. A paradoxical enhancement in NBT reduction (oxidase 
activity) was seen when low doses Or brief incubation periods 
with the agents were employed. However, and in agreement with 
Malawista and Bodel (1967) and Curnutte and Babior (1975), when 
longer incubation periods (> 5 min) or higher doses (>0.001 pM) 
were used, an inhibition of oxidase activity was observed. 
Control experiments with lumicolchicine, a photoproductwhich is 
unable to bind to tubulin and disrupt microtubules, showed 
lumicolchicine to be without effect in experiments where 
colchicine produced an inhibition in the rate of dye reduction. 
Incubation of cytochalasin B- treated granulocytes 
with a microtubule-disrupting agent either before, during, or 
after the incubation with cytochalasin B led to an inhibition 
in the usual stimulatory response seen with cytochalasin B. 
Assuming that microfilaments (cyto B) and microtubules (colch or 
VBL) were disrupted by these drug treatments, it appears that 
the stimulatory response seen with cyto B is bi-phasic, consisting 
of an initial disruption of the microfilaments by cyto B followed 
by a phase (characterized by the stimulation) which is dependent 
upon the presence of intact microtubules. Furthermore, it 
appears as though microfilament and microtubule disruption have 
nearly opposite effects on plasma membrane NBT reduction. That 
is, microfilaments provide a constraint against plasma membrane 
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oxidase activity and thus cyto B-treated granulocytes show 
enhanced NBT reduction, while microtubules are required for 
activity and therefore VBL, VCR or colchicine treatment produces 
an inhibition of dye reduction. 
To make certain that microfilaments and microtubules 
were indeed disrupted by the respective drug treatments, the 
additional control experiments presented in Sections 5 - 9 of this 
thesis were performed. 
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FIG. 4.1. Plot of the effect of drug dose upon the rate of NBT 
reduction. Each point represents the mean of at least 
3 determinations, and is the OD at 515 nm/1.3 x 10 6 cells/5 min. 
SEM values were ± 10% of each individual mean. The control value 
(0.095 ± .010) was obtained from experiments with 15 donors. In 
all experiments the time of exposure to any agent was 10 min 
Values significantly different from the control (p 0.05) are 
indicated by an asterisk. 
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FIG. 4.2. Plot of the effect of incubation time with the agents 
on the rate of NBT reduction. Each point represents 
the mean of at least 3 determinations and is the OD at 515 nm/ 
1.3 x 106 cells/5 min. SEM values were ± 12% of each individual 
mean. The control value (0.095 ± .010) was obtained from experi-
ments with 15 donors. In all experiments the dose of each agent 
was 1 iiN. Values significantly different from the control 
Op 0.05) are indicated by an asterisk. 
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FIG. 4.3. Plot of the effects of incubating granulocytes with 
cyto B and colch simultaneously for 5 min (at 3 
different doses) before measuring the initial rate of NBT dye 
reduction. Each point represents the mean of 3 experiments per-
formed in triplicate, and is the OD at 515 nm/1.3 x 10 6 cells/ 
5 min. SEM values were ± 11% of each individual mean. The 
control value (0.095 ± .010) was obtained from experiments with 
15 donors. Values significantly different from the control 
(ID -1. 0.05) are indicated by a (f). 
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FIG. 4.4. The effects of pre-incubating granulocytes with VBL 
for 5 min followed by a 5 min incubation with cyto 
B (at the same dose and in addition to the VBL). Four doses were 
tested, and each point represents the mean of 3 experiments 
performed in triplicate. SEM values were ± 10% of each individual 
mean. The control value (0.095 ± 0.010) was obtained from ex-
periments with 15 donors. Values significantly different from 
the control Op 0,05) are indicated by a (40. 
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FIG. 4.5. The effects of pre-incubating granulocytes with 
cyto B for 5 min followed by a 5 min incubation 
with colch (at the same dose and in addition to the cyto B).' 
Four doses were tested, and each point represents the mean of 
3 experiments conducted in triplicate. 	SEM values are shown 
by the vertical bars. The control value (0.095 ± 0.010) was 
obtained from experiments with 15 donors. Values significantly 
different from the control Op 0.05) are indicated by a (*). 
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FIG. 4.6. A wavelength scan between 250 and 400 um, confirming 
the generation of lumicolchicine from colchicine which 
has been irradicated with UV light. Two isosbestic 
points at 255 (1) and 305 nm (2) are apparent, as is 
the minimal absorption of the irradiated sample 
(lumicolchicine) at 350.5 run. 
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FIG. 4.7. The reduction of NBT dye by colch or lumicolchicine-
treated granulocytes. Granulocytes were incubated 
with the agents at 2 AM for 10 min and then dye re-
duction was allowed to proceed for 5, 20 or 30 min 
in the presence of the agent. Points are the X ± SEM 
of 3 determinations, and are the OD at 515 um/1.3 x 10 6 
cells/5, 20 or 30 min. Values significantly different 
from the control (p 5 0.05) are indicated by a W. 
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FIG. 4.8. The standard curve for protein determinations by the 
method of Lowry et al (1951). 
TABLE 4.1 	Protein content of drug-treated 
and control monolayers 
Drug Treatment 0.D. at 540 nm 
cytochalasin B 0.033 + 0.002 
colchicine 0.034 + 0.004 
vinblastine 0.036 ± 0.003 
vincristine 0.033 ± 0.004 
control (no 0.034 ± 0.004 
treatment) 
* Representing the protein content of the mono- 
layers (see section 4.3.5). Values are the 
X ±SEM of 2 experiments, each conducted in 
duplicate. From Fig. 4.8, an 0.D. of 0.034 
is equivalent to a protein content of 32.5 
pg/ml. None of the values for treated mono-
layers is significantly different from the 
control value. 
SECTION 5 
MICROFILAMENT AND MICROTUBULE DISRUPTION 
AND OXIDASE ACTIVITY 
(PHAGOCYTIC GRANULOCYTES) 
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5.1 	INTRODUCTION  
This section of the thesis describes experiments 
monitoring the oxidase activity (NBT reduction) from phagocytic 
granulocytes exposed to drugs known to disrupt microtubules or 
microfilaments. It will be recalled that similar drug treatments 
of non-phagocytic granulocytes resulted in changes in the initial 
rate of NBT reduction (section 4.3). As discussed in section 4.4, 
those experiments suggested that microtubules and microfilaments 
may play opposite roles in controlling plasma membrane oxidase 
activity. It was thought that comparable experiments with 
phagocytic granulocytes might help clarify the mechanism behind 
the changes in oxidase activity, and therefore such studies were 
performed and are presented herein. 
5.2 	METHODS  
5.2.1 	Preparation of the drugs in HSS  
Colchicine, VBL and lumicolchicine were prepared as 
stock solutions of 1 mM in water, while cyto B was dissolved at 
the same concentration in DMSO. Dilutions of these stock 
solutions were then carried out (as outlined in section 4.2.1) 
to prepare HSS which contained any one drug at a concentration 
(during tests) of either 1 or 2 pM. [The 2 uM concentration 
was used where the drug was to be subsequently diluted, by half, 
when mixed with polystyrene latex beads (section 5.2.2).] 
Lumicolchicine was prepared as described in section 4.2.5 and used 
as a control for the experiments with colchicine (see Appendix 
IV). 
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As cyto B was dissolved in DMSO, the control 
experiments for cyto B-treated granulocytes were conducted using 
HSS which contained DMSO at the appropriate concentration of 
0.25% v/v (see section 4.2.2). 
The concentration of the agents (including lumicolchicine) 
during incubation was 1 pM. 
	
5.2.2 	Preparation of the polystyrene latex beads  
Polystyrene latex beads with a mean diameter of 0.79 pM 
were dialyzed against three changes of water for 24 hours. A 
stock dilution was prepared by adding 50 pl of these beads to 
2.0 ml of HSS. This was the standard bead dilution for virtually 
all procedures in which a phagocytosable stimulus was required. 
The exception was the bead dilution used for experiments where 
the beads were to be presented to granulocytes which had been 
preincubated with a drug. For these experiments it was 
necessary to prepare a mixture of beads with drug so that the 
cells would continue to be exposed to the drug at the same 
concentration during phagocytosis. The required mixture 
contained 1 volume of beads (at twice the standard dilution) 
and 1 volume of drug, at 2 pM. In this way the exposure to the 
particular drug was maintained at the desired concentration 
(1 pM) during phagocytosis. 
5.2.3 	Phagocytosis of polystyrene latex beads  
Granulocyte monolayers of 1.3 x 10 6 cells were prepared 
by adding 50 pl of isolated granulocytes (section 2.2.13) to 
100 pl of HSS (with or without drug at 1 pM). The monolayers 
were then incubated for 10 min at 37°C. After this time 100 pl 
of dialyzed polystyrene latex beads (section 5.2.2) was added to 
each drug-free monolayer, whereas 100 pl of the bead/drug 
mixture was added to each drug-containing monolayer. 
Phagocytosis was allowed to proceed for 30 min at 37 °C 
and was then terminated by vigorously rinsing each monolayer in 
excess CMFH at 4oC. The monolayers were then allowed to dry in 
air before being extracted into 1.0 ml of spectral grade dioxane 
for 2 hours at room temperature. Phagocytosis was then quantitated 
by measuring the O.D. at 259 nn, which represents the polystyrene 
content of the granulocyte monolayers (Weisman and Korn, 1967). 
Parallel experiments were conducted with monolayers 
which were taken to the stage of rinsing to remove uningested 
beads, but were instead air-dried and extracted into NaOH. These 
granulocytes were processed as described in section 4.2.7 and 
were used tq quantitate the protein content of the monolayer. 
5.2.4 	Preparation of monolayers for scanning electron microscopy  
Glass adherent granulocytes which had been incubated 
with or without drugs and then exposed to polystyrene latex 
beads were processed for scanning electron microscopy as described 
previously (Dewar and Wolowyk, 1979). These experiments were run 
in parallel to those described in section 5.2.3. Briefly, the 
monolayers were rinsed of uningested beads and then exposed to 
0.1% buffered glutaraldehyde (section 5.2.5) and allowed to fix 
for 30 min. The coverslips were then removed to fresh fixative 
(at 2%) for another 30 min. After this time they were rinsed 
in several changes of CMFH to remove any unreacted glutaraldehyde. 
Dehydration was then started by exposure to increasing concen-
trations of ethanol (section 5.2.6). The ethanol concentrations 
used were 1.8, 10, 20, 40, 50, 70, 80, 90% and absolute ethanol, 
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in that order. The coverslips were exposed to each ethanol for 
2 min and twice to absolute ethanol. After the final ethanol 
exposure the coverslips were air-dried and then glued onto a 
scanning electron microscope stub. A thin coating of carbon and 
gold was applied under vacuum before the cells were observed in 
a JEOL scanning electron microscope at 25 kV accelerating voltage 
and no tilt. 
	
5.2.5 	Buffered glutaraldehyde fixatives  
A 2% buffered glutaraldehyde was prepared by mixing 
++ 10 ml of Ca++ and Mg -free salt solution (Appendix II) with 
10.6 ml glutaraldehyde EM (25%) and adding sufficient water for 
100 ml. To this was added 10 ml of 155 mM glucose and 20 ml of 
HEPES buffer (Appendix II). 
The 2% buffered glutaraldehyde was used to prepare 
fixative at 0.1% concentration, in the following manner: 
5 ml of 2% fixative was mixed with 95 ml of CMFH (Appendix II). 
Me fixatives were both prepared on the day of use. 
5.2.6 	Ethanol solutions for dehydration  
Benzene-free absolute ethanol was mixed with water to 
make 1.8, 10, 20, 40, 50, 70, 80, and 90% (v/v) solutions. 
These solutions were always prepared on the day of use. 
5.2.7 	NBT reduction by drug-treated phagocytic granulocytes  
Granulocyte monolayers were prepared by adding 50 pl 
of isolated granulocytes (section 2.2.13) to 100 pl of HSS, with 
or without drug at 1 gm, and incubating for 10 min at 37 °C. After 
this time the monolayers were incubated for 5 or 20 min with 
beads (± drugs) to give the following experimental conditions:- 
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- monolayers incubated with beads 
- monolayers incubated with drug 
- monolayer'§ incubated with beads and drug simultaneously 
For those monolayers incubated with beads or drug only, 
100 pl of the standard bead dilution (section 5.2.2) or 100 pl of 
HSS containing drug at 1 11M (section 5.2.1) was added. For those 
monolayers exposed to beads and drug simultaneously, 100 p1 of 
the 1:1 mixture of beads and drug was added (section 5.2.2). By 
this procedure all monolayers were made comparable. As before, 
the concentration of drug during the incubation was 1 pM and the 
control HSS for those experiments where cyto B was present 
contained DMSO at 0.25% v/v (see section 4.2.2). 
After the 5 or 20 min incubation period, 200 pl of 
NBT solution (section 3.2.3) was added to each monolayer and 
reduction was allowed to proceed for 5 min. Therefore the total 
exposure to drug and/or beads was 10 or 25 min, respectively. 
Reduction was terminated by repeatedly rinsing each monolayer in 
CMFH at 4oC. The reduction of NBT was quantitated spectrophoto-
metrically as described in section 3.2.4.1, and results were 
expressed as OD at 515 nm/1.x10 6 granulocytes/5 min. 
Parallel experiments were conducted with monolayers 
which were taken through the incubation period but not presented 
with NBT dye. Instead, these monolayers were rinsed in CMFH, 
air-dried, and used for protein determinations as described in 
section 4.2.7. 
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5.3 	RESULTS  
5.3.1 	Phagocytosis of polystyrene latex beads  
As shown in Table 5.1, granulocytes exposed to any one 
of the drugs (colch, VBL, cyto B) while phagocytosing showed a 
marked impairment in phagocytosis. Control incubations with DMS0 
at 0.25% (for those monolayers exposed to cyto B) or lumicolchicine 
(for those exposed to colch) did not display an inhibition in 
polystyrene uptake. The inhibition of phagocytosis was not 
complete with any of these agents, but was most pronounced with 
cyto B, which gave a 55% inhibition when compared with the control. 
The protein content of comparable drug or bead-treated monolayers 
was not significantly different from untreated (control) mono-
layers (Table 5.2, groups 1 and 2). 
5.3.2 	Scanning electron microscopy  
The majority of untreated granulocytes were observed 
adhering to the glass coverslips with cytoplasmic extensions 
projecting in all directions. The surface of these cells was 
relatively smooth, with only a few surface undulations or ruffles 
(Fig. 5.1). Some of the untreated granulocytes displayed an 
elongated pseudopod as well as the rounded cell body (Fig. 5.2). 
In contrast, no such pseudopodia were seen in the granulocytes 
incubated with cyto B, colch or VBL. Otherwise, the general 
surface ultrastructure of the drug-treated granulocytes was 
not remarkably unlike that of the control cells, as both 
populations exhibited a variety of surface features. It was 
notable however, that a proportion (15 of 175 examined) of 
the granulocytes exposed to cyto B had more marked surface 
undulations than the control cells (Fig. 5.3). 
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At first glance, granulocytes exposed to polystyrene 
latex beads presented the same general appearance as non-phagocytic 
granulocytes. However, closer examination at higher magnifications 
revealed areas of surface protrusion containing engulfed beads. 
These ingested beads were identifiable (by their smooth profiles 
and size) only when situated very close to the surface of the cell 
(Fig. 5.4). When compared with non-phagocytic granulocytes, none 
of the granulocytes presented with beads displayed pronounced 
pseudopodia adherent to the glass coverslip. Granulocytes 
exposed to colch, VBL, DMSO (0.25%) and lumicolchicine while 
phagocytosing did not appear to differ markedly from the drug-free 
control cells in surface morphology. In contrast, cyto B- 
treated granulocytes showed many adherent and incompletely ingested 
beads on the cell surface (Fig. 5.5). 
5.3.3 	NBT reduction by phagocytic, drug-treated granulocytes  
5.3.3.1 	Cytochalasin B-treated granulocytes  
As shown in Table 5.3, granulocytes exposed to cyto B 
while ingesting polystyrene latex beads displayed a significant 
stimulation in NBT reduction when compared with untreated 
(phagocytic) granulocytes. The stimulation was apparent in 
granulocytes incubated for 5 or 20 min with the agents (Table 
5.3), but was greatest (at 23% above the appropriate control) 
after 5 min incubation. The solvent used to dissolve cyto B was 
without effect in these experiments (Table 5.3 , DMSO 0.25%). 
Phagocytosis itself was also stimulatory to NBT reduction by 
glass-adherent granulocytes (line 3, Table 5.3). 
5.3.3.2 Colch and VBL-treated granulocytes  
As shown in Tables 5.4 and 5.5, both colch and VBL 
treatment of phagocytosing granulocytes resulted in a 
significant depression in the rate of NBT reduction. The in-
hibition was most pronounced with granulocytes incubated with 
VBL for 20 min, and in this case dye reduction was 38% below 
the appropriate control (phagocytic, line 2, Table 5.5). Incubation 
of non-phagocytic or phagocytic granulocytes with lumicolchicine 
had no effect on dye reduction (Table 5.4). As before, phago-
cytosis itself resulted in a marked enhancement in the rate of 
NBT dye reduction (Tables 5.4, 5.5). 
5.3.4 	Protein content of drug-treated phagocytic monolayers  
Granulocyte monolayers exposed to beads and drug 
(VBL, colch, cyto B) simultaneously showed the same protein 
content as control (untreated) monolayers (Groups 3 and 4, 
respectively, Table 5.2). 
5.4 	DISCUSSION 
Micromolar doses of colchicine and VBL were found to 
similarly impair the ability of granulocytes to phagocytose 
polystyrene latex beads (Table 5.1). In parallel experiments 
lumicolchicine had no effect, suggesting that microtubule dis-
ruption was responsible for this impairment in colchicine or 
VBL-treated cells (see Appendix IV). Examination of the 
literature reveals that there is some controversy over whether 
microtubule-disrupting agents always inhibit ingestion in 
granulocytes (see Table 5.6). For example, both Malawista 
(1971) and Lehrer (1973) maintain that the ingestion of 
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Staphylococcus Aureus is unaffected by colchicine. Similarly 
Oliver, Ukena and Berlin (1974) state that the uptake of paraffin 
oil droplets containing Oil Red 0 is not inhibited by colchicine, 
but others provide evidence to the contrary (Stossel et al, 
1972). The reason for these discrepancies is not known, but 
it is notable that the choice of particle may influence the out-
come of tests of phagocytic function in drug-treated granulocytes 
(see Lehrer, 1973; Cannarozzi and Malawista, 1973). Furthermore, 
different results probably arise as a result of methodological 
differences in the phagocytic assays themselves. In this regard, 
it is certain that spectrophotometric methods (Stossel et al, 1972) 
or isotopic procedures (Root and Metcalf, 1977) for quantitating 
phagocytosis are far superior to techniques employing light 
microscopical counts of ingested particles, and yet many 
investigators use the latter (see Stossel, 1973a,b). 
The impairment of phagocytosis in granulocytes treated 
with colchicine or VBL undoubtedly provides part of the explanation 
for the decreased oxidase activity ow reduction) also observed 
in these cells (see Tables 5.4 and 5.5, respectively). However, 
as discussed in the text to follow, several other factors need 
to be considered when studying the impairment in oxidase activity 
in phagocytic granulocytes. As shown in Tables 5.4 and 5.5, 
phagocytic granulocytes incubated for 20 min with colch or VBL 
showed a marked drop in the rate of NBT reduction (- 40% below 
the drug-free control). Lumicolchicine had no effect on 
phagocytosis (Table 5.1) or on the oxidase activity of phagocytic 
granulocytes (Table 5.4) in experiments where colchicine and 
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VBL produced a similar inhibition, suggesting that these 
responses were mediated by microtubule disruption (see Appendix 
IV) 	It is clear that the observed inhibitions in NBT dye 
reduction and phagocytosis were not artefacts due to loss of 
granulocytes from the coversaps,as the protein content of drug-
treated and control monolayers was almost identical (Table 5.2). 
The colchicine or VBL-induced inhibition of 
phagocytic oxidase activity has been observed by many other 
investigators, despite the fact that the methods for assaying 
oxidase activity have varied (see Table 5.7). It is notable 
that the few workers who have not found an impairment of 
phagocytic oxidase activity by these drugs employed oxygen 
uptake as a guage of oxidase activity. Two points can be made 
with respect to this type of assay:- 
(i) oxygen uptake should probably not be considered equivalent 
to measuring oxidase activity by other methods, notably cytochrome 
C reduction, and therefore the results of such assays must be 
interpreted with caution (see the discussion to follow with 
respect to Zabucchi's experiments) 
(ii) using oxygen uptake, Lehrer (1973) showed that the choice 
of particle would influence the outcome of tests of oxidase 
activity in colchicine-treated phagocytic granulocytes. For 
example, he found little impairment of oxygen uptake by 
colchicine-treated granulocytes ingesting Candida albicans, 
even though colchicine markedly impaired phagocytosis of the 
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micro-organism itself. Conversely, he showed that the ingestion of 
Staphylococcus aureus was not affected by colchicine while the 
post-phagocytic increase in oxygen uptake was markedly diminished 
under the same conditions. Lehrer concluded that oxidase activity 
is not directly linked to phagocytosis in granulocytes, and this 
has been confirmed by others (see for example Goldstein et al, 
1975, 1977; Roos et al, 1976; Johnston and Lehmeyer, 1976; 
DeChatelet et al, 1976; Stendahl et al, 1977). From such 
experiments twQ conclusions can be drawn, namely that (1) 
perturbation of the plasma membrane (and not phagocytosis 
per se) is responsible for the enhancement in oxidase activity, 
and that (2) impairment of phagocytosis cannot be considered as 
the complete explanation for the diminished oxidase activity 
observed in colchicine or VBL-treated granulocytes. Alternative 
approaches to understanding this finding are discussed below, with 
reference to the experiments of Jandl et al (1978). 
In addition to the experiments with colchicine and 
VBL, studies with cyto B were also presented in this section of 
the thesis. The majority of investigators find (in agreement 
with the results presented herein) that treatment of phagocytic 
granulocytes with cyto B gives an enhancement in oxidase activity 
(see Tables 5.3 and 5.8). The two dissenting reports are 
remarkable in that:- 
(i) one of these groups is not consistent in its findings. This 
group has found the usual enhancement in superoxide production 
from cyto B-treated phagocytic granulocytes (Goldstein, Roos 
et al, 1975; Roos, Goldstein et al, 1976), as well as an 
absence of effect with cyto B (Roos, Homan-Maller and Weening, 
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1976). Examination of the latter report indicates that insufficient 
cytochrome C was present in their assay to detect the release of 
superoxide. For example, Fig. 4 from their paper shows •that a 
doubling of the cytochrome C concentration leads to the detection 
of enhanced superoxide release from cyto B-treated versus control 
granulocytes. Therefore, this group has not provided any strong 
evidence against the usual findings. 
(ii) the report from Zabucchi et al (1978) measured phagocytic 
oxidase activity via oxygen uptake, finding this to be inhibited 
by cyto B. Two other groups have also detected the same drop in 
oxygen uptake (Roos, Homan-Muller and Weening 1976; Root and 
Metcalf, 1977). However, these two groups simultaneously 
monitored superoxide production as well, and found it to be 
enhanced [see (i) above]. Thus it seems that oxygen uptake and 
superoxide production (specifically, cytochrome C reduction) 
cannot be considered equivalent methods for measuring the 
oxidase activity of granulocytes. Therefore, the report by 
Zabucchi et al (1978) does not provide firm proof that 
phagocytic oxidase activity is inhibited by cyto B. 
Some insight into the mechanism behind the observed 
stimulation in oxidase activity with cyto B is provided by the 
experiments of Jandl et a/(1978). They showed that (in the 
absence of cyto B) the superoxide-generating activity of 
phagocytic granulocytes declines with time, and they likened 
this phenomenon to a termination of the respiratory burst. 
Jandl et al suggested that the termination arose when a plasma 
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membrane oxidase 1 was degraded and inactivated by the act of 
phagocytosis. Furthermore, they found that phagocytosis was 
impaired by cyto B and therefore suggested that in cyto B-
treated granulocytes the oxidase was not internalized with 
subsequent termination of its activity. 
It is relevant at this point to discuss the problems 
of studying oxidase activity from cyto B-treated, intact, 
phagocytic granulocytes. As shown in Table 5.1, the experiments 
in this thesis indicate that cyto B markedly but not completely 
inhibits phagocytosis of polystyrene latex beads. It was 
initially thought that the remnant phagocytosis detected 
spectrophotometrically in such cells was artefactual - a reflection 
of beads binding to the cell surface. Although scanning electron 
microscopy confirmed that bead adherence to cyto B-treated cells 
was occurring (Fig. 5.5), transmission electron microscopy showed 
that some beads were indeed ingested (see section 9.3). Many 
other investigators have also reported that granulocytes treated 
with cyto B show a marked impairment in phagocytosis, and that 
this is a result of the disruption of microfilaments by this drug 
(see Reaven and Axline, 1973; Boxer et al, 1974; Stossel, 1977; 
and Appendix IV). A residual phagocytic activity has been found 
even when very high doses of cyto B were employed, and is 
hypothesized to occur through a microfilament-independent process 
(Zigmond and Hirsch, 1972). 
As indicated in Table 5.9, some investigators 
argue that the impairment of phagocytosis by cyto B is absolute, 
2 Subsequent work by others lends support to their reasoning that 
a plasma membrane oxidase activity was being measured (see 
Appendix I). 
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while others (in accord with the results in this thesis) provide 
evidence that the inhibition is only partial. To add to the 
disagreement one report maintains that cyto B can inhibit or 
stimulate phagocytosis of the same micro-organism, depending 
upon the dose used (Cannarozzi and Malawista, 1973). It is 
very difficult to reconcile these divergent results, especially 
when a difference of opinion exists despite the use of the same 
particle (see Table 5.9). Interestingly, whether or not a 
complete inhibition of phagocytosis was reported, almost all 
investigators have reported that cyto B-treated granulocytes 
show many adherent and incompletely ingested particles on the 
cell surface. These granulocytes have been found to release 
enhanced amounts of superoxide (discussed above) as well as 
lysosomal enzymes into the external medium and have therefore 
been called 'secretory' cells (Weissmann et al, 1973). This 
term has been used because the granulocytes respond to the 
adherent particles by mobilizing the cytoplasmic granules, 
which fuse with the plasma membrane underneath the particle. 
In effect these regions of the plasma membrane subtending 
the adherent particles can be thought of as false (incompletely 
internalized) phagosomal membranes. With granule fusion, the 
lysosomal enzymes are extruded from the cell and are therefore 
detectable in the external medium (see for example Henson, 
1972; Weissmann et al, 1973; Zurier, Hoffstein and Weissmann 
1973 a,b; Hawkins 1973; Zurier et al, 1974; Hoffstein et al 
1974 and Henson and Oades, 1975). It has been stated by one 
group of investigators in particular that granulocytes rendered 
secretory by cyto B are completely unable to ingest the particles 
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used as a stimulus for secretion (Zurier, Hoffstein and Weissmann, 
1973a,b; Goldstein, Roos, Kaplan and Weissmann, 1975; Roos, 
II 
Goldstein, Kaplan and Weissmann, 1976; Roos, Homan-Muller and 
Weening, 1976). On this basis, Roos, Homan-Muller and Weening 
(1976) refer to the superoxide release as coming from a plasma 
membrane oxidase which is stimulated by continual contact with 
the particles without subsequent phagocytosis. However, it is 
incorrect on their part to conclude that the superoxide originates 
only from a plasma membrane oxidase in these cyto B-treated 
granulocytes, for two reasons:- 
(i) these granulocytes have been shown able to ingest particles 
to some extent (see Table 5.9), and 
(ii) in these cells the granules fuse with the plasma membrane 
underneath adherent particles. 
By both of these processes, some of the superoxide released would 
have to be accredited to a granule-located oxidase (see Appendix 
I). Thus in studying the oxidase activity of cyto B-treated 
granulocytes, the presence of particles makes it impossible to 
state that the detected superoxide comes only from the plasma 
membrane. In contrast, non-phagocytic granulocytes do not 
appear to present the same problem, as granule fusion with the 
plasma membrane does not occur in cyto B-treated granulocytes 
in the absence of particles (Henson, 1971 a,b; Henson, 1972; 
Zurier, Hoffstein and Weissmann, 1973b; Henson and Oades, 1975). 
For this reason the mechanisms behind the release of superoxide 
from the plasma membrane are more easily studied and interpreted 
when non-phagocytic granulocytes are employed. 
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5.5 	SUMMARY 
In this section of the thesis the results of experiments 
on phagocytic granulocytes are presented. These experiments were 
undertaken in an attempt to uncover the mechanism behind the 
observed changes in oxidase activity brought about by the treatment 
of non-phagocytic granulocytes with microtubule and microfilament-
disrupting agents (see section 4.4). 
It was found that agents known to disrupt microtubules 
(colch, VBL) or microfilaments (cyto B) were able to markedly 
impair phagocytosis of polystyrene latex beads. Cytochalasin B 
was the most potent in this regard. Treatment of granulocytes 
with cyto B also resulted in the phenomenon of beads adhering to 
the surface of the granulocytes without being ingested, although 
some beads were fully internalized. 
NBT reduction (as a guage of oxidase activity) was also 
examined in phagocytic granulocytes exposed to these agents. 
Granulocytes incubated with cyto B while phagocytosing showed 
enhanced oxidase activity when compared to untreated phagocytic 
cells. In contrast, VBL and colch exposure resulted in an 
inhibition in NBT reduction from phagocytic granulocytes. 
Several groups of investigators have also observed these opposite 
results. As the microtubule and microfilament-disrupting agents 
gave a similar inhibition in phagocytosis yet opposite results 
in tests of oxidase activity, it is apparent that oxidase activity 
and phagocytosis are not linked in granulocytes. This point 
has also been made by others. It is therefore evident that the 
decrease in phagocytosis can provide some (but not all) of the 
explanation for the drop in NBT reduction seen in colch or 
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VBL-treated granulocytes. However, an interpretation of the 
results of the experiments with cyto B is much more difficult. 
For example, other investigators have provided evidence that the 
cytoplasmic granules fuse with the plasma membrane subtending 
particles adhering to the surface of cyto B-treated granulocytes. 
Therefore it is likely that the superoxide present in the 
external medium surrounding such cells (and thus the enhanced 
oxidase activity detected herein by NBT reduction) could have 
arisen from a granule oxidase. In conclusion it is evident that 
in studies of phagocytic granulocytes it cannot be concluded 
that the superoxide released is from the plasma membrane oxidase 
alone. For.this reason it seems that such studies are not as 
useful as experiments on non-phagocytic granulocytes when 
attempting to examine the role of microtubules and microfilaments 
in controlling the activity of a plasma membrane oxidase. 
FIG. 5.1 Scanning electron micrograph of a glass-adherent 
(top) 	granulocyte. The surface of the cell is relatively 
smooth, with two rounded projections (asterisks) 
which probably delineate underlying nuclear lobes. 
Magnification 7,500 x. 
FIG. 5.2 A granulocyte migrating on glass. The leading 
(bottom) 	lamellipodium (right) and rounded cell body 
regions are clearly seen. This cell also dis-
plays a relatively smooth surface profile. 
Magnification 10,400 x. 

FIG. 5.3 A granulocyte which has been incubated 5 min with 
cytochalasin B. In contrast to the granulocyte 
cell surfaces in Figs. 5.1 and 5.2, the surface 
membrane of this cell is markedly ruffled. 
Long and short villous projections from the 
granulocyte cell surface can be seen. 
Magnification 5,900 x. 

FIG. 5.4 A granulocyte which has been exposed to polystyrene 
(top) 	latex beads. As in Fig. 5.1, a rounded region which 
probably represents a nuclear lobe can be seen at 
'A'. The smaller round surfaces (asterisks) are the 
size of the latex beads (cf. Fig. 5.5). These four 
beads appear to be internalized, as a thin covering 
membrane can be seen to surround them. 
Magnification 11,700 x. 
FIG. 5.5 A granulocyte which has been treated with cytochalasin 
(bottom) 	B and exposed to polystyrene latex beads. Many beads 
are adherent to the cell surface. One bead is 
attached to the surface of the cell by a stalk-like (4) 
projection. Magnification 11,300 x. 

TABLE 5.1 	Phagocytosis by drug-treated granulocytes  
Treatment 	 OD at 259 nm (polystyrene) 
Drugs - cytochalasin B 	 0.041±0.006 
colchicine 0.068±0.004 
vinblastine 	 0.058±0.002 
Controls - no treatment 0.0911- 0.005 
- lumicolchicine 	 0.092±0.007 
- DMSO 0.25% v/v 0.093±0.006 
OD values shown are the R ± SEM of 6 determinations (3 experiments 
performed in duplicate), representing the polystyrene content of 
the granulocytes. All of the drugs produced a significant depression 
in phagocytosis with p <.01 compared to the untreated control. 
* DMSO content of cyto B-treated monolayers. 
TABLE 5.2 	Protein content of treated granulocyte monolayers  
Group 	Treatment 	OD at 540 nm (protein) 
1 	cytochalasin B 0.032t0.002 
colchicine 	 0.036±0.002 
vinblastine 0.031±0.004 
2 	phagocytosis of polystyrene 	0.035±0.005 
beads 
3 	cytochalasin B/phagocytosis 	0.034±0.004 
colchicine/phagocytosis 0.033±0.002 
vinblastine/phagocytosis 	0.039±0.007 
4 	control - no treatment 0.034±0.004 
OD values shown are the X ± SEM of 4 determinations (2 experi-
ments in duplicate), representing the protein content of 
granulocyte monolayers. Monolayers for groups 1 and 4 were 
exposed to the drugs at 1 pM (or no drug in the case of the 
control) for 40 min (section 5.2.3). Group 2 monolayers were 
incubated with polystyrene beads for 30 min (section 5.2.3). 
Group 3 were exposed to the drugs at 1 pM while ingesting beads, 
for 30 min (section 5.2.5). 
TABLE 5.3 	NBT reduction by cyto B-treated phagocytic granulocytes  
Incubation Time 
5 min 20 min 
0.103±.008 0.097±.004 
0.105±.004 0.102±.008 
0.136±.008 0.171±.008 
0.131±.005 0.168±.007 
0.167±.004 0.198±.009 
Treatment 
1. control - no treatment 
2. DMSO 0.25% v/v 
3. phagocytosis of beads 
4. phagocytosis/DMSO 0.25% v/v 
5. phagocytosis/cyto B 
Values given are OD (of NBT,at 515 nm/1.3x10 6 granulocytes/5 min, 
and are the R ± SEM of 9 determinations (3 experiments in triplicate). 
All treatments (except for DMSO 0.25%) resulted in significantly 
enhanced NBT reduction (p <.01 for each treatment when compared with 
its 5 or 20 min control). In addition, granulocytes exposed to 
cyto B while phagocytosing (line 5) showed a significant stimulation in 
NBT reduction when compared with phagocytosing granulocytes (line 3). 
For both 5 and 20 mm treatments in these cases, the probability was 
also <.01. 
* DMSO content of monolayers exposed to 1 1.114 cytochalasin B. 
TABLE 5.4 	NBT reduction by colchicine-treated phagocytic granulocytes  
Incubation Time 
5 min 20 min 
0.092±.006 0.096±.003 
0.094±.003 0.091±-008 
0.142±.005 0.182±.006 
0.148±.003 0.178±.004 
0.122±.004 0.110±.003 
Treatment 
1. control (no treatment) 
2. lumicolchicine 
3. phagocytosis of beads 
4. phagocytosis/lumicolchicine 
5. phagocytosis/colchicine 
Values given are OD (of NBT) at 515 nm/1.3x10 6 granulocytes/ 
5 min, and are the X ± SEM of 9 determinations (3 experiments 
in triplicate). All treatments (except for lumicolchicine) 
resulted in significantly enhanced NBT reduction (ID <.01 for 
each treatment when compared with the appropriate 5 or 20 min 
control). However, granulocytes exposed to colchicine while 
phagocytosing (line 5) showed a significant depression in 
reduction when compared with phagocytosing granulocytes (line 3). 
For both 5 and 20 min treatments in these cases, p <.01. 
TABLE 5.5 	NBT reduction by VBL-treated phagocytic granulocytes  
Treatment Incubation Time 5 min 	20 min 
1. control (no treatment) 0.098±.004 0.102±.004 
2. phagocytosis of beads 0.137±.008 0.190±.007 
3. phagocytosis/VBL 0.113±.005 0.116±.003 
Values given are OD (of NBT) at 515 nm/1.3x106 
granulocytes/5 min, and are the R ± SEM of 6 
determinations (2 experiments in triplicate). All 
treatments resulted in significantly enhanced NBT 
reduction Op <.01 for each treatment when compared 
with its 5 or20 min control). However, granulocytes 
exposed to VBL while phagocytosing beads (line 3) 
showed a significant drop in NBT reduction when 
compared with phagocytosing granulocytes (line 2). 
The drop in both cases had a probability <.01. 
TABLE 5.6 	Phagocytosis by colch or VBL-treated granulocytes * 
Phagocytosable particle 	Slight or no inhibition 	Inhibition 
of phagocytosis by drugs 	of phago- 
cytosis by 
drugs 
polyvinyltoluene beads 
polystyrene beads 
Ukena and Berlin (1972) 	Lehrer (1973) 
Lehrer (1973), 
and this thesis 
(Table 5.1) 
heat killed yeast 	Penny et al (1966) 
zymosan 	 Weissmann, 
Dukor and 
Zurier (1971) 
C. albicans 	 Lehrer (1973) 
starch seeds of Chang (1975) 
Saponaria vaccaria 
paraffin oil emulsion 	Oliver, Ukena and Berlin 	Stossel et a/ 
containing Oil Red 0 (1974) 	 (1972) 
Staph.albus 	Malawista and Bodel (1967) 
Staph. aureus 502A 
Streptococcus 
uric acid crystals 
monosodium urate 
crystals 
sodium orotate crystals 
Malawista (1971), 
Lehrer (1973) 
Malawista and Bodel (1967) 
Goldfinger, 
Howell and 
Seegmiller 
(1965) 
Malawista and 
Seegmiller 
(1965) 
Malawista and 
Seegmiller 
(1965) 
* see section 5.4 
TABLE 5.7 	Oxidase activity of phagocytic granulocytes 
exposed to colch or VBL 
Procedure for assay- Phagocytosable No effect Decrease in activity 
ing oxidase activity particle from 	drugs from drugs 
02 uptake E. mycoides Zabucci et al (1978) 
02 uptake C. albicans Lehrer (1973) 
cytochrome C reduction E. 	ooli C. Curnutte and Babior (1975) 
02 uptake S. aureus 502A Malawista (1971), and 
02  uptake 
02 uptake 
02 uptake 
NBT reduction 
(spectrophotometric) 
NBT reduction 
(histochemical) 
Staph. albus 
polyvinyltoluene beads 
polystyrene beads 
polystyrene beads 
freeze-dried bacterial 
extract (Sigma Code 
840 -15) 
Lehrer (1973) 
Malawista and Bodel (1967) 
Lehrer (1973) 
Lehrer (1973) 
this thesis (Tables 5.4 
and 5.5) 
Toso, Chilosi and Antoci 
(1978) 
see section 5.4 
TABLE 5.8 	Oxidase activity of phagocytic granulocytes  
exposed to cyto B* 
Procedure for assay- 
ing oxidase activity 
Phagocytosable 
particle 
Depression or no 
effect from cyto B 
Stimulation from 
cyto B 
cytochrome C reduction 
02 uptake 
NBT reduction 
(spectrophotometric) 
cytochrome C reduction 
cytochrome C reduction 
cytochrome C reduction 
02 uptake 
02 uptake 
02 uptake 
cytochrome d reduction 
02 uptake 
02 uptake 
E. coli C 
latex beads 
polystyrene beads 
opsonized zymosan 
opsonized zymosan 
opsonized zymosan 
opsonized zymosan 
opsonized zymosan 
Staph. aureus 502A 
Staph. aureus 502A 
B. mycoides 
paraffin oil emulsion 
containing Oil Red 0 
Zabucchi et al (1978) 
Roos, Homan-Muller and 
Weening (1976) 
Jandl et a/ (1978) (see text) 
Roos, Homan-Milner and 
Weening (1976) 
Zabucchi et al (1978) 
Root and Metcalf (1977) 
Zabucchi et al (1978) 
Zabucchi et a/ (1978) 
Curnutte and Babior (1975) 
this thesis (Table 5.3) 
Goldstein, Roos, Kaplan 
and Weissman (1975), 
Roos, .Goldstein, Kaplan 
and Weissmann (1976), and 
Jandl et al (1978) (see text) 
Roos, Homan-Milller and 
Weening (1976)• (see text) 
Root and Metcalf (1977) 
see section 5.4 
TABLE 5.9 (continued) 
Phagocytosable particle 	Inhibition of phagocytosis by cyto B 	Incomplete inhibition of 
phagocytosis by cyto B 
Staph. aureus 502A Malawista, Gee and Bensch 
(1971) 
Zigmond and Hirsch (1972) 
Cannarozzi and Malawista 
(1973) (see text) 
Root and Metcalf (1977) 
Staph. aureus 209? 	 Okuda et al (1976) 
Staph. albus 'air' Zigmond and Hirsch (1972) 
E. coli K38 	 Zigmond and Hirsch (1972) 
E. coli Davies et a/** (1973) 
Latex beads Zigmond and Hirsch (1972), and 
this thesis (Table 5.1) 
S. typhimurium RIA 	 Zigmond and Hirsch (1972) 
see section 5.4 	** These authors do not state that the inhibition was incomplete, 
but their data points strongly in that direction. 
TABLE 5.9 	Phagocytosis by cyto B-treated granulocytes  
Phagocytosable particle 	Inhibition of phagocytosis by cyto B 	Incomplete inhibition of 
phagocytosis by cyto B 
zymosan 
opsonized zymosan 
starch granules from 
sweet potatoes 
starch particles from 
Saponaria vaccaria 
monosodium urate crystals 
B. mycoides 
Zurier, Hoffstein and Weissmann (1973 
a,b) 
Goldstein, Roos, Kaplan and Weissmann 
(1975) 
Roos, Homan-Muller and Weening (1976) 
Roos, Goldstein, Kaplan and Weissmann 
(1976) 
Zigmond and Hirsch (1972) 
Skosey et al (1974) 
Jandl et al (1978) 
Tou and Stjernholm (1975) 
Cannarozzi and Malawista (1973) 
(see text) 
Spillberg, Gallacher and 
Mendell (1975) 
Zabucchi et al (1978) 
SECTION 6 
ASSAY OF THE PRESENCE OR ABSENCE OF 
MICROTUBULES IN DRUG-TREATED GRANULOCYTES 
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6.1 	INTRODUCTION  
Concanavalin A (con A) is a plant lectin which binds 
to most plasma membrane glycoproteins bearing a-mannopyranosyl 
molecules (Hunt and Marchalonis, 1974). Consequently there are 
many different con A receptors on the cell surface (Allan, 
Auger and Crumpton, 1972; Henkart and Fisher, 1975), and these 
are heterogeneous with respect to their affinity for the lectin 
(Allan, Auger and Crumpton, 1972; Cuatrecasas, 1973). 
Fluorescently labelled con A (con A-FITC) has been 
used by many investigators to study the surface distribution of con 
A binding sites. By incubating cells with con A-FITC and then 
examining them under ultraviolet light, it has been shown that 
the binding sites for the lectin are randomly distributed on most 
cell types •(reviewed by Schreiner and Unanue, 1976) including 
granulocytes (Oliver, Zurier and Berlin, 1975; Oliver and Zurier, 
1976; Oliver, 1976 a,b). With the passage of time the randomly 
distributed bound con A induces its own surface redistribution 
into caps (or single aggregates) localized to one end or pole of 
the cell (Oliver, Zurier and Berlin, 1975). Similarly, bound con 
A moves into a cap when cytoplasmic microtubules are disrupted by 
colchicine or other anti-mitotic agents. This phenomenon has 
been observed in many cell types (reviewed by Nicolson, 1976; 
Schreiner and Unanue, 1976), including mouse and human 
granulocytes (Oliver, Zurier and Berlin, 1975; Oliver and Zurier, 
1976; Oliver, 1976 a,b) and leukaemic granulocyte precursors 
(Lotem, Vlodavsk Y and Sachs, 1976). 
Oliver and her colleagues have taken advantage of this 
observation in designing an assay for the presence or absence 
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of microtubules in granulocytes (reviewed in Oliver, 1976 a,b). 
The assay involves labelling the con A-binding sites on the plasma 
membrane with con A-FITC and then examining the surface distribu-
tion of the bound con A by fluorescence microscopy. As detailed 
by these authors, a marked increase in the proportion of 
granulocytes which show a capped pattern of fluorescence provides 
evidence that microtubules have been disrupted (reviewed in 
Oliver, 1976 a,b). 
The aim of the experiments presented herein was to use 
the assay of Oliver and her colleagues to determine if cytoplasmic 
microtubules are disrupted by drug treatment of the granulocytes 
using the experimental conditions described in section 4.2 of 
the thesis. Treatment of the granulocytes with the agents in 
question (the microtubule-disrupting agents colchicine, VBL and 
VCR) produced significant changes in the rate of NBT reduction 
from the plasma membrane, and it was proposed that this effect 
was mediated by microtubule disruption (section 4.4). Therefore 
the experiments described in this section of the thesis were 
designed to determine if microtubules were indeed disrupted by 
these agents. 
6.2 	METFODS 
The assay for the presence or absence of microtubules 
in granulocytes (using con A-FITC) was taken from Oliver, 
Albertini and Berlin (1976). The experiments presented herein 
were comparable to those presented in section 4.2 with respect 
to the doses and incubation times with the microtubule-
disrupting agents, colch, VBL and VCR. 
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6.2.1 	The assay for con A receptor redistribution  
Monolayers of granulocytes were prepared on glass 
coverslips by adding 10 pl of the granulocyte suspension (= 
2.5 x 105 cells; isolated as described in section 2.2.13) to 
50 pl of CMFH, and incubating at 37°C for 5 min. Then 50 pl 
of HSS (at 37°C) with or without drugs (section 6.2.3) was 
added to the monolayer and the granulocytes incubated 5 min. 
After this time 100 pl of con A-FITC at 20 pg/ml in CMFH at 37 °C 
(section 6.2.4) was added and the monolayers incubated for 
fixed time periods of 2, 5 or 10 min. The final drug and con 
A-FITC concentrations for these experiments were 1 gm and 
10 pg/ml, respectively. [The drugs were not removed during this 
incubation with the fluorescent lectin and therefore the 
concentrations reported refer to the concentrations present at 
the time of incubation with con A-FITC. This experimental 
procedure was also followed by Oliver, Albertini and Berlin (1976).] 
The incubations were terminated by repeated and vigorous rinsing 
of the monolayers in several changes of CMFH (at 4 °C) containing 
sodium azide (0.1% w/v) to reduce pinocytosis of the con A-FITC 
(Preud'homme and Labaume, 1976) 1 . 
The monolayers were then air-dried, fixed in absolute 
ethanol for 5 min and dried again. The coverslips were inverted 
and mounted in 1:1 phosphate-buffered saline :glycerol (section 
1At this stage, representative monolayers were used for post-
incubation viability determinations using Eosin Y. 
6.2.5), and then sealed with nail varnish (Preud'homme and 
Labaume, 1976). Monolayers prepared in this fashion were examined 
in a Leitz Orthoplan fluorescence microscope with Ploemopak 2 for 
incident light illumination. The surface distribution of the 
bound lectin was scored as described in section 6.2.2. 
	
6.2.2 	Scoring the surface distribution of the bound con A-FITC  
The percentage of granulocytes showing a random, patched 
or capped distribution of fluorescence was determined. As defined 
by Oliver, Zurier and Berlin (1975), capped cells exhibited either 
a polar shell of fluorescence or a more concentrated knob or pro-
trusion on the membrane; patched cells showed small clumped 
aggregates which were often perinuclear; and random cells were 
diffusely (= uniformly) labelled by the fluorescent con A. 
The distribution of fluorescence was observed on at 
least 100 cells in any One experimental group. All tests were 
performed in duplicate, and the entire experiment was conducted 
twice. 
6.2.3 	Preparation of the drugs in HSS  
The drugs were prepared at 4 um in HSS to provide a 
final drug concentration of 1 4M during incubation with con 
A-FITC (section 6.2.1). To prepare the drugs in HSS the 
following dilution procedure was employed:- 
2 Filter block 1 21 exciting filter BP 450-490, beam splitting 
mirror RIG 510 (for blue excitation), and suppression filter 
LP 515. 
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stock solution of drug in HSS = 1 mM = 1000 0 = (a) 
0.1 ml (a) + 0.9 ml HSS = 100 pM = (b) 
0.1 ml (b) + 0.9 ml HSS = 10 pM = (c) 
0.1 ml (c) + 2.4 ml HSS 4 4M = (d) 
Dilution (d) was used in the experiments. Parallel 
(control) experiments were performed using drug-free HSS. 
	
6.2.4 	Fluorescently labelled concanavalin A  
Fluorescein isothiocyanate labelled con A (con A-FITC) 
with a fluorescein/protein ratio of 1.1 was used to prepare a 
stock solution of 6.0 mg/ml in CMFH. Aliquots (100 pl) of this 
solution were stored at -20°C. To obtain the dilution required 
for experiments (20 pg/ml), the following procedure was followed:- 
stock solution of 6.0 mg/ml = (a) 
0.1 ml (a) + 0.9 ml CMFH = 0.6 mg/ml = (b) 
1.0 ml (b) + 4.0 ml CMFH = 0.12 mg/ml = (c) 
1.0 ml (c) + 5.0 ml CMFH = 0.02 mg/ml = (d) 
Dilution (d) was used in the procedure described above 
(section 6.2.1), giving a final con A-FITC concentration of 
10 pg/ml during the incubation. 
6.2.5 	Preparation of phosphate-buffered saline:glycerol  
The phosphate-buffered saline (PBS) of Dulbecco and 
Vogt (1954) was used for these experiments, and contained (per 
litre):- 
8.0 g NaCl 
0.2 g KC1 
1.15 g disodium hydrogen phosphate 
0.2 g potassium dihydrogen phosphate, to a pH of 7.3 
The PBS:glycerine for mounting of coverslips 
contained 1 volume of PBS to 1 volume of glycerol. 
6.3 	RESULTS 
	
6.3.1 	Post-incubation viability  
As assessed by Eosin Y staining, the post-incubation 
viability of con A-FITC labelled, drug-treated granulocytes was 
93%, whereas control (untreated) granulocytes were > 95% viable. 
The differences in viability between treated and untreated 
granulocyte monolayers were not statistically significant. 
6.3.2 	The surface distribution of con A-FITC on drug-treated granulocytes  
Untreated granulocytes displayed a predominantly 
(> 80%) homogeneous or random distribution of fluorescence 
(Figure 6.1). As shown in Tables 6.1 - 6.3, incubation of 
granulocytes with any one of the three agents tested (colch, VBL 
or VCR, respectively) caused con A receptor translocation as 
indicated by the altered distribution of random, patched or 
capped cells when compared with the control. 
Very high percentages of granulocytes with a 
patched distribution of bound con A-FITC were observed in the 
drug-treated monolayers. For example, 65% of the cells were 
patched in the colchicine-treated, 10 min incubated group (Table 
6.1). In contrast, comparatively few patched granulocytes were 
seen (5%) in the control (untreated) group (Figures 6.2, 6.3 
and Tables 6.1 - 6.3). The percentage of capped cells (Fig 6.4) was 
markedly increased in the drug-treated versus control granulocyte 
preparations. By examining the data presented in Tables 6.1 - 
6.3, it can be seen that the three agents showed only minor 
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differences in their ability to induce con A receptor 
redistribution within the time periods studied. 
6.3.3 	Time course ofcon 'A receptor redistribution  
Translocation of the con A receptors was very 
rapid in the drug-treated (but not the untreated) monolayers, 
being evident within 2 min of incubation with con A-FITC. 
Redistribution was apparently complete within 5 min as very 
little further change was observed at 10 min (Tables 6.1 - 6.3). 
As the time course of redistribution was similar with all three 
agents, the data from experiments with colchicine were used to 
represent the sequential change in fluorescence distribution 
(with time) as a bar graph (Figure 6.5). 
6.4 	DISCUSSION 
In agreement with Oliver, Zurier and Berlin (1975), 
Oliver (1976 a,b), and Oliver and Zurier (1976), it was observed 
that concanavalin A receptors are found in a predominantly random 
or homogeneous distribution on the granulocyte cell surface. In 
contrast, granulocytes incubated with any one of the three agents 
tested (colch, VBL or VCR) displayed con A receptor translocation 
as indicated by the altered distribution of random, patched or 
capped cells. As shown by Oliver and her coworkers, such 
alterations in the surface distribution of the bound lectin signify 
that cytoplasmic microtubules are disrupted (Oliver, Albertini 
and Berlin, 1976). The dose employed (1 pM) and brief incubation 
periods used with these agents (2, 5 or 10 min) in these 
experiments with con A were comparable to the experimental con-
ditions used in section 4.2 of this thesis. In section 4.2, the 
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drugs in question (colch, VBL and VCR) produced significant 
changes in granulocyte plasma membrane NBT reduction. It was 
concluded that it was very likely that these changes were mediated 
via a drug-induced disruption of microtubules (section 4.4). As 
the correlative experiments on con A receptor redistribution pre-
sented herein indicate that microtUbules were indeed disrupted 
by these agents, this conclusion now seems valid. 
In studying the redistribution of bound con A, 
Oliver, Albertini and Berlin (1976) observed that the small 
surface aggregates characteristic of patched granulocytes were 
intracellular, presumably due to pinocytotic internalization of 
the lectin during labelling. From their observations on mouse 
and human granulocytes these authors suggested that development 
of the three observed patterns seemed to follow the sequence: 
random 	capped 	patched; or random 	patched directly 
(endocytosis without the intermediate capped stage). In 
lymphocytes the sequence is believed to proceed in the opposite 
manner, that is: random —Iø patched 3 	capped (reviewed by 
Nicolson, 1976). [Once capped, the bound lectin is eventually 
internalized through pinocytosis (reviewed by Schreiner and 
Unanue, 1976)]. An explanation for the different sequence in 
granulocytes and lymphocytes has not been offered by Oliver and 
her colleagues, but the fact that (compared to granulocytes) 
lymphocytes pinocytose con A very slowly (Loor, 1974; de Petris, 
1975) may have some bearing on the observed discrepancy. That 
3 It should also be pointed out that in lymphocytes the 
patching phenomenon is thought to be the result of a non-
energy dependent cross-linking of multivalent ligands (such 
as con A) on the surface of the cell (reviewed by Schreiner 
and Unanue, 1976). 
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the redistribution of receptors on the cell surface varies with 
different cell types has also been discussed by other investigators. 
For example, although most cell types including lymphocytes 
(Edelman, Yahara and Wang, 1973) are able to redistribute bound 
lectin into caps (reviewed by Oliver, Zurier and Berlin, 1975; 
Nicolson, 1976), some cell types like SV40-transformed fibro- 
blasts only do so in the presence of microtubule disruption 
(Rosenblith et al, 1973). These differences between cell types 
are not understood, but for the example cited, the fact that 
most fibroblasts have an extensive cytoplasmic microtubular 
system while lymphocytes do not may be relevant (reviewed by 
Nicolson, 1976). 
Using electron microscopy to count the number of 
cytoplasmic microtubules within a defined cellular area, it has 
been shown that the binding of con A to the granulocyte cell 
surface induces the assembly of microtUbules (Hoffstein et al, 
1976; Oliver, Albertini and Berlin, 1976; Oliver, 1976 a,b). 
It is thought that the bound con A becomes firmly anchored in 
the membrane by virtue of transmembrane connections between the 
lectin's receptor and microtubules underlying the plasma 
membrane. In fact it is believed that Con A induces these trans-
membrane connections (Edelman, Yahara and Wang, 1973; Oliver, 
Zurier and Berlin, 1976; reviewed by Nicolson, 1976, 1977). It 
is thought that by disrupting microtubules, colchicine frees the 
bound con A from these transmembrane connections with the micro-
tubules, and thus enhances the translocation of the lectin within 
the plane of the membrane. However, an alternative hypothesis• 
to explain the colchicine-induced enhancement in receptor 
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redistribution has been put forward by Edidin and Weiss (1972) 
and Unanue and Karnovsky (1974). These workers have suggested 
that cell or membrane movements are required to produce aggregates 
(such as caps) of ligand-receptor complexes. It is thought that 
con A binding immobilizes the cell (indeed, this has been demon-
strated in granulocytes by Ryan, Borysenko and Karnovsky, 1974), 
and that codchicine facilitates capping only by restoring cell 
movement. In this regard it has been shown that normal and 
leukaemic lymphocytes display enhanced cell movement (Jarvis, 
Snyderman and Cohen, 1976) as well as enhanced con A 
redistribution (reviewed by Schreiner and Unanue, 1976) after 
colchicine treatment. Unfortunately, agents known to enhance 
granulocyte cell movement do not concomitantly enhance con A 
capping (Oliver, Zurier and Berlin, 1975). 
Romeo and his coworkers have shown that the binding 
of con A to the granulocyte cell surface activated the cell, in 
a fashion akin to the post-phagocytic metabolic burst (reviewed 
by Romeo et al, 1975). Furthermore, they found that removal 
of the bound con A terminated or 'shut off' this activation. 
These workers interpreted this to mean that a plasma membrane 
switch or trigger for granulocyte activation is put in the 'off' 
position when the clustered con A receptors on the cell 
surface resume their normal homogeneous distribution upon 
removal of the lectin. 
With reference to their scheme, it seems there may 
be some support in vivo from studies of humans and mice afflic-
ted with the Chediak-Higashi syndrome. The granulocytes of 
affected mice or humans are able to ingest normally but then 
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they show a delay in degranulation and the release of lysosomal 
enzymes into the phagocytic vacuoles (Oliver, 1976 a, b; Boxer 
et al, 1976). Consequently the bactericidal ability of these 
granulocytes is compromised. Furthermore, the azuxophilic and 
specific granules in these cells aggregate or fuse during 
granulocyte maturation (Rausch, Pryzwansky and Spitznagel, 1978). 
It is thought that the abnormal fusion of the granules and the 
delay in degranulation both represent impaired microtubule 
function in these cells (Oliver, 1976 a, b; Rausch, Pryzwansky 
and Spitznagel, 1978). In addition, studies of the con A capping 
phenomenon in these granulocytes have demonstrated that the 
cells cap spontaneously with the binding of the lectin whereas 
control granulocytes cap as readily only when treated with 
colchicine (reviewed by Oliver, 1976 b). This finding further 
emphasizes that the defect is at a microtubular level (Oliver, 
Zurier and Berlin, 1975; Oliver, 1976 b). [Recently it was 
shown that by elevating the levels of cGMP (a manoeuvre which 
promotes microtubule assembly in Chediak-Higashi granulocytes), 
the abnormal degranulation and capping phenomena were restored 
to normal (reviewed by Oliver, 1976 b).] 
The abnormal clustering or redistribution of con A 
receptors on the cell surface may be related to the delay in 
degranulation, as both are microtubule-mediated events (Oliver 
1976 b; Boxer et al, 1977). That is, it seems reasonable to 
assume that surface receptors redistribute before a signal is 
conveyed (via the cytoskeleton) to the interior of the cell 
(reviewed by Nicolson, 1977). In granulocytes such signals could 
undoubtedly influence such events as the post-phagocytic 
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metabolic burst and degranulation 4 . Therefore if receptor 
redistribution is aberrant as in the Chediak-Higashi syndrome, it 
would not be uhusual to find that degranulation is also impaired. 
6.5 	SUMMARY 
In this section of the thesis the assay designed by 
Oliver and her colleagues was used to determine if treatment of 
granulocytes with uM doses of colchicine, VBL or VCR for brief 
periodsof time (< 10 min) resulted in the disruption of micro-
tubules. The assay involves examining the distribution of bound 
fluorescein-labelled concanavalin A (con A-FITC)on the granulo-
cyte cell surface by fluorescence microscopy (Oliver, Albertini 
and Berlin, 1976). Oliver and her coworkers have established that 
alterations in the surface distribution of the bound lectin 
signify that cytoplasmic microtubules are disrupted. 
In the experiments presented herein, it was observed 
that the fluorescence pattern of con A-FITC on the surface of 
untreated granulocytes was predominantly random or homogeneous, 
as other investigators have demonstrated (Oliver, Zurier and 
Berlin, 1975; Oliver, 1976 a,b; Oliver and Zurier, 1976). In 
contrast, granulocytes incubated with colchicine, VBL or VCR 
4 It is likely that signalling of the cell interior would require 
the participation of microfilaments as well as microtubules, 
because cell surface phenomena including the redistribution of 
bound ligands are known to be influenced by both cytoskeletal 
elements (Nicolson, 1976; Nicolson, 1977). Such a dual influence 
from both cytoskeletal elements appears to be established for 
granulocytes, as a representative experiment demonstrated that 
the colchicine-induced enhancement in con A capping was 
inhibited when cytochalasin B was present during the incubation 
(Ryan, Borysenko and Karnovsky, 1974). 
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displayed marked con A receptor translocation into patched 
or capped surface distributions, indicating that cytoplasmic 
microtubules were indeed disrupted by the drug treatments. 
FIG. 6.1 Granulocytes (untreated) showing a random 
(top) 	(homogeneous) distribution of Con A-FITC on the 
cell surface. These cells were stained with 
methyl green as a fluorescent counterstain 
(Schenk and Churukian, 1974) to demonstrate the 
nuclear lobes. Magnification 1,400 x. 
FIG. 6.2 Granulocytes (untreated) showing a patched distribution 
(middle) of Con A-FITC. The patchy labelling is localized to 
the perinuclear region in cells 'A' and 'B'. 
Magnification 2,500 x. 
FIG. 6.3 Granulocytes (untreated) displaying patched (A,C,D) 
(bottom) and capped (B) distributions of con A-FITC. 
Magnification 3,200 x. 

FIG. 6.4 	Granulocytes which have been incubated 5 min 
with colchicine (see text). Cells with a 
capped distribution of con A-FITC are indicated 
by the asterisks. A granulocyte with a random 
fluorescence pattern is seen at 'A' (bottom). 
Notice that the size of the cap is markedly 
different in the two granulocytes shown in the 
two photographs. Magnification (top and bottom) 
4,400 x. 
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TABLE 6.1 	The effect of colchicine treatment on con A-FITC receptor translocation  
Control 	Incubation time with con A-FITC 
Distribution 	 in the presence of colchicine  (untreated 
2 min 5 min 10 min 
capped 12 36 34 31 
patched 5 49 62 65 
random 83 15 5 4 
Numbers represent the percentage of granulocytes showing a random, patched 
or capped distribution of con A-FITC. The cells were exposed to colchicine 
at 11714 for 5 min and then incubated with con A-FITC (in the presence of the 
drug) for another 2, 5 or 10 min. At least 100 granulocytes were then 
counted (in each of 2 experiments) to determine the distributions given in 
this table. 
TABLE 6.2 	The effect of VBL treatment on con A-FITC receptor translocation  
Distribution Control 
(untreated) 
Incubation time with con A-FITC 
in the presence of VBL 
2 min 5 min 10 min 
capped 12 39 40 34 
patched 5 51 59 63 
random 83 10 1 3 
Numbers represent the percentage of granulocytes showing a random, 
patched or capped distribution of con A-FITC. The cells were exposed 
to VBL at 1 11M for 5 min and then incubated with con A-FITC (in the 
presence of the drug) for another 2, 5 or 10 min. At least 100 
granulocytes were then counted (in each of 2 experiments) to determine 
the distributions given in this table. 
TABLE 6.3 	The effect of VCR treatment on con A-FITC receptor redistribution  
Distribution Control (untreated) 
Incubation time with con A-FITC 
in the presence of VCR 
2 min 5 min 10 min 
capped 12 42 34 30 
patched 5 50 62 65 
random 83 8 4 5 
Numbers represent the percentages of granulocytes showing a random, patched 
or capped distribution of con A-FITC. The cells were exposed to VCR at 
1 pM for 5 min and then incubated with con A-FITC (in the presence of the 
drug) for another 2, 5 or 10 min. At least 100 granulocytes were then 
counted (in each of 2 experiments) to determine the distributions given 
in this table. 
SECTION 7 
EXPERIMENTS WITH THE FLUORESCENT MEMBRANE 
PROBE, ANS 
7.1 	INTRODUCTION 
1-anilino-8-naphthalene sulphonate (WS) is a 
chromophore which is not fluorescent in water (Stryer, 1965) 
but becomes fluorescent in hydrophobic environments, for 
example, when dissolved in organic solvents or associated with the 
non-polar regions of proteins (Stryer, 1965; Dodd and Radda, 1967; 
Edelman and McClure, 1968). ANS also interacts with biological 
membranes and presumably binds at specific chemical sites 
(possibly phospholipids) distributed throughout the thickness of 
the membrane (Azzi et al, 1969; Vanderkooi and Martonosi, 1969). 
The binding site is a relatively hydrophobic environment 
compared to the water phase outside the cell membrane (Azzi 
et a/, 1969) and therefore the binding of ANS to the membrane 
produces a fluorescent complex (Rubalcava et a/, 1969; Harris, 
1971; Vanderkooi and Martonosi, 1971). The changes in 
fluorescence of membrane-bound ANS are a reflection of the 
changes in the microenvironment of the chromophore (Stryer, 
1965). 
ANS has been used as a fluorescent probe to study 
(i) hydrophobic protein binding sites (Weber and Young, 
1964; Stryer, 1965) 
(ii) conformational states of proteins (Stryer, 1965; 
Dodd and Radda, 1967). 
(iii)the rates of allosteric transitions (Dodd and Radda, 
1968) 
(iv) the dynamic state of membranes, for example, skeletal 
muscle membrane preparations (Vanderkooi and 
Martonosi, 1969), mitochondrial membrane fractions 
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(Azzi et a/, 1969), and erythrocyte membranes 
(Freedman and Radda, 1969; Robak et al, 1975). 
It is thought that changes in ANS fluorescence occur 
when the polarity of its environment is altered, for example, 
by spatial re-arrangements of proteins or changes in the lipid-
protein interactions in the membrane (Azzi et al, 1969; 
Vanderkooi and Martonosi, 1969). Other changes in the micro-
environment such as in the pH or viscosity of the medium are 
apparently of lesser quantitative significance (Vanderkooi and 
Martonosi, 1969). It has been said that ANS is a better probe 
for membrane structure than electron spin or nuclear magnetic' 
resonance because it allows one to correlate the time course of 
the observed changes in membrane structure with the functional 
state of the membrane (Azzi et al, 1969). With mitochondria' 
membranes for example, a marked increase in fluorescence from 
the ANS-membrane complex was seen within seconds of the 
addition of substrates (succinate, ATP, NADH, 0 2 ), and these 
changes in fluorescence were related to but not synchronous with 
electron transport processes in the mitochondrial membranes 
(Azzi et a/, 1969). 
The aim of the studies presented in this section of 
the thesis was to investigate (by using ANS-labelled granulocytes) 
whether the drug-induced changes in plasma membrane oxidase 
activity were associated with a structural change in the plasma 
membrane. The results of the experiments on plasma membrane 
oxidase activity (Section 4) suggested the possibility that 
the drugs in question influence oxidase activity by acting 
directly on the plasma membrane rather than on microtubules 
and microfilaments. 
7.2 	METHODS 
The methods outlined below were taken from Romeo, 
Cramer, and Rossi (1970) and Robak et al (1975). 
	
7.2.1 	Labelling of the granulocyte plasma membrane with ANS  
Granulocytes were isolated as described in section 
2.2.13, except that they were resuspended (after the final wash) 
at a concentration of 4.5 x 10 7 cells/ml in CMFH. The granulocytes 
were divided into two aliquots: those to be labelled with ANS 
and control (unlabelled) granulocytes. The viability of the 
granulocytes as assessed by Eosin Y dye exclusion was 98%. 
. To label the cells, excess ANS solutions (30 pM in 
HSS) was added to the granulocytes in a plastic conical test 
tube. The tube was then incubated for 5 min at 37 °C in a water 
bath. Unlabelled granulocytes were handled in parallel and 
incubated in HSS without added ANS. After labelling, the 
granulocytes were harvested by centrifugation, washed in CMFH 
at 4oC, and resuspended in CMFH at 4.5 x 10 7/ml. Post-labelling 
viability was 90%. 
7.2.2 	Fluorescence intensity of ANS-labelled granulocytes  
To compare the fluorescence intensity of labelled and 
unlabelled granulocytes, fluorimeter cuvettes of 900 pl capacity 
were filled with 70 pl CMFH at 37 °C. To the cuvette was then 
added 10 pl of labelled or unlabelled granulocytes (= 4.5 x 10 5 
cells) in CMFH at 37 °C. The contents of the cuvette were mixed 
with the microlitre pipette and the fluorescence intensity was 
measured with a Baird Atomic fluorimeter set at 380 nm 
(excitation) and 472 nm (fluorescence). The fluorescence intensity 
87 
88 
was recorded immediately after mixing and again after 5 and 10 
minutes incubation in the cuvette. 
The effect of varying the number of granulocytes added 
to the cuvette on the fluorescence intensity was also investigated. 
For these experiments 10 - 60 pl of granulocyte suspension 
(= 4•5 - 27.0 x 105 cells) were added to the cuvette and the 
procedure as outlined above was followed. 
7.2.3 	The fluorescence intensity of drug-treated granulocytes  
The experimental procedures used were comparable to 
those presented in Section 4 with respect to the doses and 
incubation times with the microtubule or microfilament-disrupting 
agents. 
The fluorimeter cuvettes were filled with 700 pl of 
CMFH at 37 °C and to this was added 10 pl of labelled granulocytes. 
The baseline fluorescence intensity was recorded immediately 
after the addition of the cells. Then 80 pl of the drug or 
control in CMFH at 37 oC was added to the cuvette and the contents 
mixed with the pipette. The final concentration of each 
particular drug was 1 pM at testing. The fluorescence intensity 
was recorded immediately after addition of the drug or control, 
and again after 5 or 10 min incubation. The drugs examined were 
cytochalasin B, VBL, VCR, colch and lumicolchicine (section 
4.2, Appendix IV). 
The control for experiments with cytochalasin B was 
DMSO in CMFH at a concentration of 0.11 % v/v at testing 
(section 7.2.5). 
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7.2.4 	Preparation of the drugs  
All drugs were dissolved in CMFH (except cyto B, which 
was dissolved in DMSO) at 1 mM. Successive dilutions of these 
1 mM stock solutions were made to give a 11 pM drug dilution 
which was added to the fluorimeter cuvettes. As the drug was 
diluted 10-fold by the contents of the cuvette the concentration 
pf each drug at testing was 1 4M. The dilution procedure was 
as follows:- 
stock solution of drug in CMFH = 	1 mM = (a) 
0.1 ml (a) + 2.9 ml CMFH 	. 	33 pM = (b) 
1.0 ml (b) + 2.0 ml CMFH 	. 	11 11/4 = (C) 
Dilution (c) was added to the fluorimeter cuvettes for tests. 
7.2.5 	Controls for the drug incubations 
As the stock solutions of colch, lumicolch, VBL, and 
VCR were prepared in CMFH the control for these drugs was CMFH 
without added drug. Cytochalasin B, in contrast, was prepared 
as a stock solution in DMSO and therefore successive dilutions 
of this solvent were made to obtain the appropriate control, as 
indicated below:- 
DMSO at 100 % v/v = control stock solution = 	(a) 
0.1 ml (a) + 2.9 ml CMFH = 3.3 % v/v DMS0 	= 	(b) 
1.0 ml (b) + 2.0 ml CMFH = 1.1 % v/v DMS0 	= 	(c) 
Dilution (c) was used as the control for cyto B incubations, 
and therefore at testing the final concentration of DMSO in 
these experiments was 1.1 % x 1/10 = 0.11 % v/v DMSO in CMFH. 
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7.2.6 	Experiments with phagocytic granulocytes  
These experiments were a repeat of the studies performed 
on guinea pig granulocytes by Romeo, Cramer, and Rossi (1970). 
The only modification from their experimental procedure was in 
the use of human rather than guinea pig granulocytes. 
To 700 pl of GMFH at 37°C in the fluorimeter cuvette 
was added 10 pl of labelled granulocytes (= 4.5 x 10 5 cells). 
The contents of the cuvette were mixed with the microlitre pipette 
and the fluorescence intensity was recorded immediately. To the 
cuvette was then added 10 pl of dialyzed polystyrene latex beads 
(0.79 pm mean diameter, prepared as described in section 5.2). 
The contents of the cuvette were again mixed and the fluorescence 
intensity recorded immediately, and after 5 and 10 min incubation 
with the beads. 
For control experiments the beads were added to 
unlabelled granulocytes, or to a solution of 33 pM INS in CMFH, 
or to CMFH at 37oC. The procedure followed was otherwise exactly 
as described above for labelled granulocytes. 
7.3 	RESULTS  
7.3.1 	Fluorescence intensity of ANS-labelled granulocytes  
As shown in Fig. 7.1, unlabelled granulocytes dis-
played some intrinsic fluorescence but this was considerably 
less than the fluorescence intensity of the ANS-labelled 
granulocytes. In both cases the number of granulocytes in the 
cuvette was 4.5 x 10 5 . 
The fluorescence intensity of the labelled granulocytes 
was stable for at least 10 min (Fig. 7.1), and was a linear 
function of the number of ANS-labelled granulocytes added to the 
fluorimeter cuvette (Fig. 7.2). 
7.3.2 	The fluorescence intensity of drug-treated granulocytes  
When the drugs (cyto B, colch, lumicolchicine, VBL, or 
VCR) were added to the cuvettes an immediate slight drop in the 
fluorescence intensity was observed (Fig. 7.3). No further change 
in the fluorescence intensity occurred with the passage of 5 or 
10 min time. 
The same immediate (slight) drop in fluorescence was 
seen when the drug-free controls (CMFH or DMSO, section 7.2.5) were 
added to the labelled granulocytes (Fig. 7.3). As with the drug- 
treated granulocytes, there was no further change in the 
fluorescence with the passage of time. 
7.3.3 	Experiments with phagocytic granulocytes  
As shown in Fig. 7.4, polystyrene latex beads (in 
CMFH or in a solution of ANS in CMFH) displayed some intrinsic 
fluorescence. When the beads were added to unlabelled granulocytes 
a slight rise in fluorescence was observed, but this increase was 
not of the magnitude of the increase in fluorescence seen when 
beads were added to labelled granulocytes (Fig. 7.4). The 
increase in fluorescence occurred within a few seconds of the 
addition of beads to labelled or unlabelled granulocytes, and 
then showed no further rise with the passage of 5 or 10 min time. 
7.4 	DISCUSSION 
• 1-anilino-8-naphthalene sulphonate (NS) is a 
chromophore which when bound to biological membranes becomes 
fluorescent (Rubalcava et al, 1969; Harris, 1971; Vanderkooi 
and Martonosi, 1971). It is a very useful probe for studying the 
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dynamic state of membranes because a change in the fluorescence 
intensity from the bound ANS indicates that an alteration in 
plasma membrane structure has occurred, usually through bio-
chemical or physical activity (Stryer, 1965; Azzi et a/, 1969; 
Vanderkooi and Martonosi, 1969; Rossi, Romeo and Patriarca, 1972). 
It has been shown for example, that membrane-active drugs can 
increase or decrease the fluorescence intensity of ANS-labelled 
human erythrocyte membranes (Wiethold et al, 1973; Robak et al, 
1975). With this in mind experiments designed to monitor the 
fluorescence intensity of drug-treated, ANS-labelled human 
granulocytes were undertaken and are presented herein. As the 
aim of this work was to investigate whether the drug-induced 
changes in plasma membrane oxidase activity (see Section 4) were 
associated with a structural change in the plasma membrane, the 
design of these experiments was made comparable to that presented 
in Section 4. 
The linear relationship between the fluorescence 
intensity and the number of granulocytes indicates that granulo-
cytes incubated with 30 pM ANS for 5 min at 37 °C were successfully 
labelled with ANS. The binding of ANS to the plasma membrane of 
granulocytes or lysed erythrocytes has been shown to occur very 
quickly, and is virtually complete by 5 min (Freedman and Radda, 
1969; Romeo, Cramer and Rossi, 1970). 
There was an immediate slight drop in the intensity of 
fluorescence when labelled granulocytes were exposed to any of 
the microtubule or microfilament-disrupting agents tested (colch, 
VBL, VCR or cyto B). However the same response was seen when 
the labelled granulocytes were incubated with the control 
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solutions (CMFH, DMSO or lumicolchicine). Therefore it was 
readily apparent that the immediate slight drop in fluorescence 
arose from adding the small volume of control - or drug-containing 
solution to the existing volume in the fluorimeter cuvette. 
After this initial change no further change in the fluorescence 
intensity was seen even when the incubation with any one agent or 
the appropriate control was continued for as long as 10 min. 
This finding indicated that a true change in the plasma membrane 
structure of drug-treated granulocytes had not occurred. 
As discussed in section 4.4, an incubation of 5 or 10 
min with any one microtubule or microfilament-disrupting agent 
was sufficient to induce a marked change in plasma membrane 
oxidase activity. Therefore it may be concluded from these 
correlative experiments with ANS-labelled granulocytes that the 
microfilament and microtubule-disrupting agents were not acting 
directly on the plasma membrane to induce a change in plasma 
membrane structure, which thereby influenced plasma membrane 
oxidase activity. Employing complementary experimental techniques, 
Schlessinger et al (1976), Alstiel and Landsberger (1977), and 
Edidin (1977) have also concluded that microfilament and 
microtubule-disrupting agents do not act directly upon the plasma 
membrane to bring about a response. 
In addition to the experiments with drug-treated 
granulocytes, the experiments of Romeo, Cramer and Rossi (1970), 
and Rossi, Romeo and Patriarca (1972) on ANS-labelled phagocytic 
guinea pig granulocytes were repeated, using human granulocytes. 
These authors hypothesized that the metabolic burst of phagocytos-
ing granulocytes (and in particular the enhanced activity of a 
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granule-associated NADPH oxidase) was regulated by an alteration 
of the granulocyte plasma membrane. This theory was based on 
their own experimental observations and the studies of several 
other groups of investigators (reviewed in Rossi, Romeo and 
Patriarca, 1972) which showed that:- 
(i) the increases in respiration and HMPS activity seen 
in phagocytosing granulocytes occur within a few 
seconds of contact with particles 
(ii) these increases in metabolic activity are accompanied 
by a precocious activation of a granule-associated 
oxidase 
(iii)the increases can only be seen when intact phagocytes 
are used, and 
(iv) phagocytosis is not necessary for these increased 
metabolic events, in that the increased metabolic 
events can be reproduced by agents (such as 
surfactants and antibodies) which act on the 
granulocyte cell membrane. 
To study whether an alteration in the cell membrane 
had occurred with phagocytosis Romeo, Cramer and Rossi (1970) 
conducted experiments With the fluorescent membrane probe, ANS. 
For their studies the plasma membrane of intact guinea pig 
granulocytes was labelled with ANS. Upon observing a dramatic 
and instantaneous increase in the fluorescence intensity 
of the ANS-granulocyte complex when granulocytes were presented 
with polystyrene latex beads, the authors suggested that a 
conformational change in the plasma membrane had taken place 
once the granulocytes had contacted the beads. 
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As shown in Fig. 7.4, their experimental observations 
with guinea pig granulocytes were confirmed in this laboratory, 
using human granulocytes. A dramatic increase in the fluorescence 
intensity of ANS-labelled human granulocytes occurred within 
seconds of contact with polystyrene latex beads. The magnitude 
of this increase in fluorescence was greater than that seen when 
the beads (which displayed some intrinsic fluorescence) were 
added to unlabelled granulocytes, a solution of ANS in CMFH, or 
CMFH alone. There was no further increase in the fluorescence 
intensity with the passage of time. A similar finding by Romeo, 
Cramer and Rossi (1970) led these workers to conclude that the 
observed change in fluorescence was due to the initial collision 
between granulocytes and beads and not phagocytosis per se. 
From such experimental observations these workers postulated a 
scheme wherein (i) contact between beads and the granulocyte 
plasma membrane produced a change in the membrane, and (ii) this 
change in the plasma membrane was followed by either release of 
an unidentified chemical mediator or direct communication between 
the plasma membrane and cytoplasmic granules, so that (iii) 
a signal was transmitted to the granule-bound NADPH oxidase, 
resulting in (iv) enhanced oxidase activity (H2 02 and NADP+ 
production) and thence HMPS activation (see Appendix I). 
It seems reasonable to re-evaluate their hypothetical 
scheme, taking into account the more recent papers showing that 
the cyanide-insensitive oxidase is not restricted to a granule 
location, but is found in the plasma membrane of granulocytes 
as well (Appendix I). With this in mind, the instantaneous 
enhancement in plasma membrane ANS fluorescence and oxidase 
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activity upon contact between beads and granulocytes (Romeo, 
Cramer and Rossi, 1970) may indicate that contact-induced changes 
in the structure of the plasma membrane directly stimulate plasma 
membrane oxidase rather than granule-associated oxidase activity. 
With respect to this point, it is interesting to note that these 
authors later emphasize that their granule fractions are probably 
contaminated with plasma membrane (Rossi, Romeo and Patriarca, 
1976). Hence it is not possible for these workers to ascribe 
their observed contact-induced increase in oxidase activity to a 
granule fraction-associated oxidase only. A similar problem 
arises when working with intact phagocytic granulocytes, in that it 
is very difficult to partition an observed change in oxidase 
activity into that which has come from either the plasma membrane 
or granule-associated oxidase (see section 5.4). 
7.5 	SUMMARY 
In this section of the thesis experiments with ANS- 
labelled granulocytes are described. ANS is a chromophore 
which, in binding to the plasma membrane of intact granulocytes 
becomes fluorescent. A change in the fluorescence intensity 
of this membrane-bound probe signifies that a change in the 
probe's microenvironment (presumably the structure of the membrane) 
has occurred. Therefore this chemical has been used by several 
groups of investigators to study the dynamic state of biological 
membranes after treatment with membrane-active drugs. 
In section 4.3 of this thesis it was found that 
treatment of granulocytes with microtubule or microfilament-
disrupting agents led to changes in the activity of the plasma 
membrane oxidase. The aim of the correlative experiments 
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presented herein was to determine if the microtuble or 
microfilament-disrupting drugs were acting directly on the 
plasma membrane to induce a change in the structure of the 
membrane (as measured by the fluorescence of ANS), which might 
then be responsible for the observed changes in oxidase activity. 
As no such drug-induced changes in plasma membrane structure 
(ANS fluorescence) were observed, it was concluded (in 
agreement with Schlessinger et al, 1976; Alstiel and 
Landsberger, 1977; and Edidin, 1977) that the microfilament and 
microtubule-disrupting agents do not act directly upon the 
plasma membrane to bring about a response. 
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FIG. 7.1. The fluorescence intensity of CMFH (baseline, at 'a'); 
unlabelled granulocytes (b) and ANS-labelled 
granulocytes (c). The pen recorder was allowed to 
run for 10 min, as indicated. 
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FIG. 7.2. The fluorescence intensity as a function of the 
number of ?NS-labelled granulocytes present in the 
cuvette. For this experiment 10-60 pl of cells were 
present (as indicated). The fluorescence intensity of 
10 pl (= 4.5 x 105 granulocytes) has arbitrarily been 
set at 10 units. 
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FIG. 7.3. The fluorescence intensity of drug-treated, ANS-labelled granulocytes. 
Where indicated by the small arrows, 80 pl of cyto B (a); colch (b); 
lumicolchicine (c); VBL (d) or VCR (e) was added to a fresh (control) 
cuvette. At (f) and (g), 80 pl of CMFH or DMSO in CMFH (respectively) 
was added to the cuvette. 
with 
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no 
granulocytes 
FIG. 7.4. The fluorescence intensity of drug-treated, un- 
labelled and ANS-labelled granulocytes. The 
additions (arrows) to the fresh (control) cuvettes were CMFH (a); 
CMFH + polystyrene latex beads (b); ANS (c); ANS + beads (d). 
On the right-hand side of the tracing the additions to fresh 
cuvettes were unlabelled granulocytes (e); unlabelled 
granulocytes + beads (f); labelled granulocytes (g) and labelled 
granulocytes + beads (h). By subtraction the changes in 
fluorescence intensity were:- 
(b) - (a) = 8 	(f) - (e) = 12 
(d) - (c) = 9 (h) - (g) = 38 
SECTION 
MICROFILAMENT AND MICROTUBULE DISRUPTION 
AND HMPS ACTIVITY 
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8.1 	INTRODUCTION 
The hexose monophosphate shunt (HMPS) is a metabolic 
pathway whereby glucose is oxidized to a five-carbon sugar 
(ribulose-5-phosphate) and CO 2 while NADP+ acts as an electron 
acceptor (Babior, 1978). The pathway is shown in Figure 8.1. 
In erythrocytes the HMPS serves to generate reducing 
equivalents (in the form of NADPH) which are used by the cell to 
protect both haemoglobin and the red cell membrane from oxidant 
stress (Lionetti, 1974; Desforges, 1976). It has not been 
established whether the HMPS in granulocytes has a similar role, 
that is, to generate 'protective' reducing power. However it has 
' been suggested that the formation of reducing equivalents (NADPH) 
coupled to the glutathione peroxidase - glutathione reductase 
system might protect the granulocyte's enzymes against inactivation 
by H2 02 (Little and O'Brien, 1968). This H 2 02 could come from 
the granulocyte itself (as excess 11202 generated above anti- 
microbial requirements) or from ingested micro-organisms 
(Klebanoff, 1968). 
As discussed in Section 1, phagocytic granulocytes 
display a metabolic burst characterized by a cyanide-insensitive 
increase in 0 2 uptake, the production of 0; and H 2 02 , and a 
cyanide-insensitive stimulation of HMPS activity, events which 
are crucial for oxygen-dependent killing by granulocytes. 
Phagocytosis activates a cyanide-insensitive NADH oxidase and/or 
a cyanide-insensitive NADPH oxidase, either of which is capable 
- of the 02 production. The activation of this 0 2 producing 
enzyme accounts for the observed increase in 0 2 uptake and the 
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stimulation of the HMPS ) . Normally only 10% of the granulocyte's 
glucose enters the HMPS (Beck, 1958), but with phagocytosis and 
the resultant NADP and GSSG production (Eggleston and Krebs, 
1974, Appendix I), a 7-fold increase in the glucose oxidized via 
the HMPS occurs (Sbarra and Karnovsky, 1959). 
The aim of the experiments described in this section 
was to examine HMPS activity in non-phagocytic granulccytes which 
had been exposed to cytochalasin B, colchicine, vinblastine (VBL) 
or vincristine (VCR). These drugs had been found to affect 
02 
- 
production in non-phagocytic granulocytes (Section 4), there- 
fore it was desirable to investigate whether or not this change in 
02 production was associated with any change in glucose oxidation 
via the HMPS. The effects of some of these drugs on non-
phagocytic granulocytes have been examined by other investigators, 
and their findings are discussed in section 8.4 along with the 
results of these experiments. 
8.2 	METHODS  
8.2.1 	Pooled human serum  
Venous blood (60 ml) was collected from six healthy 
volunteers and centrifuged for 15 min at room temperature at a 
force of 1500 x g. The plasma was then removed and allowed to 
clot. The resultant serum was pooled and stored in 2 ml 
aliquots at -70°C. 
1 This is the view held by the majority of workers, for example 
Baehner et al, (1970) and DeChatelet et al (1972b). However, 
some investigators believe that the increase in HMPS activity 
precedes oxidase activity, and hence superoxide production 
(Strauss et al, 1969). In this alternative scheme, phagocy-
tosis activates glutathione reductase and thence the HMPS, 
and these events are followed by the increase in oxygen 
uptake and oxidase activity (see also Appendix I). 
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8.2.2 	Phosphate buffer  
The buffer used in these experiments contained 
(in g/m1):- 
NaC1 8.0, MgC1 2 x 6H20 0.2, KC1 0.2, CaC1 2 
(fused) 0.11, Na2HPO4 1.15, and KH 2PO4 0.2, 
with a final pH of 7.4. 
8.2.3 	Colchicine, VBL, VCR, cytochalasin B, DMSO  
8.2.3.1 	Drug dilutions  
All drugs were prepared as a stock solution of 1 mM 
in water and then dilutions of this stock solution were used in 
the preparation of HSS. The only exception was cytochalasin B 
which was prepared as a stock solution in DMSO. However all 
subsequent dilutions of the drugs (including cytochalasin B) 
were made with water. Successive dilutions as outlined below 
were made to obtain concentrations of the drugs which, when 
used to prepare HSS, would result in a final drug concentration 
at testing of 1, 0.1, or 0.01 pM in HSS:- 
stock solution = 	1 mM (a) 
0.1 ml (a) + 2.9 ml water = 33 pM (b) 
0.1 ml (b) + 0.9 ml water = 3 pM (c) 
0.1 ml (c) + 0.9 ml water = 0.3 pM (d) 
To obtain HSS with 1 pM drug, 1 volume of (b) was 
used to replace 1 volume of the water used in preparing HSS 
(Appendix II). HSS containing drug at 0.1 pM and 0.01 pM were 
prepared in the same way, using drug dilutions (c) and (d) 
respectively. 
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8.2.3.2 Pre-incubation of granulocytes with the drugs  
Isolated granulocytes (2 x 10 6 cells in 100 pl CMFH) 
were incubated in 200 pl HSS with or without the drugs, for 5 or 
15 min at 37°C. These incubations were carried out in plastic 
tubes. The drug concentrations used for these incubations were 
1, 0.1 and 0.01 pM. The control for cytochalasin B-treated 
granulocytes was HSS with the appropriate DMSO content (section 
8.2.3.3.). The control for colchicine, VBL or VCR-treated cells 
was HSS. 
During the pre-incubations with the agents or controls, 
KCN was present at 1.5 mM. Experiments with granulocytes pre-
incubated in 3.0 mM KCN were also performed. 
After the 5 or 15 min pre-incubations, the granulocytes 
were washed and then resuspended in 100 pl CMFH for HMPS activity 
measurements (section 8.2.4). 
8.2.3.3 DMSO control for cytochalasin B-treated granulocytes  
Cytochalasin B was dissolved in DMSO at 1 mM to give 
stock solution (a) (section 8.2.341). Therefore in those experi-
ments where the effects of cytochalasin B were being studied, 
control HSS containing DMSO at the appropriate concentration had 
to be prepared. DMSO was used as the control stock solution, and 
using the dilution format outlined in section 8.2.3.1, the DMSO 
concentrations were:- 
100% v/v = (a) 
(a) x 1/30 = 3.3% v/v = (b) 
(b) x 1/10 = 0.33% v/v = (c) 
(c) x 1/10 = 0.03% v/v = (d) 
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Dilutions (b), (c) and (d) were then used in the 
preparation of control HSS for the cytochalasin B experiments. 
Following the method discussed in section 8.2.3.1, the final 
DMSO content (% v/v) during pre-incubation of the granulocytes 
was therefore:- 
for 1 pM cytochalasin B or its control ... 0.25% v/v DMSO 
for 0.1 pM 	II 	 ti 	 ... 0.03% v/v DMSO 
for 0.01 pM It 	 II 	 ... 0.003% v/v DMSO 
8.2.4 	HMPS activity assay  
The HMPS assay used in these experiments was that of 
Hosking, Fitzgerald and Shelton (1978). It is based on the prin- 
ciple aE•quantitating 14C-1-glucose oxidation to 14CO2' as 
discussed by Beck (1958), Sbarra and Karnovsky (1959), and Reed 
(1969). As indicated in the reaction below, for each molecule 
of 14CO2 evolved, one molecule of 
14C-1-glucose is oxidized via 
the HMPS:- 
+ 14 	 + 	14 2 NADP + C-1-glucose 	2 NADPH + 2 H + CO2 HMPS 
A universal container with two compartments and a 
screw-top with rubber plug, through which injections could be 
made, was used for the assay (Fig. 8.2). The smaller compartment 
contained the pre-incubated granulocytes (2 x 10 6 cells in 100 pl 
CMFH), 700 pl of buffer (8.2.2) containing 0.8 PCi of 14C-1-glucose, 
25 pl of pooled human serum (8.2.1), and an additional 100 pl of 
buffer to replace the phagocytosable stimulus normally used by 
Hosking et al. 
The larger compartment contained a mini-scintillation 
vial containing 0.4 ml Hyamine Hydroxide 10X. 
Once the granulocytes had been added, the universal 
container was capped and then incubated for 1 hour at 37 °C to allow 
glucose oxidation to take place. After this time 1 ml of 2M-HC1 
was injected through the rubber plug into the smaller compartment 
to arrest the glucose oxidation. The vials were left capped and 
allowed to stand at room temperature for one hour to ensure com-
plete absorption of the liberated 14CO2 by the Hyamine Hydroxide. 
After this time the mini-vial was removed and 5 ml of Packard liquid 
scintillation fluid was added. The vials were sealed with caps and 
counted in a Packard 2450 Tri-Carb liquid scintillation spectro-
meter to quantitate HMPS activity. 
8.2.5 	Quantitation of HMPS activity  
Activity is expressed as nmol glucose oxidized with 
the liberation of 14CO2 from the formula: 
glucose oxidized = cpm (drug treated) - cpm (control)  
(nmol) 	0.87 ( a ) x 2220 (b ) x 3 (c) 
where (a) = the counting efficiency of the beta 
scintillation counter (87%) 
(b) = cpm in one nanoCurie (Braestrup and Vikterlof, 
1974) . 
(c) = activity of the purchased 14C-1-glucose, i.e. 
3 nanoCurie/nanomole. 
and cpm = counts per minute. 
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8.3 	RESULTS 
8.3.1 	Pre-incubation with cytochalasin B  
Pre-incubation of non-phagocytic granulocytes for 5 
or 15 min.with cyto B in DMSO had no effect on HMPS activity 
(Table 8.1). Similarly the concentrations of DMSO present during 
these experiments had no significant effect on.HMPS activity (Table 
8.1). 
8.3.2 	Pre-incubations with VCR, VBL, or colchicine  
Some interesting results were seen when non-phagocytic 
granulocytes were pre-incubated with these agents. However, only 
one of these agents (VCR) produced statistically significant 
effects. After 5 min pre-incubation, VCR at 0.1 and 1.0 pM showed 
a significant stimulation in HMPS activity compared with the 
control (Table 8.2). By examining the results for both 5 and 15 
min pre-incubations with VCR it is apparent that the stimulation 
observed was dose-dependent. Although this trend was seen with 
VCR, it was not observed with the other two microtubule-disrupting 
agents, VBL and colch. In fact, VBL and colch pre-treatment for 
15 min resulted in a trend which was opposite that seen with 
VCR. That is, with increasing doses of VBL or colch, the HMPS 
activity diminished compared with the appropriate control. 
With 5 min pre-incubations, VBL and colch showed no such dose-
response trend (Table 8.2). 
8.3.3 	The effect of incubation time with the agents or controls  
The number of nanomoles of glucose oxidized after 5 
or 15 min pre-incubations with the control buffer were virtually 
identical (65±5 versus 67±8, respectively, Tables 8.1 and 8.2). 
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Similarly there was very little difference in the values for 5 
min or 15 min pre-incubated granulocytes treated with DMSO or 
cyto B (Table 8.1). Granulocytes pre-incubated for 5 min or 
15 min with the microtubule-disrupting drugs, VBL, VCR, or colch, 
showed almost identical values also (Table 8.2). The exception 
was once again with VCR, where the nanomoles glucose oxidized 
after 5 min pre-incubation were slightly higher, for each of the 
three doses tested, than after 15 min pre-incubation. 
8.3.4 	The effect of potassium cyanide  
Nqn-phagocytic granulocytes exposed to 3.0 mM KCN 
for 5 min or 15 min showed a pronounced stimulation of HMPS 
activity when compared with the appropriate 5 or 15 min KCN-free 
controls (Table 8.3). Exposure to 1.5 mM KCN resulted in a 
statistically significant stimulation as well, but only with the 5 
min pre-incubation. The stimulations with KCN at 5 and 15 min 
were dose-dependent. 
8.4 	DISCUSSION 
These experiments were conducted to determine if 
the observed enhancement or depression in superoxide production 
from non-phagocytic granulocytes (Section 4) was associated with 
a similar change in the activity of the HMPS. It has been 
established that phagocytic granulocytes display a stimulation 
of the HMPS along with enhanced superoxide production (see 
section 1.3). It is generally believed that the production of 
superoxide occurs before HMPS activation (Baehner et al, 1970; 
DeChatelet et al, 1972b, but some investigators hold the opposite 
viewpoint (Strauss et al, 1969). With this latter possibility 
in mind, it was necessary to investigate whether the IMPS was 
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affected by the drug treatments. The experiments described in 
this section were not designed to clarify if superoxide production 
follows or precedes HMPS stimulation, however. 
In studying the activity of the plasma membrane 
oxidase in Section 4, potassium cyanide was present to ensure 
that the appropriate 'cyanide-insensitive' metabolic burst (section 
1.3) was being measured. Therefore, KCN was also present in these 
experiments so that it could be determined whether the drug-
induced changes in oxidase activity were associated with a 
parallel change in HMPS activity. Only a few studies of the 
effects of cyto B, VBL, VCR or colch on HMPS activity in non-
phagocytic granulocytes have been reported, and none of the 
studies involved KCN-treated non-phagocytic granulocytes. Never-
theless, although they cannot be considered comparable to the 
experiments presented herein, those studies must be discussed. 
The findings from one group of investigators are 
very difficult to evaluate because they mention that the HMPS 
activity of non-phagocytic granulocytes was both inhibited by 
cyto B (Roos et al, 1976), and unaffected (Roos, Homan-Muller and 
Weening, 1976). In agreement with the latter report, Hawkins 
(1973) also found that cyto B treatment of non-phagocytic 
granulocytes does not affect HMPS activity. Although an inhibition 
of HMPS activity by cyto B was observed in this thesis (in 
agreement with the reports from Malawista, Gee and Bensch, 1971; 
Zigmond and Hirsch, 1972; Okuda et a/, 1976; and Roos et al, 
1976), this inh4bition was not statistically significant 
(Table 8.1). Furthermore, parallel results were seen with DMSO 
at the appropriate control concentrations (Roos et al, 1976, and 
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this thesis), and therefore the inhibition of HMPS activity by 
cyto B can be attributed to the DMSO used as a solvent for the 
cyto B. As none of the above investigators reported an enhancement 
in HMPS activity, it seems certain that the stimulated oxidase 
activity of cyto B-treated granulocytes is not due to or 
associated with HMPS activity. 
Several laboratories have studied the effects of 
VBL, VCR or colch on glucose oxidation via the HMPS. Lehrer 
(1973), using colch, and more recently Pickering et a/ (1978) 
with VBL and VCR, have observed an inhibition of non-phagocytic 
HMPS activity by these agents. In contrast to these findings, 
and therefore in agreement with the results presented herein, 
Malawista and Bodel (1967), Malawista (1971), Tsan et al (1976a) 
and Zabucchi et al (1978) have found that VBL and/or colch have 
no effect on HMPS activity of non-phagocytic granulocytes. These 
latter studies were conducted under experimental conditions which 
were comparable to the methods used in this thesis (except for 
the omission of KCN), whereas the experiments described by 
Pickering et a/, and Lehrer cannot be considered comparable. 
For example, Lehrer observed an inhibition of HMPS activity with 
doses of colchidine' (6000 pM) far in excess of those used in 
this thesis (and by others) to specifically cause the disruption 
of microtubules (Wilson et al, 1974; Wilson, 1975; Owellen et al, 
1976). Similarly the experiments of Pickering et al (1978) are 
not comparable to those presented herein because they measured 
HMPS activity of drug-treated whole blood, rather than isolated 
granulocytes. It would appear therefore, from the results presen-
ted in this section, and from those of the most comparable 
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studies that VBL or colch treatment does not affect the HMPS 
activity of non-phagocytic granulocytes. 
It is interesting to note that a significant 
stimulation in HMPS activity with VCR treatment was observed, and 
this stimulation was dose-dependent. It was most unusual to find 
this stimulation when colch, and in particular VBL, did not give 
the same result 2 . 	In most reports describing in vitro work with 
VCR and VBL, the same response is observed with these two vinca 
alkaloids, presumably because both drugs possess the entire 
dimeric alkaloid structure necessary for biological activity 
mediated by binding to tubulin and disruption of microtubules 
(Wilson, 1975; Wilson et al, 1975; Owellen et al, 1976). 
However, VCR differs slightly from VBL in that VCR has a CHO 
(rather than CH3 ) group attached to nitrogen in the lower 
indole portion of the molecule (Appendix IV). It is certain that 
this slight structural alteration accounts for the different 
therapeutic response observed in vivo and therefore the clinical 
applications of these two alkaloids (Spiers, 1974). It is likely 
that this slight structural difference is also responsible for 
the unexpected stimulation of HMPS activity observed herein with 
VCR. 
It should be mentioned that Pickering et al (1978) 
also observed an enhancement of resting HMPS activity with VCR. 
A similar discrepancy was found by Malawista (1971), who showed 
that colchicine had no effect whereas VBL caused an inhibition 
in the HMPS activity of non-phagocytic granulocytes. 
109 
However, because of their unusual methodology (as described above) 
and the presence of prednisone in the incubation with VCR, these 
results do not necessarily confirm those presented herein. 
In conclusion, the results of these experiments on 
HMPS activity do not parallel the findings of the experiments on 
the oxidase activity of drug-treated granulocytes (see section 4.3). 
Therefore it is not reasonable to assume that the observed changes 
in oxidase activity were associated with or due to alterations in 
HMPS activity brought about by these agents. The apparent 
separation between oxidase activity and the HMPS in these experi- 
ments was at first viewed as an unexpected finding. However, chronic 
granulomatous disease granulocytes have abnormal oxidase yet normal 
HMPS activity (Baehner and Nathan, 1967; Holmes, Page and Good, 
1967; Tsan et al, 1976a; Oliver et a/, 1976). Therefore the 
results presented in this section of the thesis cannot be considered 
unusual. 
As mentioned above, potassium cyanide was present during 
the drug incubations to ensure that the appropriate 'cyanide-
insensitive' metabolic burst was being measured. It has long been 
maintained that the post-phagocytic HMPS activation is cyanide-
insensitive (section 1.3). However, recent reports show that 
cyanide can in fact stimulate post-phagocytic oxygen consumption 
(Reed and Tepperman, 1969; Klebanoff and Hamon, 1972, DeChatelet 
et a/, 1977), as well as HMPS activity (Klebanoff and Pincus, 1971; 
DeChatelet et al, 1977). An enhancement in the HMPS activity of 
non-phagocytic granulocytes was observed in this thesis (Table 8.3). 
This enhanced HMPS activity in resting or phagocytoshIggranulocytes 
exposed to cyanide occurs because cyanide inhibits the heme- 
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containing proteins, catalase and myeloperoxidase. These two 
enzymes are used by the granulocyte to detoxify the peroxide 
produced by oxidase activity (Reed, 1969). In the presence of 
cyanide this peroxide is not detoxified, and it can therefore 
be consumed by the glutathione reductase-glutathione peroxidase 
system. The utilization of peroxide by this system will result 
in the formation of NADP + , which stimulates the HMPS (Reed, 1969, 
as illustrated in Appendix I, Fig. I.1). 
8.5 	SUMMARY 
In this section of the thesis, the HMPS activity of 
drug-treated (cyto B, VBL, VCR, colch) non-phagocytic granulocytes 
was examined. Overall, these agents had no effect on HMPS activity 
from non-phagocytic granulocytes, although one of the drugs (VCR) 
produced an unexpected stimulation compared with the control. 
As the results from these and similar experiments 
on HMPS activity by Malawista and Bodel (1967), Malawista (1971), 
Tsan et al (1976), Roos et al (1976) and Zabucchi et al (1978) 
did not parallel the results of experiments on the oxidase 
activity of drug-treated granulocytes, it cannot be concluded that 
the drug-induced changes in oxidase activity (see section 4.3) were 
associated with or due to a change in HMPS activity. The apparent 
separation between oxidase activity and the HMPS in these experiments 
was at first viewed as an unexpected finding. However, chronic 
granulomatous disease granulocytes have abnormal oxidase yet normal 
HMPS activity, therefore the results presented herein are not 
unusual. 
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FIG. 8.1 The first steps of the hexose monophosphate 
shunt, as modified from Chayen et al (1973). 
Ehzymes involved are:- 
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FIG. 8.2. The universal container with two compartments and a 
screw-top with rubber plug. The smaller compartment 
14 contained the granulocytes, buffer, C-1-glucose and 
pooled human serum. The larger compartment contained 
(as shown in the photograph) a plastic mini-
scintillation vial. 
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TABLE 8.1  
Values given are the TC ± SEM of 4 determinations (2 experiments, 
each conducted in duplicate), and indicate the number of nmoles 
glucose oxidized. The values are not statistically significant 
when compared with the appropriate (5 or 15 min) control . 
a) DMSO at 0.25% v/v 
b) DMSO at 0.03% v/v 
DMSO at 0.003% v/v 
TABLE 8.1 5 or 15 min pre-incubation with cyto B or DMS0  
Agent and dose Incubation time 5 min 15 min 
Cyto B 
Control for cyto B 
Control 
1 UM 
0.1 pM 
0.01 pM 
1 pMa) 
b) 0.1 pM 
c) 0.01 pM 
0 pM 
57 ± 6 
73 ± 2 
55 ± 3 
56 ± 1 
75 ± 1 
54 ± 1 
65 ± 5 
62 ± 2 
71 ± 2 
60 ± 7 
61 ± 3 
68 ± 3 
62 ± 7 
67 ± 8 
TABLE 8.2 
Values given are the X ± SEM of 4 determinations (2 experiments, 
each conducted in duplicate), and indicate the number of nmoles 
glucose oxidized. The values [except for a) and b)] are not 
statistically significant when compared with the appropriate 
control. 
For a) p < .005 compared with the control (5 min) 
and b) p < .02 compared with the control (5 min) 
TABLE 8.2 	5 or 15 min pre-incubation with VBL, VCR or colch 
Agent and dose Incubation time 
5 min 15 min 
VBL 1 pM 60 + 11 60 ± 3 
0.1 64± 	8 65 ± 4 
0.01 55 + 	8 72 ± 3 
VCR 1 0 90 + 	1a) 90 ± 6 
0.1 83 + 	2b) 74 ± 5 
0.01 79 + 13 67 ± 4 
colch 1 	. pM 73 ± 2 61 ± 5 
0.1 63 ± 13 69 ± 3 
0.01 76 ± 1 74 ± 3 
control 0 65 ± 5 67 ± 8 
TABLE 8.3 	The effects of.cyanide on HMPS activity 
Incubation 
(min) 
Period Dose 	(mM) 
(Control) 0 	1.5 3.0 
5 
15 
54 
51 
± 1 
± 5 
65 
67 
± 5a) 
± 8c) 
91 ± 5b) 
127 ± 4d) 
Values given are the R ± SEM of 4 determinations (2 experiments, each 
conducted in duplicate), and indicate the number of nmoles glucose 
oxidized. Except for c), the values are significantly greater than 
the appropriate control, that is:- 
a) 	p < .025 	and b), 	p < 0.01 
SECTION 	9 
ULTRASTRUCTURAL STUDIES OF NBT REDUCTION 
BY GRANULOCYTES 
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9.1 	INTRODUCTION  
Using two complementary techniques, Briggs et al (1975) 
examined the ultrastructural location of cyanide-insensitive 
oxidase activity in granulocytes. The first technique involved 
studying the sites of oxidase activity through the formation of 
H2 02 . As discussed in section 1.4, the cyanide-insensitive oxidase 
catalyzes the formation of superoxide, and is therefore ultimately 
responsible for the production of H 2 02 in the following reactions:- 
202 + NAD(P)H 	oxidase 	202 + NAD(P)
+ + H+ 
20 + 2H+ 	superoxide 	 02 + H202 
dismutase 
The authors detected the cellular locations of H 2 02 
production with exogenous CeC1 3' The cerium ions formed a 
precipitate with the H202 (presumably cerium perhydroxide),.and 
this precipitate was deposited at the site of its formation. 
The second correlative study by Briggs et al 
involved examining the deposition of reduced NBT as the result 
of oxidase activity. As discussed in section 3.1, NBT is 
- reduced to formazan via 0 2 generated as a result of oxidase 
activity, and the formazan remains in situ at the cellular site 
of its production. 
With these complementary studies the authors showed 
that the cyanide-insensitive oxidase was located on the surface 
of granulocytes, and that the oxidase was NADH-dependent (see 
Appendix I). Moreover they showed that the plasma membrane 
enzyme was internalized during phagocytosis and retained its 
enzymic capacity (as detected by H 2 02-dependent cerium deposition) 
within the phagocytic vacuole. 
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In this section, electron microscopical studies of the 
cellular sites of oxidase activity, as monitored by formazan 
deposition, are described. The aim of these experiments was to 
examine the surface distribution of reduced NBT dye, and to study 
the effects of prior drug treatment of phagocytic or resting 
granulocytes, on the distribution of these sites of enzyme activity. 
9.2 	METHODS 
	
9.2.1 	Preparation of drugs in HSS  
Colchicine and cytochalasin B were prepared in HSS 
as described in section 4.2. The final concentration of these 
agents in HSS was 1 4M. 
9.2.2 	Granulocyte pre-incubations with the drugs  
Isolated granulocytes (section 2.2.13) were centri-
fuged in plastic conical test tubes and the supernatant CMFH 
removed. The cells were then resuspended in HSS containing 
colchicine or cyto B, and incubated with the agents for 10 min 
at 37oC. If the granulocytes were to be used for phagocytic 
studies, the procedure outlined in section 9.2.3 was followed, 
otherwise the drug-treated granulocytes were washed in CMFH 
at 4oC. Control (untreated) granulocytes were handled in 
parallel but not exposed to the drugs. 
9.2.3 	Granulocyte incubations for phagocytic stimulation  
Drug-treated or untreated granulocytes to be used for 
phagocytic studies were presented with polystyrene latex beads 
in HSS (as detailed in section 5.2), and incubated with the 
beads for 10 min at 37°C. Ingestion was stopped by washing the 
cells in excess CMFH at 4°C to minimize the particle-cell contact. 
Control granulocytes were handled in parallel but not exposed 
to the beads. 
9.2.4 	Incubation of granulocytes for NBT reduction studies  
Resting or phagocytic, drug-treated (or control) 
granulocytes were used in the incubations for NBT reduction 
(section 9.2.4.1). The solutions and procedure followed were 
taken from Briggs et al (1975). 
9.2.4.1 	Incubation for NBT reduction  
The granulocytes were centrifuged and resuspended in 
Trig/sucrose solution (pH 7.0, section 9.2.4.2) for a brief wash 
of 5 min at 4oC. They were then resuspended in the NBT incubat-
ing solution (sction 9.2.4.3) and incubated for 30 min at 37 °C. 
After this time the cells were washed for 5 min in cold Tris/ 
sucrose washing solution (9.2.4.2), and then fixed in glutaraldehyde 
(section 9.2.5.1). Control granulocytes were handled in the 
same way but not exposed to NBT dye. After fixation in glutaralde-
hyde, the cells were prepared for electron microscopy, as detailed 
in section 9.2.7. 
9.2.4.2 Washing solution for NET incubations  
This solution consisted of 0.1 M Tris maleate with 
i% sucrose, pH 7.0 (adjusted with 5 M- NaOH). The washing 
solution was prepared on the day of use. 
9.2.4.3 *NBT incubating solution  
This solution consisted of 0.1 M Tris maleate, pH 7.0 
with 0.71 mM NADH and 0.6 mM NBT. The solution was prepared just 
before use and Millipore-filtered (0.45 pm) to remove any 
undissolved NBT. 
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9.2.5 	Electron microscopy solutions 
9.2.5.1 Glutaraldehyde fixative  
Electron microscopy grade glutaraldehyde was used to 
make a 2% glutaraldehyde in CMFH solution. The solution was 
prepared by mixing 1.1 ml glutaraldehyde (25%), 1 ml Ca +2 and 
M
+2 g free concentrated salt solution, 1 ml glucose, 155 mM, 
2 ml HEPES buffer, 58.5 mM, pH 7.4 (Appendix II), and 7.9 ml 
water. The final composition of the fixative was:- 
2% glutaraldehyde, 142.9 mM Na+ , 6.0 mM K1- , 11.9 mM 
glucose, 9.0 mM HEPES, with a pH of 7.4. The fixative 
was prepared on the day of use. 
9.2.5.2 Washing solution for electron microscopy  
The solution described by Sabatini et al (1963) was 
used for washes, and consisted of 0.2 M sucrose in 0.1 M sodium 
cacodylate, pH 7.4. 
9.2.5.3 Osmium tetroxide fixative  
The osmium tetroxide fixative contained 1% 0s0 4 in 
0.1 M sodium cacodylate, pH 7.4. The fixative was prepared every 
few months, as required, and stored at 4°C in a glass container 
with a tight-fitting (glass) stopper. 
9.2.5.4 Spurr's resin for electron microscopy  
The embedding material used for electron microscopy 
was a low viscosity epoxy resin described by Spurr (1969). 
The resin was prepared by mixing (in order):- 
10.0 g vinyl cyclohexene dioxide (resin) 
6.0 g diglycidyl ether of polypropylene glycol 
(resin) 
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26.0 g nonenyl succinic anhydride (hardener) and 
0.4 g dimethylaminoethanol (accelerator) 
Mixing was accomplished by gently swirling the 
Erlenmeyer flask after the addition of each component. The 
resin was prepared every few weeks and was stored covered (to 
protect from moisture) at -20°C. 
9.2.6 	•Thin section stains for electron microscopy  
9.2.6.1 Uranyl acetate  
This heavy metal uranium stain was adapted from 
Watson (1958). It was prepared as a saturated solution in 50% 
ethanol by adding 8 g UO2 (C2H302 ) 2 x 2 H2 0 to 100 ml of 50% 
ethanol in water. After mixing, the solution was stored in an 
amber bottle and allowed to settle for 2 days before use. The 
stain was made up monthly, and it was centrifuged for clarifi-
cation before use. 
9.2.6.2 	Lead citrate  
The lead citrate solution was prepared following the 
suggestions of Reynolds (1963). 1.76 g sodium citrate 
(Na3C6H507 x 2H2 0) was dissolved in 40 ml water and to this was 
added 1.33 g lead nitrate. The mixture was tightly stoppered 
and stirred for 30 min. After this time 10 ml of 1 M - NaOH was 
added and the solution stirred for a further 5 min. This 
solution was prepared monthly and stored in a clear glass bottle. 
9.2.7 	Processing of granulocytes for electron microscopy  
Treated or untreated granulocytes to be examined by 
electron microscopy were fixed in glutaraldehyde, post-fixed in 
osmium tetroxide, embedded in resin (using a modification of 
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Spurr's technique (Spurr, 1969), thin-sectioned, and finally 
stained on grids with uranyl acetate and lead citrate. 
Fixation in 2% glutaraldehyde (section 9.2.5.1) was 
started at room temperature ( -25°C) for 5-10 min and was then 
completed at 4°C for a total fixation of 3 hours. The unreacted 
glutaraldehyde was removed by centrifuging the cells in two 
successive washes at 4 °C (solution 9.2.5.2). The cells were then 
post-fixed in osmium tetroxide for 30 min at room temperature 
(section 9.2.5.3). After osmium the granulocytes were again 
washed twice, and then dehydrated in a graded series of ethanols. 
The ethanol in water solutions (in order of use) were 50, 70, and 
100% v/v. The cells were exposed to each ethanol solution for 
10 min, and to the absolute ethanol twice. To further ensure 
dehydration and to provide a solvent which would be compatible 
with the embedding resin, the cells were then exposed to 
propylene oxide twice (10 min and 30 min, respectively). The 
granulocytes were then resuspended in 300 ul of a mixture of 
Spurr's resin (9.2.5.4) and propylene oxide (1:1) for 60 min at 
room temperature. Then 300 pl of fresh Spurr's resin was added 
to increase the ratio of resin:propylene oxide to 3:1. The cells 
were left in this mixture at room temperature for one hour to 
promote infiltration of resin into the cells. After this time 
the granulocytes were centrifuged and the resin/propylene oxide 
mixture removed. They were then resuspended in 300 ul of fresh 
resin and transferred with a Pasteur pipette to BEEN capsules. 
At this point the granulocytes were centrifuged (60 min x 500g x 
25oC) to the bottom cavity of the capsules. These capsules were 
then incubated at 70°C for 24 hours to polymerize the resin. 
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The polymerized blocks were removed from the capsules 
and sectioned on an LKB III ultramicrotome with glass knives. 
Thin sections were collected on 400-mesh Formvar-coated (Pease, 
1964) copper grids . These grids were placed section-side down 
on drops of uranyl acetate stain (one grid per drop of stain), 
and stained for 15 min at room temperature. They were then rinsed 
of stain by immersion 20 times in two successive beakers of 
water. The grids were not allowed to dry before being placed onto 
drops of lead citrate, and stained 8 min at room temperature. The 
stained grids were thoroughly rinsed once more, allowed to dry, 
and then examined in an Hitachi HS-7S electron microscope. 
9.3 	RESULTS 
9.3.1 	Untreated granulocytes 
The ultrastructure of the mature granulocyte has 
been described by Bainton et al (1971). The most prominent 
feature of the granulocyte is the segmented or multi-lobed 
nucleus. Sometimes a connecting strand of chromatin can be 
seen between two lobes. The cytoplasm is replete with large 
azurophilic granules which can vary in shape from round to 
oval. The smaller specifics are interspersed with the larger 
azurophilic granules in the cytoplasm. Very few if any 
mitochondria are present in the mature granulocyte. Occasional 
glycogen deposits may be seen, and sometimes the cell has been 
sectioned through the cell centre, revealing the centriole. 
Vacuoles may be found in the cytoplasm and occasionally they 
contain post-phagocytic, partially digested debris. The 
surface outline of the cell is usually irregular, in contrast 
to the rounded shape of lymphocytes. Sometimes microtubules 
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are visible in the cytoplasm, and in the region underneath 
the plasma membrane. Many of these features can be seen in Figures 
9.1.A and B. 
	
9.3.2 	Phagocytic granulocytes  
Granulocytes which have ingested polystyrene latex 
beads can be distinguished from those which have not by virtue 
of the presence of numberous beads within the cell, and the 
absence of many cytoplasmic granules. The granule numbers are 
depleted through degranulation into the phagocytic vacuoles, as 
described in section 1.2. The phagocytic vacuoles are 
bordered by membrane derived from the cell surface during the 
process of ingestion (section 1.2). Sometimes the polystyrene 
latex beads are partially extracted during processing for electron 
microscopy and as a result, appear as a sphere with variations in 
electron density. The cell surface of post-phagocytic granulocytes 
is usually fairly smooth, although sometimes a long projection or • 
pseudopod is seen. The typical features of granulocytes which 
have ingested polystyrene latex beads are seen in Fig. 9.2. 
9.3.3 	Non-phagocytic granulocytes exposed to NBT dye  
Reduced NBT (formazan) deposition at the cell surface 
was of low electron density and evenly distributed over the cell 
surface. The reduced dye was visible mainly where two cells 
came in contact (Fig. 9.3). 
9.3.4 	Colchicine-treated non-phagocytic granulocytes  
Granulocytes exposed to colchicine often showed a 
rounded cell profile with numberous small projections off the 
cell surface. Occasionally small vacuoles were seen at 
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the cell surface as well. The granules were present and appeared 
to be intact (Figs. 9.4.A and B). When these colchicine-treated 
cells were incubated with NBT dye, patchy deposits of reduced dye 
were seen on the cell surface. Occasionally a very large patch 
of formazan was seen at the cell surface, and the surface depos-
ition of dye was always more visible where two cells touched 
(Figs. 9.5.A and B). 
	
9.3.5 	Cyto B-treated non-phagocytic granulocytes  
Almost all cyto B-treated cells showed some ultra-
structural change at the cell surface. Blebbing of the membrane 
or unusual cellular projections were prominent findings. Vacuo]e 
formation at the cell surface (especially within the blebs) was 
often seen. Sometimes the granules, although not depleted in 
numbers, were localized to a particular region or end of the 
cell after cyto B treatment. These features are shown in Figs. 
9.6.A,B,C, and D . 
When cyto B-treated granulocytes were incubated with 
NBT dye, deposits of formazan were localized to the peripheral 
vacuoles found at regions of cell surface blebbing. Not all 
vacuoles contained formazan, however (Figs. 9.7.A and B). 
9.3.6 	Phagocytic granulocytes incubated with NBT  
Phagocytic granulocytes incubated with NBT showed heavy 
formazan deposits within the phagocytic vacuoles, and only a 
faint deposition at the cell surface. Cytoplasmic granules were 
often depleted. Most phagocytic granulocytes showed a large 
number of beads per cell section examined (mean number from 20 
cells counted = 40 beads). These cells are shown in Fig. 9.8. 
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9.3.7 	Colchicine-treated phagocytic granulocytes  
Colchicine-treated phagocytic granulocytes presented 
fewer beads per cell section examined (mean value from counts 
performed on 20 cells = 20 beads). Otherwise the appearance of 
these cells was similar to the control phagocytic granulocytes 
[cf. Figs. 9.9 (colchicine) and 9.2 (control)] . Colchicine-
treated phagocytic granulocytes incubated with NBT dye showed 
light formazan deposition within the phagocytic vacuoles (Figs. 
9.10.A and B), but little or no dye on the cell surface. 
9.3.8 	Cyto B-treated phagocytic granulocytes  
Cytochalasin B-treated phagocytic granulocytes showed 
fewer beads eaten per cell section examined, than control granulo-
cytes (mean value for 20 cells counted = 18). Granules were 
often depleted in numbers. The most striking finding was the 
presence of partially ingested beads attached firmly to the 
cell surface. For example, in Figure 9.11 at least 12 such 
beads can be seen. 
When cyto B-treated phagocytic granulocytes were 
incubated with NBT dye, a very heavy deposit of formazan within 
the phagocytic vacuoles was observed. Where beads were par-
tially ingested, formazan was found outside the cell, close to 
the sites of attachment of these beads (Fig. 9.12). In the 
granulocyte illustrated, an incompletely closed phagocytic 
vacuole is seen, and formazan appears to be deposited outside 
the cell surface in this region (Fig. 9.12). There are few 
granules present in the section of the cell shown. 
9.4 	DISCUSSION 
Treatment of granulocytes with colchicine produced 
ultrastructural changes at the cell surface. Colchicine-treated 
cells were generally rounded, whereas control granulocytes had an 
irregular cell profile. In addition, small projections off the 
cell surface were commonly observed after colchicine treatment. 
The 'rounding-up' of colchicine-treated cells has been documented 
by others (Brown and Bruck, 1973; reviewed by Burnside, 1975). 
The formation of projections and ruffles at the cell surface of 
colchicine-treated fibroblasts has also been observed (Vasiliev 
et a/ 1970; Gail and Boone, 1971). It has been suggested by 
Vasiliev et al that the ruffling is a form of enhanced cell 
surface activity due to colchicine-induced microtubule disruption 
(see Appendix IV). Therefore, Vasiliev et al proposed that micro-
tubules provide a way of stabilizing the resting cell surface. 
Colchicine-treated granulocytes showed a patchy, rather 
than the usual faint, homogeneous deposition of reduced NBT dye 
at the cell surface. (In both colchicine-treated and control 
granulocytes, the formazan deposits were best seen where two 
cells came in contact.) The patchy distribution of NBT dye at 
the cell surface indicates that the location of the plasma membrane 
oxidase within the plasma membrane has been altered by colchicine 
treatment. In this regard, it has been shown that the topographical 
organization of transport sites (Ukena and Berlin, 1972) and 
lectin-binding sites (Oliver et al, 1974) within the plasma mem-
brane of granulocytes is altered after colchicine treatment. It 
was concluded that microtubules, which were disrupted by colchicine, 
were required for the topographical organization of the 
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granulocyte plasma membrane (Oliver et al, 1974; Berlin, 1975). 
It is likely therefore, that the observed inhibition of plasma 
membrane NBT reduction by colchicine (see section 4.3) arose 
from a detrimental alteration of plasma membrane organization 
after microtubule disruption. A recent review by Coleman has 
outlined the evidence with respect to how the overall organiz-
ation of the membrane is very often crucial for the activity of 
a membrane-bound enzyme (Coleman, 1973). 
Cytochalasin B-treated granulocytes displayed blebbing 
and vacuole formation at the cell surface. These features of 
cytochalasin B treatment have been observed with human, horse, 
and rabbit granulocytes (Zigmond and Hirsch, 1972) as well as 
other cell types (Butcher and Perdue, 1973; Holtzer et al, 
1973; Mayhew and Maslow, 1974; Godman et al, 1975; Bhisey 
and Freed, 1975). Based on such morphological observations 
with mouse peritoneal macrophages, Bhisey and Freed (1975) 
proposed that the blebs may have been due to cytochalasin B-
induced changes in the composition of the cell surface and per-
haps the plasma membrane itself. This view is supported by 
the more recent finding that cytochalasin B, by acting to dis-
rupt a microfilament system located just underneath the cell 
membrane (see Appendix Iv) can bring about marked changes in the 
movements of cell surface components (see also section 6.4). 
When cytochalasin B-treated granulocytes were 
incubated with NBT dye, it was found that the deposits of formazan 
were localized to those vacuoles contained within surface blebs. 
It was initially thought that the dye in those vacuoles might 
have been reduced by granule rather than plasma membrane-produced 
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superoxide, and, hence that these vacuoles were very similar to 
phagocytic vacuoles. However the vacuoles inside surface blebs 
were morphologically unlike phagocytic vacuoles (cf. Figs. 9.2 and 
9.6.A,B, and C), and cytoplasmic granules were not observed fusing 
with the membrane of the vacuole. Other investigators have shown 
that the granules do not fuse with the plasma membrane of cyto B- 
treated, non-phagocytic granulocytes (Henson, 1971 a,b; Henson, 1972; 
Zurier, Hoffstein and Weissmann, 1973; Henson and Oades, 1975). 
In addition, Goldstein et al (1975, 1977) and Roos et a/ (1976) 
showed that cytochalasin B treatment of non-phagocytic granulocytes 
resulted in a release of superoxide which was quite separate from 
the release of granule enzymes from the cell, and suggested there-
fore, that the superoxide was released from the cell surface. 
Thus it seems certain that the reduced dye in these surface vacuoles 
emanated from plasma membrane oxidase activity, and that the vacuoles 
contain the oxidase in their limiting membrane. There is morphologi-
cal evidence of their formation from the plasma membrane in Fig. 
9.6.C. The reduction of NBT dye at the cell surface and the form-
ation of these vacuoles occurred too quickly to determine if vacuole 
formation had to occur before dye reduction in cytochalasin B-treated 
granulocytes. It can be concluded, however, that the reduction of 
dye is not required before vacuole formation occurs, because other 
workers have observed vacuolization after cytochalasin B treatment 
of granulocytes in the absence of NBT (Zigmond and Hirsch, 1972). 
As detailed in section 4.3, cytochalasin B treatment of non-phagocytic 
granulocytes resulted in a time and dose-dependent stimulation of 
NBT reduction by the plasma membrane oxidase. That finding, in 
combination with the increased cell surface activity (blebbing and 
vacuole formation) reported herein, suggests that cytochalasin 
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B-sensitive microfilaments underlying the membrane may provide 
a constraint against plasma membrane oxidase activity. 
Ultrastructural studies with drug-treated phagocytic 
granulocytes provided some interesting and unexpected results. 
Formazan deposition in the phagocytic vacuoles of the colchicine-
treated phagocytic granulocytes was considerably less than in 
control cells. This finding agrees with the observed inhibition 
of superoxide production (NBT reduction) by colchicine-treated 
phagocytic granulocytes (section 5.3), and the experimental 
results of others (Curnutte and Babior, 1975). Cytochalasin 
B-treated granulocytes, in contrast, showed very heavy formazan 
deposition within the phagocytic vacuoles, and some deposition 
outside the cell near sites of bead attachment to the membrane. 
Some of the formazan within the vacuoles may have been formed 
first at the plasma membrane and then internalized with phago-
cytosis, because formazan was seen outside the cell at an 
incompletely fused phagocytic vacuole (Fig. 9.12). An alternative 
explanation provided by the studies of Weissmann et al (1975a,b) 
is that the NBT dye was reduced by superoxide from a granule 
oxidase. These authors found that cytochalasin B inhibited 
the ingestion of zymosan particles 1 but did not affect the 
binding of zymosan to the granulocyte membrane. Consequently, 
1 Although Weissman et a/ (l975a,b) found that cytochalasin B 
completely inhibited the ingestion of zymosan, it is clear 
from the experiments presented in this thesis (section 5.3 
and Figs. 9.11 and 9.12) and by others (Table 5.9) that 
cytochalasin B does not completely inhibit phagocytosis of 
all types of particles by the granulocyte. 
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this situation resulted in the release of granule enzymes to the 
exterior of the cell through a process the authors termed 'reverse 
endocytosis'. In effect, these granulocytes were degranulating 
to the exterior because the granules were merging with the plasma 
membrane underlying the attached bead, rather than the proper 
(interior) phagosome membrane (see also section 5.4). 
In agreement with Briggs et al (1975) very little 
formazan was found on the surface of phagocytic granulocytes even 
though heavy deposits were evident within the phagocytic vacuoles. 
The absence of formazan at the surface of these cells would 
suggest that during phagocytosis, the plasma membrane oxidase is 
2. very rapidly and selectively incorporated Into the phagosome 
membranes at the expense of the cell surface. 
9.5 	SUMMARY 
Colchicine and cytochalasin B both produced ultra-
structural changes at the granulocyte cell membrane. The effects 
of cyto B treatment were the more dramatic and included plasma 
membrane blebbing and vacuole formation. Colchicine-treated 
granulocytes showed a patchy distribution of reduced NBT dye 
(indicative of the production of superoxide by the cyanide-
insensitive oxidase) at the cell membrane. Untreated cells in 
contrast showed a homogeneous distribution of reduced dye at the 
2 The granulocyte plasma membrane proteins which bind the 
lectins, concanavalin A and Ricinus communis agglutinin 
have been shown to be rapidly and selectively incorporated into 
the phagosome membrane during phagocytosis (Berlin, 1975). 
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cell surface. The patchiness probably represents a colchicine-
induced alteration in the location of the oxidase within the 
plasma membrane. 
Cytochalasin B-treated granulocytes exposed to NBT 
dye displayed formazan deposits in cell surface vacuoles located 
at areas of plasma membrane blebbing. Based on the ultrastructural 
observations presented herein and the experiments of Goldstein 
et al, Henson et al, and Zurier, Hoffstein and Weissmann (see 
section 9.4) with cytochalasin B, it seems certain that the dye 
within these vacuoles was reduced via plasma membrane, rather 
than the granule-produced superoxide. 
Phagocytic granulocytes incubated with NBT dye showed 
very heavy deposits of formazan within the phagocytic vacuoles 
but little dye at the cell surface. A likely explanation for 
this finding is that the plasma membrane oxidase is rapidly and 
selectively incorporated into the phagosome membrane at the expense 
of the cell surface location. 
FIG. 9.1.A. Untreated, non-phagocytic granulocytes. Features 
	
(top) 	evident are the multilobed nucleus and the 
azurophilic (large) and specific (small) granules. 
A few cytoplasmic vacuoles are seen. 
Magnification 15,300X. 
FIG. 9.1.B. A higher magnification of the granulocyte cytoplasm. 
(bottom) 	Microtubules in cross section can be seen at A and 
B; and underneath the plasma membrane (arrows) 
several longitudinal profiles of microtubules are 
evident. Magnification 52,300X. 

FIG'. 9.2. A granulocyte which has ingested polystyrene latex 
beads. Fewer granules are seen in such cells 
(cf. FIG. 9.1.A). Magnification 19,500X. 

FIG. 9.3. Two non-phagocytic granulocytes which have been ex- 
posed to NBT dye. The deposition of reduced dye at 
the cell surface is visible where the two cells touch 
(arrows). Magnification 15,100X. 

FIGS. 9.4 A and B. Non-phagocytic granulocytes which have been 
exposed to colchicine. Small projections off the 
cell surface are often seen (arrows). Cytoplasmic 
and surface vacuoles are also frequently observed. 
The azurophilic and specific granules are present 
and appear to be intact. The granulocyte in the 
bottom photograph has the rounded appearance of 
colchicine-treated granulocytes (see section 9.4). 
Very few microtubules were seen in these cells. 
Magnification 	(top) 16,000X 
(bottom) 14,800X 

FIGS. 9.5 A and B. Non-phagocytic granulocytes exposed to 
colchicine and incubated with NBT dye. Reduced 
dye is evident in a patchy distribution on the 
cell surface (top, arrows). As indicated in 
FIG. 9.3, the reduced dye was readily seen where 
two cells touched (bottom photograph). Occasionally 
a very heavy deposit of formazan was present on 
the plasma membrane (asterisk, bottom photograph). 
Magnification 	(top) . 18,400X 
(bottom) 42,100X 

FIGS. 9.6 A and B. Cytochalasin B-treated non-phagocytic 
granulocytes. Ultrastructural changes at the 
cell surface are evident in the form of blebs 
(arrows) and projections (asterisks). Vacuole 
formation in the region of these blebs and pro-
jections is seen in the lower photograph, at 
I, 2, 3 and 4. The granules are present and 
appear to be intact, although they seem to be 
localized to one half of the cell in the top 
photograph. 
Magnification 	(top) 	12,000X 
(bottom) 	48,400X 
B 
FIGS. 9.6 C and D. Cytochalasin B-treated, non-phagocytic 
granulocytes. Alterations to the cell surface 
are present in the form of projections (arrows) 
and vacuole formation (asterisks). As indicated 
for FIGS. 9.6 A and B, the granules are present 
and appear to be intact in these cells. 
Magnification 	(top) 	15,200X 
(bottom) 	35,700X 

FIGS. 9.7 A and B. Cytochalasin B-treated, non-phagocytic 
granulocytes which have been incubated with NBT 
dye. Deposits of formazan are present in the 
peripheral vacuoles found at regions of cell 
surface blebbing (arrows). 
Magnification 	(top) 	20,100X 
(bottom) 	20,700X 
B 
FIG. 9.8. Phagocytic granulocytes incubated with NBT dye. 
Heavy formazan deposits are seen within the 
phagocytic vacuoles (arrows).•Cytoplasmic granules 
are depleted in numbers. 
Magnification 20,800X 

FIG. 9.9. Colchicine-treated phagocytic granulocytes. These 
cells contained fewer beads per cell (on average) 
than control granulocytes. (cf. FIG. 9.2). 
Magnification 19,200X 

FIG. 9.10.A and B. Colchicine-treated phagocytic granulocytes 
incubated with NBT dye. In contrast to untreated 
cells (see FIG. 9.8), these granulocytes displayed 
a light deposition of formazan with the phagocytic 
vacuoles (arrows). 
Magnification 	(top) 	32,800X 
(bottom) 	15,800X 

FIG. 9.11. Cytochalasin B-treated phagocytic granulocytes. These 
(top) 	cells contained fewer beads per cell (on average) than 
control phagocytic granulocytes. Cytoplasmic granules 
appear to be depleted in numbers. Many adherent or 
partially internalized beads were seen at the cell 
surface of these granulocytes (arrows). 
Magnification 	14,600X. 
FIG. 9.12. Cytochalasin B-treated, phagocytic granulocytes 
(bottom) 	which have been incubated with NBT dye. A very 
heavy deposit of formazan is present in the 
phagocytic vacuoles. On the right-hand side, an 
incompletely closed phagocytic vacuole appears to 
be releasing dye to the outside of the cell 
(arrow). Faint deposits of reduced dye are seen 
at points of bead attachment to the cell surface 
(at 1, 2 and 3). Few cytoplasmic granules are 
evident in this cell section. 
Magnification 	16,000X. 

SECTION 10 
DISCUSSION 
10.1 Introductory Remarks 
The studies described in this thesis examined the 
possible role of the cytoskeletal elements (microfilaments and 
microtubules) in controlling the activity of the granulocyte 
plasma membrane oxidase. There have been no detailed investigations 
of this topic published to date. These studies were prompted by 
the recent reports of 
(i) a plasma membrane location for this enzyme (Appendix I) 
and 
(ii) plasma membrane phenomena (such as capping and the 
control of the topographical organization of the 
granulocyte plasma membrane during phagocytosis) which are under 
the 'control of the cytoskeletal elements (see section 1.7). 
This thesis examined the conflicting literature on 
the nucleotide specificity and location of the oxidase within the 
granulocyte (Appendix I). In vitro techniques for isolating 
granulocytes from human peripheral blood, and for quantitating the 
activity of the plasma membrane oxidase were developed (Sections 
2, 3 and Appendix III) and used for these investigations of 
the role of the cytoskeleton in controlling oxidase activity 
(Sections 4, 5, 9). The involvement of microfilaments and 
microtubules in oxidase activity was studied by using pharmaco-
logical agents known to disrupt these structures in vitro 
(cytochalasin B, and colchicine, vinblastine, vincristine, 
respectively - see Appendix IV). Control experiments were 
also performed to ensure that microfilament and microtubule 
disruption by these agents provided the best explanation 
for the results presented herein (see Sections, 5, 6, 7 and 
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Appendix IV). Correlative experiments were conducted to determine 
if a change in HMPS activity was associated with the observed 
changes in plasma membrane oxidase activity brought about by the 
drug treatments (Section 8). In this final section of the thesis 
the evidence supporting the involvement of microfilaments and 
microtubules in controlling plasma membrane oxidase activity is 
discussed and presented in conjunction with the relevant findings 
from other laboratories. 
10.2 	The problems of studying the granulocyte plasma membrane oxidase  
For these studies it was necessary to devise an 
in vitro technique to monitor plasma membrane oxidase activity 
without interference from the granule oxidase (see section 3.1 
and Appendix I). It was reasoned that it would be desirable 
to work with intact granulocytes because methods for isolating 
plasma membrane fragments which retain their full biological 
activity and are not physically altered (for example, turned 
'inside-out' during preparation) have not been perfected 
(See Bennett and Cuatrecasas, 1973 and Crumpton et al, 1977). 
Furthermore, these plasma membrane fragments do not maintain 
functional or physical relationships with the cytoskeletal 
elements, and are therefore not suitable for studies on the 
role of microfilaments and microtubules in controlling plasma 
membrane oxidase activity. 
It was also reasoned that the best method for examining 
the plasma membrane oxidase would be to use non-phagocytic 
granulocytes and to quantitate oxidase activity via NBT reduction. 
In the absence of phagocytosis NBT is unable to cross the 
granulocyte plasma membrane and therefore is reduced at the cell surface 
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and remains in situ at the site of reduction (see section 3.4). 
In phagocytic granulocytes however, NBT enters the cell along with 
the ingested particle and once reduced intracellularly it cannot 
be determined if the dye reduction was the result of granular 
or plasma membrane oxidase activity (see section 5.4). Although 
it seemed that granulocytes exposed to colchicine or cytochalasin 
B (to arrest phagocytosis) would be useful for studying the plasma 
membrane oxidase, this was not so because it was observed that 
the inhibition of phagocytosis was only partial with these agents 
(see sections 5.4 and 9.4). Cytochalasin B-treated granulocytes 
were also unsuitable because many particles adhered to the surface 
of these cells. This situation resulted in the fusion of cyto-
plasmic granules with the plasma membrane subtending the particle, 
and the inability therefore to ascribe oxidase activity to a 
granule or plasma membrane oxidase only (see section 5.4). For 
these reasons it was decided to conduct experiments on non-
phagocytic granulocytes. In support of this decision, it has 
been shown by many investigators that granulocyte oxidase activity 
is not dependent upon phagocytosis in any case (Lehrer, 1973; 
Goldstein et al, 1975, 1977; Roos et al, 1976; Johnston and 
Lehmeyer, 1976; DeChatelet et al, 1976; Stendahl et a/, 1977). 
10.3 	The relevant experimental findings  
Experiments on non-phagocytic granulocytes showed 
that microfilament disruption by cytochalasin B resulted in 
enhanced oxidase activity, while microtubule disruption by 
colchicine, vinblastine or vincristine produced a dual effect : 
a paradoxical enhancement (with low doses or brief exposures to 
the agents) or an impairment in oxidase activity. A few other 
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investigators have also reported either the stimulation with micro-
filament or inhibition with microtubule disruption (Malawista and 
Bodel, 1967; Curnutte and Babior, 1975; Nakagawara et al, 1975, 
1976a; Okuda et al, 1976; Zabucchi et al, 1978). Such results 
suggest that the cytoskeletal elements play opposite roles in con-
trolling plasma membrane oxidase activity, with microtubules being 
necessary for, and microfilaments acting as a constraint against 
oxidase activity. The requirement for microtubules was highlighted 
in the experiments described herein, where the usual enhancement in 
oxidase activity with cytochalasin B was ablated when the granulo-
cytes were concomitantly incubated with a microtubule-disrupting 
agent (see section 4.3). Qualitatively similar results with these 
agents were also observed in experiments with phagocytic granulo-
cytes, but for the reasons outlined above (section 10.2), these 
experiments were deemed unsuitable for studying plasma membrane 
oxidase activity after drug treatments. 
The activity of the granulocyte HMPS was not similarly 
affected by the drug treatments and thus oxidase activity and }IMPS 
activity seem to be independently regulated in the granulocyte. 
This situation is reminiscent of the separation between 
(i) oxidase activity and phagocytosis (section 10.2) 
(ii) phagocytosis and lysosomal enzyme release (Zurier, 
Hoffstein and Weissman, 1973 a,b; Goldstein et al, 1975; 
Roos et al, 1976; Roos, Homan-Muller and Weening, 1976) 
(iii) the abnormal oxidase yet normal HMPS activity of chronic 
granulomatous disease granulocytes (Baehner and Nathan, 
1967; Holmes, Page and Good, 1967; Tsan et al, 1976a; 
Oliver et al, 1977). 
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Electron microscopy revealed that colchicine-treated 
granulocytes had a patchy distribution while untreated granulocytes 
showed an homogeneous pattern of NBT-dye reduction at the cell 
surface. This suggests that the decrease in oxidase activity 
observed with colchicine was associated with or due to a loss 
in the topographical organization of the plasma membrane. 
It is very likely that a colchicine-induced disruption of micro-
tubules produced the loss of plasma membrane organization by 
facilitating the movement of proteins (perhaps including the 
oxidase) within the membrane (see section 1.7). It was shown by 
fluorescence microscopy that colchicine caused a translocation 
of concanavalin A-binding proteins in the membrane. Therefore 
it seems reasonable to assume that a similar movement of the 
oxidase occurred because the concanavalin A-binding proteins and 
the oxidase share two important properties, namely 
(i) both appear to be granulocyte plasma membrane ecto- 
proteins [Nicolson and Singer, 1974; Oliver, Ukena 
and Berlin, 1974 (con A-binding proteins); Briggs et a/, 
1975; Goldstein et al, 1975, 1977; Root and Metcalf, 1977 
(oxidase)], and 
(ii) both appear to be selectively removed from the plasma 
membrane and incorporated into the phagosome membrane 
during phagocytosis [Oliver, Ukena and Berlin, 1974 (con A-
binding proteins); Briggs et al, 1975; Segal et al, 1978; 
Segal and Jones, 1978, 1979 (oxidase - see Appendix I)]. 
•As mentioned above, cytochalasin B treatment of 
granulocytes resulted in enhanced plasma membrane oxidase 
activity spectrophotometrically. In addition, cytochalasin B 
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treatment appeared to induce increased cell surface activity 
in general, as electron micrographs showed surface undulations 
and blebs as well as peripheral vacuole formation in these 
granulocytes (section 9.3). These ultrastructural features of 
cytochalasin B-treated cells have also been described by others 
(Zigmond and Hirsch, 1972; Butcher and Perdue, 1973; Holtzer 
et al, 1973; Mayhew and Maslow, 1974; Godman et al, 1975; 
Bhisey and Freed, 1975; Sundqvist and Otteskog, 1978). 
An examination of these peripheral vacuoles in 
cytochalasin B-treated non-phagocytic granulocytes showed them to 
be a location for NBT dye reduction. The reduced dye in these 
vacuoles was most likely emanating from a plasma membrane rather 
than granule oxidase activity because granules were not seen fusing 
with these non-phagocytic vacuoles (section 9.3). This conclusion 
is strengthened by the reports from other laboratories, showing 
that 
(i) the granules do not fuse with the plasma membrane of 
cytochalasin B-treated, non-phagocytic granulocytes 
(Henson, 1971 a,b; Henson, 1972; Zurier, Hoffstein and 
Weissmann, 1973a; Henson and Oades, 1975) and that 
(ii) oxidase activity and lysosomal enzyme release from the 
granules occur independently in cytochalasin B-treated 
granulocytes (Goldstein et al, 1975; Roos et al, 1976). 
Assuming the dye reduction in these vacuoles to be from plasma 
membrane oxidase activity, the oxidase was probably incorporated 
into the vacuole membrane at the time of vacuole formation in 
the cytochalasin-B treated cells. The experiments presented in 
this thesis did not attempt to determine if this dye was 
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reduced before or after vacuole formation. However, it can be 
reasoned that dye reduction from the cell surface oxidase does 
not have to occur before these peripheral vacuoles form, because 
Zigmond and Hirsch (1972) have observed vacuole formation in 
cytochalasin B-treated granulocytes not reducing NBT dye. 
The observations presented herein, and the suggestions 
from the other workers that cytochalasin B treatment:- 
(i) disrupts a microfilamentous barrier under the plasma 
membrane, thereby facilitating the fusion of granules 
with the plasma membrane subtending attached particles (Zurier, 
Hoffstein and Weissmann, 1973a; Goldstein et al, 1975; Hoffstein, 
Goldstein and Weissmann, 1977) 
(ii) prevents the granulocyte respiratory burst from being 
terminated (Jandl et al, 1978) and 
(iii) enhances immunoglobulin receptor redistribution on 
the granulocyte cell surface (Sajnani, Ranadive 
and Movat, 1975) indicate that microfilaments generally 
play a negative role in granulocyte function. Therefore, the 
usual consequence of microfilament disruption by cytochalasin B 
is enhanced granulocyte activity. 
10.4 	Conclusions to be drawn from these studies  
Although the evidence presented herein suggests that 
the cytoskeletal elements play a role in controlling the activity 
of the plasma membrane oxidase, it is difficult to devise a 
scheme incorporating the results. It is a particularly hard 
task when so many divergent results have been reported from 
studies with the traditional microfilament and microtubule-
disrupting agents (see sections 4.4 and 5.4), and especially 
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when dual effects are observed with the same agent. It is 
interesting to note that comparable studies of granulocyte 
functions other than oxidase activity are also difficult to 
interpret for the same reasons. [For example, Becker and Showell 
(1974) observed that colchicine and vinblastine inhibit chemo-
taxis at high doses yet enhance it at low doses. Similarly, the 
dose of cytochalasin B employed will determine whether random 
migration (Becker et a/, 1972) or phagocytosis is enhanced or 
inhibited by drug treatment (Cannarozzi and Malawista, 1973). 
From these reports it is also evident that the different 
granulocyte functions which have been shown to be mediated via 
the cytoskeletal elements (see Becker, 1976 for a brief review) 
are not all interdependent or inseparable events. Thus, micro-
filament disruption is known to inhibit chemotaxis and 
phagocytosis (Borel and Stahlein, 1972; Zigmond and Hirsch, 1972) 
but enhance lysosomal enzyme release (Zurier, Hoffstein and 
Weissmann, 1973a; Becker and Showell, 1974; Goldstein et al, 
1975; Hoffstein, Goldstein and Weissmann, 1977) and oxidase 
activity (Nakagawara et al, 1976a; Okuda et al, 1976a and 
Zabucchi et al, 1978).] Nevertheless, a scheme concerning the 
participation of the microfilaments and microtubules in 
granulocyte plasma membrane oxidase activity has been devised, 
and is shown in Fig. 10.1. By virtue of their attachments to 
the enzyme or to adjacent proteins, the microfilaments are 
envisaged to physically constrain the oxidase within the plasma 
membrane. In this way the microfilaments hold the activity of 
the oxidase in check, and thus the enzyme is freed and active once 
the microfilaments are removed. However, the oxidase is optimally 
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active only as long as the microtubules are present to ensure 
that the necessary plasma membrane topography for the 
enzyme's activity is maintained. As shown in Fig 10.1, the 
microtubules may also be attached to the enzyme and to the micro-
filaments. With such a scheme it is reasonable to assume that 
the binding of particles to the surface of the granulocyte would 
result in the recruitment of microtubules to that area to aid 
ingestion and promote oxidase activity. However, some recent 
work by Berlin and Oliver (1978) would suggest that the opposite 
situation occurs. These workers found that microtubules were not 
located in the pseudopod region of phagocytic granulocytes, 
or the region underneath concanavalin A caps. Conversely, 
microfilaments were found in those regions. These findings imply 
that microfilaments are needed but microtubules are not required 
for ingestion, and perhaps the metabolic burst accompanying 
phagocytosis. Similar findings have not been reported by others, 
and in fact Berlin and Oliver (1978) admit that it is not easy to 
explain some aspects of their work. For example, it is difficult 
to understand how concanavalin A receptors can move from a region 
containing microtubules 1 to one free of them and yet rich in 
microfilaments (Berlin and Oliver, 1978; Oliver, 1978). To 
explain their unique findings they suggest that the microtubules 
control the distribution and function of the microfilaments, and 
through the microfilaments,are able to alter the topography of the 
cell surface. This is somewhat different from the scheme 
1 The binding of concanavalin A to the cell surface induces 
microtubule assembly in that region and therefore micro-
tubules subtend the regions of concanavalin A binding (see 
Oliver (1978),and section 6.4). 
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presented above and the one in which microtubules (or a 
complex of microfilaments and microtubules) modulate the cell 
surface topography, and where microfilaments control the movement 
of cell surface receptors once the microtubules are disrupted (see 
Nicolson, 1976 and Edelman, 1976). It must be emphasized that 
all of these schemes suffer from the weakness of inferring 
positive roles for the cytoskeletal elements based upon the 
results of experiments where these structures are disrupted by 
drug treatments. Nevertheless, there appears to be some 
justification for devising roles for the microfilaments and 
microtubules in granulocyte plasma membrane oxidase activity, 
as outlined in the next section (10.5). 
10.5 	The relevance of these findings to in vivo studies  
Studies of the granulocytes from patients with chronic 
granulomatous disease (CGD) have provided evidence that there is 
some justification (in vivo)for suggesting that the cytoskeletal 
elements play a role in granulocyte plasma membrane oxidase 
activity. As detailed in Appendix I, CGD granulocytes are unable 
to respond to phagocytosis with an increase in oxidase activity. 
There are a few recent reports indicating that the plasma 
membrane rather than the granule oxidase activity is defective 
in these cells (Segal and Peters, 1976, 1978; Gabig, Kipnes and 
Babior, 1978). Furthermore, lectins suCh as phytohaemagglutinin 
(PHA) and concanavalin A (con A) bind to the CGD granulocyte 
cell surface, but the cells do not then respond with the usual 
increase in HMPS and oxidase activity, even though the HMPS is 
intact (Romeo and Rossi, 1973; DeChatelet, 1975; Tsan et al 
1976a; Tsan et al, 1977; Oliver et al, 1977). In contrast, 
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the binding of either lectin by healthy granulocytes is followed 
by an increase in the number of microtubules in the cells 
(see Hoffstein, Soberman et al 1976; Weissmann et al, 1975 a,b; 
Oliver, 1976b; Oliver, Albertini and Berlin, 1976; Hoffstein 
et al, 1976; Oliver et al, 1977) as well as an increase in 
oxidase and HMPS activity (Repine et al, 1974; DeChatelet, 
Shirley and Johnston, 1976; Oliver et al, 1977). This enhancement 
in HMPS activity could be ablated if the healthy granulocytes 
were pretreated with colchicine prior to binding PHA to the cell 
surface. Thus it seems very likely that the defective oxidase 
activity of CGD granulocytes is tied in to this colchicine-
sensitive (microtubule-dependent?) mechanism for transducing 
the signal from the cell surface (PHA binding) to the interior 
(HMPS activation). [Edelman (1976) and DeChatelet (1978) have 
presented schemes where the cytoplasmic microtubules are involved 
in transducing such signals to the interior of the cell.] 
However, the defect in CGD granulocytes could arise from a more 
complex situation because:- 
(i) in contrast to the results with PHA, pretreatment 
of healthy granulocytes with colchicine prior to bind-
ing con A to the cell surface did not ablate the con A-
induced signal to increase HMPS activity (Tsan et al, 1976a) 
(ii) the amount and distribution of con A binding to the 
CGD granulocyte cell surface is normal (Tsan et al, 1976a; 
Oliver et al, 1977 respectively). Furthermore, the bound con A 
becomes redistributed into a cap in both healthy and CGD granulo-
cytes after colchicine treatment (Oliver et al, 1977) suggesting 
that CGD granulocytes have functionally normal microtubules 
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(see section 6.1). 
(iii) the studies of Nakagawara et al (1976a, 1977) showed that 
CGD granulocytes did not respond to incubation with the 
cytochalasins by exhibiting the usual enhancement in oxidase 
activity. These studies are difficult to interpret but suggest 
that the increase in oxidase activity which occurs after micro-
filament disruption is missing in CGD granulocytes. 
(iv) the cell surface of CGD granulocytes is abnormal (Lehrer, 
Olofsson and Ferrari, 1977; Segal and Peters, 1978) 
and could be responsible along with abnormal plasma membrane- 
cytoskeletal interactions for the features of CGD granulocytes 
(Oliver, 1978). 
One other disease involving the granulocytes has been 
investigated thoroughly. Chediak-Higashi granulocytes show 
impaired degranulation and chemotaxis which appear to be 
secondary to impaired microtubule function 2 . In spite of these 
two microtubule-mediated defects in function, no impairment in 
oxidase activity exists (Wolff et al, 1972). Therefore it must 
be concluded that this disease does not provide any evidence in 
favour of a role for the cytoskeleton in oxidase activity. 
It is relevant to mention that the microtubules themselves 
can be 'regulated' by oxidase activity, in that the products of 
oxidase activity (especially H202) can oxidize and thereby impair 
the function of the microtubules if the enzyme systems for 
detoxifying H2 02 are not functioning normally. Thus in patients 
2 These defects can apparently be corrected by altering the 
levels of cyclic nucleotides in the granulocytes, and thereby 
affecting the dynamic state of the microtubules (see Oliver, 
1978). 
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with a deficiency in glutathione reductase or glutathione 
synthetase there is a generalized loss of granulocyte function 
because of the microtubular defect (see Oliver, 1978). 
In conclusion, although there are only a few 
diseases which provide in vivo support, the information from 
these diseases in combination with the evidence from the in 
vitro work described herein is strongly suggestive of a role for 
the cytoskeletal elements in controlling granulocyte plasma 
membrane oxidase activity. 
10.6 	Future Work  
During the course of these studies, several lines of 
investigation which would be suitable for future work were 
uncovered, and will be mentioned at this point. 
(1) It is clear that a careful re-examination of the 
oxidase activity associated with the cytoplasmic 
granules is required. The granule oxidase activity should be 
investigated by using plasma membrane and myeloperoxidase-free 
granule fractions (see Appendix I). 
(2) Further studies of the plasma membrane oxidase of 
CGD granulocytes are required (see Appendix I). In 
addition, the granulocyte functions which have been shown to 
be mediated or influenced by the cytoskeletal elements need 
to be examined by independent laboratories. 
(3) Studies of the temporal sequence of events during the post- 
phagocytic metabolic burst are needed. Recently Tsan, 
Newman and McIntyre (1976b) provided some evidence indicating 
that superoxide production is the initial event after phagocyto-
sis, but this finding needs to be confirmed by other workers. 
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(4) 	For several reasons, an investigation of the influence of 
plasma membrane compositional changes on cell surface oxi-
dase activity is warranted. Firstly, there is evidence that the 
phospholipid composition of the granulocyte plasma membrane 
changes with phagocytosis (Elsbach, 1968; Elsbach et al, 1972). 
Secondly, studies of an NADH-dependent NBT-reductase in human 
erythrocyte. membranes (Zamudio, Cellino and Canessa-Fischer, 1969) 
- and an NADH-dependent, 0 2-generating ubiquinone reductase in beef 
heart mitochondria (Cadenas et a/, 1977; Heron, Corina and Ragan, 
1977) suggest that only the latter enzyme has a phospholipid 
requirement for optimal activity. Briggs et a/(1975) and Segal 
and Peters (1976, 1977, 1978) have provided some evidence that 
the plasma membrane oxidase of the granulocyte utilizes NADH 
as the electron acceptor. Therefore, it seems reasonable to 
suggest that studies are needed to determine if the changes in 
phospholipid composition of the membrane during phagocytosis 
can influence the activity of the plasma membrane oxidase. 
FIG. 10.1. A scheme to represent the role of microfilaments (nf) 
and microtubules (MT) in controlling plasma membrane 
oxidase activity. The oxidase (triangles) and other plasma membrane 
components (circles) are shown localized to particular regions 
within the membrane by virtue of attachments to the underlying 
mesh of microfilaments. The plasma membrane components are 
envisaged to be connected to the subtending microtubules as well. 
Hypothetical connections between the cytoskeletal elements 
are indicated by the wavy lines (top). 
As shown in the lower diagram, a suitable chemical or 
physical perturbation of the membrane disrupts the microfilaments 
in that region, leaving the microtubules free to control (and 
alter) the topography of the cell surface. With the change in 
cell surface organization the enzyme is shown located in a milieu 
favourable for its activity (see also section 10.4). 
APPENDIX I 
THE OXIDASE RESPONSIBLE FOR THE 
METABOLIC BURST 
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APPENDIX I 	THE OXIDASE RESPONSIBLE FOR THE METABOLIC BURST 
1.1 	INTRODUCTION 
With phagocytosis, granulocytes display a metabolic 
burst characterised by a cyanide-insensitive increase in 0 2 uptake, 
02 and H2 02 production, and an increase in the oxidation of 
glucose via the HMPS (section 1.3 and 1.4 of this thesis). 
Several granulocyte enzymes have been suggested as the source of 
the 92 and  H202' including myeloperoxidase (Roberts and Quastel, 
1964), D-amino acid oxidase (Cline and Lehrer, 1969; Eckstein, 
Baehner and Nathan, 1971; DeChatelet, McCall and Cooper, 1972a), 
and an NADH . or NADPH-dependent oxidase (see discussion to follow). 
As outlined by Baehner and Karnovsky (1968), the enzyme of the 
metabolic burst must display the following features:- 
(i) an insensitivity to cyanide 
(ii) H202 must be a product of the enzyme's activity
1 
(iii)the enzyme would have to be present in a large 
enough quantity in granulocytes to account for 
the oxidative stimulations seen during 
phagocytosis 
(iv)a link or relationship between the enzyme and 
the LIMPS should exist. 
1 	 - More recent work has shown that superoxide (0 2 ) is the actual product of the enzyme's activity and that H 202 is formed from 
the 02 as shown in equation 1.1 (Babior, Curnutte and McMurrich, 1976; Babior, 1978). 
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For several reasons, D-amino acid oxidase (DAAO) is 
no longer considered to be the oxidase of the metabolic burst. 
The studies of Eckstein, Baehner and Nathan (1971) showed no 
difference in the DAAO activity of healthy or chronic granulo-
matous disease (CGD) granlocytes (a disease characterised by a 
failure of the granulocytes to produce 0 2 and H202 after phago-
cytosis, as discussed in section 1.2), indicating that DAAO was 
not responsible for the 0 2 or H20 2 production. Similarly, no 
increase in HMPS activity was observed when resting or phagocytos-
ing granulocytes were incubated with D-amino acids as substrates 
for DAAO (DeChatelet, McCall and Cooper, 1972a). It has therefore 
been concluded that DAAO is unlikely to be the oxidase of the 
metabolic burst even though H 202 is a product of this enzyme's 
activity (Eckstein, Baehner and Nathan, 1971; DeChatelet, McCall 
and Cooper, 1972a). 
As mentioned above, myeloperoxidase (MPO) has also been 
considered responsible for the production of 0 2 and H 20 2 during 
phagocytosis. However, for three reasons this enzyme has been 
discounted as being involved in the oxidative events of 
phagocytosis:- 
(i) MPO-deficient patients have normal oxidase activities 
.(reviewed by Patriarca et al, 1976; McPhail, 
DeChatelet and Shirley, 1977a). 
(ii) the MPO activity of resting and phagocytosing 
granulocytes is similar, while the activity of 
the crucial oxidase rises dramatically with 
phagocytosis (McPhail, DeChatelet and Shirley, 
1977a). 
(iii) the oxidase is cyanide-insensitive while 
peroxidases, such as MPO, are known to be 
inhibited by KCN (Roberts and Quastel, 1964; 
Patriarca et al, 1976). 
Recent evidence indicates that while MPO is very 
unlikely to be the enzyme in question, it does possess NAD(P)H 
oxidase ability which, unlike its peroxidase activity, is not 
inhibited by cyanide. This and other studies which necessitate 
a re-evaluation of the role of MPO in generating 0 2 and H202 are 
discussed in section 1.3.6.2. 
1.2 	Studies with CGD and normal granulocytes  
It is widely accepted that the crucial enzyme is a 
reduced pyridine nucleotide oxidase, but there has been consider-
able debate for many years over which nucleotide (NADH or NADPH) 
is employed by the oxidase as the electron acceptor (see for 
example Karnovsky, 1962; Karnovsky, 1973; Babior, Curnutte and 
McMurrich, 1976; Babior, 1978). To study this question many 
investigators have examined the granulocytes from CGD patients. 
CGD was first recognized as a distinct clinical entity by 
Berendes, Bridges and Good (1957). It is classically an X-linked 
recessive disorder of males but can also arise in females from 
an autosomal recessive pattern of inheritance (reviewed by 
Babior, 1978). CGD granulocytes appear to ingest micro-
organisms normally (Quie et al, 1967; Stossel, Root and Vaughan, 
1972) and possess normal glycolytic pathways (Holmes, Page and 
Good, 1967), but they lack the usual post-phagocytic metabolic 
burst. They are missing the increase in 0 2 uptake, HMPS activity 
and 0/H202 production (Baehner and Nathan, 1967; Curnutte, 
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Whitten and Babior, 1974; Johnston et al, 1975), and they may or 
may not be able to degranulate normally (Quie et al, 1967; Baehner, 
Karnovsky and Karnovsky, 1968; Gold et al, 1974). As a result 
CGD granulocytes are unable to kill certain species of bacteria 
and the patients suffer from severe infections with granuloma 
formation (reviewed by Babior, 1978; Hosking, Fitzgerald and 
Shelton, 1978). Studies of CGD granulocytes have not ended the 
controversy over which pyridine nucleotide oxidase is involved, as 
investigators have demonstrated defects in NADPH-dependent oxidase 
activity (Hohn and Lehrer, 1975; McPhail et al, 1977b; DeChatelet 
et al, 1978; Gabig, Kipnes and Babior, 1978); NADH-dependent 
oxidase activity (Baehner and Nathan, 1968; Baehner and Karnovsky, 
1968; Karnovsky, 1973; Segal and Peters, 1976, 1978); both 
oxidases (Hohn and Lehrer, 1975; Babior, Curnutte and McMurrich, 
1976; Iverson et al, 1977); or neither oxidase (Nathan, Baehner 
and Weaver, 1969). 
Similarly, investigations of the oxidase activity 
of healthy (non-CGD) granulocytes have proved just as contradic-
tory. A survey of the literature reveals that most authors 
favour an NADPH oxidase, and for that reason the remainder of 
this Appendix will be primarily concerned with examining the 
arguments for and against the NADPH oxidase. It is clear that 
the debate over which oxidase is responsible for the metabolic 
burst is still unresolved, although Babior (1978) recently 
stated that he believed the evidence to overwhelmingly favour 
NADPH. 
1.3 	Arguments for and against an NADPH oxidase  
1.3.1 	The link between the oxidase and the HMPS  
It has been pointed out by several workers that a 
direct link between the activity of the oxidase and the 
stimulation of the HMPS exists when the oxidase employs NADPH, 
but not NADH (Cagan and Karnovsky, 1964; Baehner and Karnovsky, 
1968; Baehner, Gilman and Karnovsky, 1970; Patriarca et al, 
- 1971b). A reduction of 0
2 
to 0
2 
 (and ultimately H202) by an 
NADPH oxidase would result in the production of NADP , as shown 
by Babior (1978):- 
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where 1 = NADPH oxidase 
2 = superoxide dismutase 
The NADP thus produced would directly stimulate 
the HMPS, as the level of NADP + controls the rate of glucose 
oxidation by this pathway (Beck, 1958). HMPS activity then 
regenerates NADPH and completes the cycle. As shown in Figure 
1.1, H 20 2 which leaks from the phagosome would be destroyed by 
catalase, or would react with reduced glutathione (reviewed by 
Babior, 1978). The coupling of the glutathione peroxidase and 
glutathione reductase systems would result in the regeneration 
of reduced glutathione, and the production of another source of 
NADP+ to stimulate the HMPS (Reed, 1969; Stossel, 1974; Baehner 
et al, 1975). 
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If the oxidase utilized NADH however, there would 
no longer be a direct link between the production of 0 2/H20 2 and 
the stimulation of the HMPS (Cagan and Karnovsky, 1964; Baehner and 
Karnovsky, 1968; Baehner, Gilman and Karnovsky, 1970; Patriarca 
et al, 1971b). As shown in Figure 1.2, NADH is formed in the 
Embden-Meyerhof pathway where triose phosphate is converted to 
1,3-diphosphoglycerate 2 . An indirect link between the oxidation 
of NADH and the stimulation of the HMPS could be achieved in 
three ways:- 
1.3.1.1 	The glutathione peroxidase/glutathione reductase scheme  
. The NADH oxidase activity would produce 0 2 and 
H202 as shown below in equation 1.2. The H 2 02 thus produced would 
be detoxified via glutathione peroxidase, followed by the reduction 
of GSSG coupled to NADP + formation via glutathione reductase. 
The formation of NADP + in this way would then drive the RMPS (Reed, 
1969; Baehner, Gilman and Karnovsky, 1970). 
Jacobs and Jandl (1966) and Reed (1969) have shown 
that this pathwy is quantitatively very important for H 20 2 
utilization in granulocytes from species other than man. Further- 
more, it has been shown that the key enzymes glutathione 
peroxidase and reductase exist in human granulocytes (Holmes 
et al, 1970; Baehner, Gilman and Karnovsky, 1970; Bass et al, 
1977), and that enough glutathione reductase activity is present 
to account for the required re-oxidation of NADPH during 
phagocytosis (Baehner, Gilman and Karnovsky, 1970). In addition, 
2 
As discussed in sections 1.3.1.3 and 1.3.4, the NADH thus 
formed would be the substrate for both NADH oxidase and 
lactate dehydrogenase. 
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reduced glutathione levels fall dramatically (Mendelson, 
Metz and Sagone, 1977) and glutathione reductase activity rises 
within seconds of phagocytosis (Strauss et al, 1969) suggesting 
the existence of this scheme. The pathway as shown by Wilkinson, 
Powars and Hochstein (1975) is:- 
H+ 2H2 01\\ (GSSG\(NADPH + 
3 	4 
H202d// \ 2GSHI\kNADP+ ....HMPS 
stimulation 
NADH + H (02 
NAD NO 
2 
\ 2 
(1.2) 
1.3.1.2 
where 1 = NADH oxidase 
2 = superoxide dismutase 
3 	glutathione peroxidase 
4 = glutathione reductase 
GSSG = oxidized glutathione 
GSH = reduced glutathione 
A transhydrogenase  
A transhydrogenase (TH) may link the oxidized and 
reduced forms of the two pyridine nucleotides, thereby producing 
the NADP+ required to drive the HMPS (Evans and Karnovsky, 1961; 
Evans and Kaplan, 1966):- 
NAD+ + 	NADPH TH NADH 	NADP (1.3) 
 
This pathway does operate in the guinea pig, and 
transhydrogenase levels in human granulocytes are greatly in 
excess of those required to produce enough NADP + to drive the 
HMPS (Evans and Kaplan, 1966; Baehner, Johnston and Nathan, 1972). 
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1.3.1.3 	A lactate dehydrogenase  
Evans and Karnovsky (1961) have described a guinea 
pig lactate dehydrogenase (LDH) which uses NADPH and therefore 
provides the NADP + required to stimulate the IMPS. The scheme can 
be shown as:- 
LDH pyruvate 	+ 	NADPH 	• lactate 	+ 	NADP 	(I.4) 
This pathway also overcomes the problem of NADH (the usual substrate 
for LDH) becoming depleted by the NADH oxidase and therefore un-
available for the LDH-catalyzed reaction. An NADPH-dependent LDH 
has not yet been found in the human granulocyte, however (Baehner, 
Gilman and Karnovsky, 1970). 
In conclusion, any one of these three pathways could 
provide a link, albeit indirect, to couple the activity of an 
NADH oxidase to the stimulation of the HMPS. It is apparent that 
further studies are required to establish the importance of these 
three pathways in human graLulocytes. 
1.3.2 	Evidence supporting the NADPH oxidase from studies with G6PD- 
deficient patients  
Another argument put forward to support an NADPH 
oxidase is that a deficiency in G6PD can lead to a CGD-like 
syndrome, with failure in H 2 02 production and antimicrobial 
activity after ingestion (Cooper et al, 1970; Baehner, 
Johnston and Nathan, 1971; Cooper et al, 1972; Gray et al, 
1973; Babior, 1978). As shown in Figure 1.2 the activity of 
the enzyme G6PD and the reduction/oxidation of NADP +/NADPH 
are linked as the first step of the HMPS, providing the explan-
ation for the lowered NADPH oxidase activity of G6PD-deficient 
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granulocytes (reviewed by Babior, 1978). However, it has been 
pointed out that both NADH and NADPH oxidase activities are low 
in this disease, because of transhydrogenase reactions (Baehner, 
Johnston and Nathan, 1972). Therefore the existence of a 
diminished production of H 2 02 in patients with G6PD deficiency 
cannot be construed as evidence in favour of an NADPH oxidase 
as the enzyme of the metabolic burst. 
	
1.3.3 	Studies of the changes in NAD(P) +/NAD(P)H levels after  
phagocytosis  
Selvaraj and Sbarra (1967) have suggested that the 
changes in the ratios NAD +/NADH and NADP 4-/NADPH reliably reflect 
the events of the post-phagocytic metabolic burst. They found, 
as did Rossi, Romeo and Patriarca (1972) that in guinea pig 
' granulocytes, the quotient NADP +/NADPH (but not NAD+  /NADH) 
rose after phagocytosis, and therefore concluded that the 
oxidase of the post-phagocytic metabolic burst utilized NADPH. 
Recently Aellig et al (1977) also examined the ratios, and 
found that for guinea pigs these workers were correct, but for 
human granulocytes both ratios were affected similarly. Such 
studies indicate that neither oxidase is favoured, and that 
both NADH and NADPH oxidases could be involved in the oxidative 
changes in human granulocytes. 
1.3.4 	The problem of competition for NADH as substrate  
Another argument put forward to support the case 
for NADPH and against NADH is the fact that the NADH oxidase 
would have to compete against lactate dehydrogenase (LDH) for 
glycolytic NADH (Patriarca et al, 1971a,b). In guinea pig 
granulocytes,* the Km for LDH with respect to NADH has been 
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calculated to be 4 x 1o_61  while for NADH oxidase it is 
4 x 10-3M (Rossi, Romeo and Patriarca, 1972). Thus it has been 
suggested that the NADH oxidase would not be able to compete 
successfully against LDH for NADH as substrate, and therefore 
an NADH oxidase is not likely to be the critical enzyme of the 
metabolic burst (Rossi, Romeo and Patriarca, 1972). Other 
investigators had pointed out earlier that this might be a 
problem (Cagan and Karnovsky, 1964). Nevertheless, this argument 
in favour of the NADPH oxidase may be criticized for several 
reasons:- 
(i) the experiments of Rossi, Romeo and Patriarca (1972) 
were not conducted on human granulocytes, and, as 
indicated by Aellig et a/ above (section 1.3.3), 
guinea pigs cannot be considered to be comparable to 
humans with respect to the events of the metabolic 
burst. That the species are not identical can also 
be seen by examining the levels of granulocyte 
glutathione peroxidase (Baehner, Gilman and KarnovskY, 
1970; Bass et al, 1977) 
(ii) the Km values for the NADH oxidase towards NADH have 
been reported by others to be much lower. For 
example, when a plasma membrane NADH oxidase of 
human granulocytes was studied the Km was 1.7 1.0 
(Segal and Peters, 1976). As the cyanide-insenstive 
NADH oxidase may be located in the plasma membrane 
rather than the granules (the fraction studied by 
Patriarca's group), the Km value of 1.7 11M may be 
more accurate (see section 1.4). 
	1.3.5 	The K  of the NAD(P)H oxidase -towards its substrate  
It has been pointed out that the Km of the NADPH 
oxidase with respect to NADPH is much lower than the K m of 
the NADH oxidase towards NADH, and therefore an NADPH oxidase 
is more likely to be the enzyme of the metabolic burst (Rossi, 
Romeo and Patriarca, 1972; Babior, Curnutte and Kipnes, 1975; 
Babior,'Curnutte and McMurrich, 1976). 4 major criticism can be 
levelled at these studies, namely that all of the workers examined 
the Km values for oxidases found in granule fractions from 
disrupted cells, while recent evidence indicates that the KCN-
insensitive NADH oxidase at least is localized in the plasma 
membrane rather than the granule fraction (see section 1.4). 
- 1.3.6 	The Mn+2   requirement of the NADPH oxidase  
1.3.6.1 The oxidase of the granule-containing fractions  
In 1971 and 1972, Rossi and Patriarca's group 
suggested that the granulocyte NADPH oxidase located in the 
granule fraction of disrupted cells required Mn +2 for 
full activity in vitro (Patriarca et al, 1971b; Rossi, Romeo 
and Patriarca, 1972). Since those reports most investigators 
have added Mn +2 to their fractions when quantitating NADPH 
oxidase activity. The need to add Mn+2 to demonstrate NADPH 
oxidase activity was first questioned by Karnovsky (1973), and 
more recent evidence shows that the Mn +2 requirement is not 
physiological. For example, Curnutte, Karnovsky and Babior 
(1976) have shown that virtually all of the characteristics of 
the NADPH-dependent oxidase activity associated with the granule 
fraction can be reproduced in a Mn+2 - requiring granulocyte-
free system employing xanthine oxidase (from milk) to generate 
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02* In these studies, they found that the pH optimum for 
xanthine oxidase was different from reported values, and that 
an unusual stoichiometry between the amount of NADPH oxidized 
and 0 2 produced existed - with the highest rates of 0 2 production 
very little NADPH was oxidized and vice versa. From this they . 
concluded that the model xanthine oxidase system does not require 
enzyme interaction with Mn+2 or NADPH, and that a Mn+2 -catalyzed 
free radical chain reaction was responsible for the 0; production. 
Thus, Curnutte, Karnovsky and Babior (1976) have shown that a Mn +2 
-dependent NADPH oxidation can occur in the absence of a granulocyte 
fraction. However, they state that as the non-enzymatic oxidation 
of NADPH in the presence of Mn +2 is initiated by 0 '  then a true 2 
granule oxidase activity, which is NADPH-dependent, must provide 
the 0 2 required to initiate the reaction. It would appear that 
these authors cannot consider this as proof of the existence of a 
true 02 Producing granule fraction NADPH oxidase, because Auclair 
et a/(1976) have shown that 0 2 can be produced in a comparable 
system completely devoid of granulocytes. 
Thus it must be concluded that any studies which 
were conducted on a granule fraction oxidase in the presence 
of Mn+2 are open to the criticism that an enzyme-catalyzed 
oxidation of NADPH may not have been measured at all. 
The Mn+2-catalyzed oxidation of NADPH by MPO  
The problem with respect to the non-enzymatic 
oxidation of NADPH when Mn +2  is present has been revealed by 
Takanaka and O'Brien (1975). These workers have shown that 
granulocyte MPO (which would be present in most granule 
fractions from disrupted granulocytes) has an NAD(P)H oxidase 
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activity in addition to its classical peroxidase activity. This 
- oxidase activity produces 0 2' is enhanced greatly by Mn
+2 , and 
is cyanide-insensitive although the classical peroxidase activity 
of MPO is not. As with the reaction described by Curnutte, 
Karnovsky and Babior (1976), the interaction between Mn +2 and MPO 
- is mediated by 02 , is autocatalytic and involves a free radical 
chain reaction. From these studies it is clear that MPO may be • 
the source of the NAD(P)H oxidase activity observed in granule 
fractions to which Mn+2 has been added. 
As an argument against MPO as the source of the granule 
fraction NADPH oxidase activity, Patriarca et al (1976) and McPhail, 
DeChatelet and Shirley (1977a) compared the effects of various stimu-
lators and inhibitors on the NADPH oxidase activity of several 
purified peroxidases (including MPO), and the granules from 
phagocyric cells. Although both groups found striking parallels 
between the effects of these agents on the two oxidase activities 
(and concede that there is strong evidence that the oxidase 
activity of the granule fractions may be due to MPO), they point 
out that there are several reasons for excluding MPO as being 
responsible:- 
(i) MPO-deficient patients have normal oxidase 
activity (reviewed by Patriarca et al, 1976; 
McPhail, DeChatelet and Shirley, 1977a) 
(ii) the critical oxidase is cyanide-insensitive while 
MPO is inhibited by cyanide (Hohn and Lehrer, 
1975; Kakinuma and Chance, 1977) 
(iii) there is no difference in MPO activity between 
resting and phagocytosing granulocytes, whereas 
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phagocytosing granulocytes display an increase 
in NADPH oxidase activity (McPhail, DeChatelet and 
Shirley, 1977a). 
Unfortunately these arguments against the granule 
fraction oxidase activity being due to MPO are not conclusive, 
because:- 
(i) it has not been definitively established that 
MPO-deficient granulocytes are completely lacking 
in MPO (see Patriarca et al, 1976) 
(ii) the NADPH oxidase activity of MPO has been shown 
to be cyanide-insensitive, while the peroxidase 
activity is not (Takanaka and O'Brien, 1975b) 
(iii) Paul et al (1972) have found that MPO activity does 
increase with phagocytosis, just as NADPH oxidase 
activity does. 
From the above discussion it can be seen that Mn +2 - 
containing granule fractions catalyze an oxidation of NADPH which 
must not be ascribed to a true NADPH oxidase. As outlined, the 
oxidation in the presence of Mn +2  may be due to MPO (the studies 
of Patriarca et al, 1976; McPhail, DeChatelet and Shirley, 1977a), 
or it may be a completely non-enzymatic free radical chain 
reaction (Curnutte, Karnovsky and Babior, 1976). Such studies 
detailing a Mn+2-stimulated oxidation of NADPH render many 
earlier reports on CGD and normal granulocytes open to criticism, 
for example, the studies of Rossi and Zatti, 1964; Patriarca 
et al, 1971b; Hohn and Lehrer, 1975; DeChatelet et al, 1975; 
Rossi, Romeo and Patriarca, 1972. 
It is interesting to note that although 
research has been carried out in the absence of Mn+2 by several 
groups, the controversy over an NADH or NADPH oxidase still 
exists. With reference to these studies, some favour an NADH 
oxidase:- 
- Cagan and Karnovsky (1964) 
- Baehner and Karnovsky (1968) 
- Baehner and Nathan (1968) 
- Baehner, Gilman and Karnovsky (1970) 
- Mandell and Sullivan (1971) 
- Briggs et al (1975) 
- Segal and Peters (1976, 1977, 1978) 
while some still favour an NADPH oxidase:- 
- Hohn and Lehrer (1975) 
- McPhail, DeChatelet and Shirley (1976) 
- McPhail et al (1977b) 
- Iverson et al (1977) 
- DeChatelet et al (1978) 
- Gabig, Kipnes and Babior (1978) 
- Auclair, Torres and Hakim (1978) 
and some find evidence to support either NADH or NADPH: - 
- Hohn and Lehrer (1975) 
- Babior, Curnutte and McMurrich (1976) 
- Iverson et al (1977) 
and again, some find neither oxidase is supported:- 
- Nathan, Baehner and Weaver (1969) 
- Babior, Curnutte and Kipnes (1975) 
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	1.3.7 	The levels of the oxidase in granulocytes 
As an argument against the NADPH oxidase, Karnovsky 
(1973) has pointed out that this enzyme activity does not exist 
in granulocytes at the level claimed by Patriarca et al (1971a,b), 
but only at one-tenth of that level, and therefore not enough 
NADPH oxidase activity is available to explain the oxidative events 
of phagocytosis. Patriarca and Rossi's group have agreed that 
the level is too low, but they maintain that this is overcome by the 
fact that they find the enzyme's Km towards NADPH is lowered 10- 
fold during phagocytosis (Patriarca et al, 1971b; Rossi, Romeo 
and Patriarca, 1972). However, Hohn and Lehrer (1975), who have 
conducted comparable experiments on the NADPH oxidase, found 
that the Km did not appreciably change with phagocytosis. The 
experiments of Patriarca's group and those of Hohn and Lehrer 
were conducted with Mn+2 present. In this regard, it has been 
shown that a change in Km with increasing 0 2 production (a 
situation comparable to the observations of Patriarca's group) 
can be duplicated by the Mn+2-dependent, granulocyte-free system 
studied by Curnutte, Karnovsky and Babior (1976). Therefore it 
must be concluded that the change in Km with phagocytosis may 
have been artefactually produced by Mn +2 (see section 1.3.6.1, 
above). 
1.3.8 	The rate of oxidase activity  
Although some groups of investigators report that 
the oxidation of NADPH by resting or phagocytosing granulocytes 
proceeded at a higher rate than the oxidation of NADH (Rossi, 
Romeo and Patriarca, 1972; Hohn and Lehrer, 1975; Auclair, 
Torres and Hakim, 1978), others have found just the opposite 
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(Evans and Karnovsky, 1961; Evans and Karnovsky, 1962). The 
study of Rossi, Romeo and Patriarca can be criticized because Mn +2 
was present during measurements of NAD(P)H oxidase activity (section 
1.3.6.1). • In addition, both studies finding a higher rate of 
NADPH oxidation can be questioned because the oxidase activity 
was quantitated in granule fractions only. It has recently be- 
come apparent that the plasma membrane contains a very significant 
part (if not all) of the NADH oxidase activity (see section 1.4). 
Interestingly, some investigators have recently 
stated that single oxidase which catalyzes both NADH and NADPH 
oxidations, but to different extents, may be involved. All of 
the following workers however, believe that the oxidase favours 
NADPH as the substrate:- 
- Rossi, Romeo and Patriarca (1972) 
- Allen et a/ (1974) 
- Babior, Curnutte and Kipnes (1975) 
- Johnston et al (1975) 
- McPhail, DeChatelet and Shirley (1976) 
- Iverson et al (1977) 
In contrast, Takanaka and O'Brien (1975a) have 
examined a guinea pig oxidase which can utilize NADH or 
NADPH to virtually the same extent. They provide compelling evidence 
that the cyanide-insensitive oxidase activity is located in the 
plasma membrane of the granulocyte (see also section 1.4). 
1.4 	The intracellular location of the 0 2 producing oxidase  
Since Iyer and QuasteI's early investigations in 1963, 
many other workers have found and studied the oxidase activity of 
the granule fraction of disrupted cells. For example, Patriarca's 
group found the oxidase activity of rabbit granulocytes was located 
in a granule fraction which contained the azurophilic (myeloper-
oxidase-containing) granules (Patriarca et al, 1973). Other 
groups have examined the oxidase activity of a comparable 
granule fraction from fractionated cells (Hohn and Lehrer, 1975; 
DeChatelet et al, 1975; McPhail et al, 1977b. However, not all 
investigators agree on the exact location of this oxidase - one 
group maintains that the oxidase is located in a granule fraction 
which does not contain either the azurophilic or specific granules, 
but contains instead large and dense granules (Iverson et al, 
1977, 1978). Some of these investigators found no oxidase activity 
in the supernatant (Rossi, Romeo and Patriarca, 1972; Hohn and 
Lehrer, 1975), in agreement with the early studies of Karnovsky's 
group (Evans and Karnovsky, 1961). However, a later paper by 
Karnovsky's group explained that their laboratory had failed to 
detect NADH oxidase activity in their supernatant preparations 
because they had been too diluted by the procedure for cell 
fractionation (Cagan and Karnovsky, 1964). They found that if 
the granulocytes were homogenized in sucrose, then the oxidase 
activity was equally divided between the granule and soluble 
fractions of the cell, whereas in isotonic KC1 all of the enzyme 
was localized to the soluble fraction (Karnovsky, 1973). The 
methodology used for cell fractionation is therefore quite crucial. 
Workers who have found that the oxidase is largely in the 
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supernatant or soluble fraction include Cagan and Karnovsky, 
1964; Baehner and Nathan, 1968; Baehner and Karnovsky, 1968; 
Kakinuma and Chance, 1977. 
It is interesting to note that recent work has 
focused on a plasma membrane location for the oxidase. Early 
workers suggested that the plasma membrane (Salin and McCord, 
1974), or a site close to the cell surface (Root and Stossel, 
1974) was involved because they detected large amounts of 0; 
or H2 02 in the external medium surrounding the intact granulocyte. 
As Salin and McCord emphasized, it is likely that the 0 2 comes 
from the cell surface because the intracellular presence of super-
oxide dismutase would preclude the diffusion through the cell 
of 02 produced intracellularly. Many investigators have now 
detected and studied a plasma membrane oxidase activity. All 
but Takanaka and O'Brien have examined the oxidase in human 
granulocytes:- 
- Takanaka and O'Brien (1975a,guinea pig granulocytes) 
- Briggs et al (1975) 
- Segal and Peters (1976, 1977, 1978) 
- Cohen and Chovaniec (1977) 
- Goldstein et al, (1977) 
- Briggs, Karnovsky and Karnovsky (1977) 
- Gabig, Kipnes and Babior (1978) 
- Babior et al (1978) 
- Tauber and Goetzl (1978) 
- Dewald et al (1979) 
In addition, some workers have found that their 
investigations indirectly support a plasma membrane location for 
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the oxidase (Nakagawara et al, 1977 ; Root and Metcalf, 1977; 
Jandl et a/, 1978). It is relevant to note also that some 
of the recent papers from investigators who had been studying a 
granule-fraction oxidase state that their granule fractions 'were 
not 'pure', but contained some plasma membrane contamination 
(DeChatelet et a/, 1975; Rossi, Romeo and Patriarca, 1976; 
Iverson et al, 1978). 
Some of the investigators have studied the nucleotide 
specificity of the plasma membrane oxidase, finding it to be an 
NADH oxidase (Briggs et al, 1975; Segal and Peters, 1976, 1977, 
1978), or an oxidase with greater reactivity towards NADPH than 
NADH (Tauber and Goetzl, 1978). 
It seems certain that an oxidase is located in the 
plasma membrane, but further study is required to determine the 
characteristics of this enzyme. As mentioned in the Introduction 
to this thesis, teleologically it would be sensible to have the 
oxidase located in the plasma membrane because with phagocytosis 
the enzyme would be internalized to become part of the phagocytic 
vacuole membrane, thereby facilitating the delivery of 0 -2 and 
112 0 2 to the contents of the phagosome. 
1.5 	Recent studies on the plasma membrane of CGD granulocytes 
Studies of the granulocyte plasma membrane by 
Segal and his associates have suggested that the human membrane 
contains a novel cytochrome b which is also incorporated into 
the phagosome membrane at phagocytosis (Segal et al, 1978; 
Segal and Jones, 1978, 1979). These investigators believe that 
this cytochrome is a component of the plasma membrane oxidase, 
which they had previously shown to be located in the plasma 
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membrane (Segal and Peters,.1976, 1977, 1978). This plasma 
membrane cytochrome, like the oxidase, was abnormal or undetectable 
in CGD patients, two obligate heterozygotes (the mothers of two 
affected sons), and both parents of a female CGD patient. 	Although 
Segal et a/ have not proven that the abnormality in this cytochrome 
is associated with the abnormal oxidative metabolism of CGD, their 
suggestion that the abnormal cytochrome b may be the molecular 
basis for the abnormal plasma membrane oxidase activities of their 3 
CGD patients seems reasonable. Only Segal's group and one other 
have examined the granulocytes from CGD patients and subsequently 
suggested that the actual defect in CGD is in the plasma membrane 
oxidase (Segal and Peters, 1976, 1978; Gabig, Kipnes and Babior, 
1978). The second group also provides some evidence that the 
02-producing oxidase requires flavin adenine dinucleotide (FAD) as 
a co-factor for activity (Babior and Kipnes, 1977; Gabig, Kipnes 
and Babior, 1978). 
Segal and Peters (1978) point out that the plasma 
membrane of CGD granulocytes is abnormal in other respects as 
well 7 the Kell antigen system may be absent from these 
granulocytes (Marsh et al, 1975), and fusion of the phagocytic 
vacuole with the granules may be delayed (Gold et al, 1974). To 
these may be added more recent reports indicating that the CGD 
granulocyte plasma membrane is indeed abnormal:- 
3 It must be mentioned that Borregaard et al (1979) have not 
found an absence or abnormality in this cytochrome b in the 
granulocytes of three CGD patients. 
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CGD granulocyte cell surfaces are able to 
bind the normal amount of concanavalin A but then 
the granulocytes do not show the typical lectin-
induced HMPS stimulation (Tsan et al, 1976a, 
1977) 
(ii) CGD granulocytes show a very modest increase in 
86 Rb efflux after phagocytosis whereas control 
granulocytes display a marked (6-fold) augmenta-
tion of 86Rb efflux from the cell surface 
(Lehrer, Olofsson and Ferrari, 1977). 
(iii) the studies of Nakagawara at al (1976a, 1977) 
on CGD patients (described in section 4.4 of this 
thesis) indicate that the plasma membrane oxidase 
of CGD granulocytes is defective in function. 
In conclusion, while the evidence to support the 
NADH oxidase has not been as strong as that to support the 
NADPH oxidase, many of the arguments in favour of the NADPH 
oxidase as the enzyme of the metabolic burst can be questioned 
or refuted. Future studies of this enzyme will need to re-
ekamine the oxidase activity from pure granule fractions, 
that is, granule fractions free of myeloperoxidase and plasma 
membrane contamination. It is clear that further investigations 
of the defective enzyme in CGD granulocytes are also required 
before firm conclusions as to the nature of the oxidase of the 
metabolic burst can be drawn. 
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FIG. 1.1 Activation of the 1-IMPS by an NADPH-dependent 
oxidase. The enzymes involved are:- 
1. glucose-6-phosphate dehydrogenase 
2. NADPH oxidase 
3. superoxide dismutase 
4. catalase 
5. glutathione peroxidase 
6. glutathione reductase 
and grips = hexose monophosphate shunt 
GSH = reduced glutathione 
GSSG = oxidized glutathione 
1.2 The Embden-Meyerhof pathway, as modified from Arese and Bosia 
(1973). The enzymes involved are:- 
1. glucokinase (=hexokinase) 
2. phosphoglucose isomerase 
3. phosphofructokinase 
4. aldolase 
5. triosephosphate isomerase 
6. glyceraldehydephosphate dehydrogenase 
7. phosphoglycerate kinase 
8. phosphoglycerate mutase 
9. enolase 
10. pyruvate kinase 
11. lactate dehydrogenase 
12. glucose-6-phosphate dehydrogenase 
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APPENDIX II 	THE PREPARATION OF THE HEPES PHYSIOLOGICAL 
SALINE SOLUTIONS 
HEPES physiological saline solution (HSS)  
HSS was prepared as described previously (Dewar et al, 
1976). That is, 10 ml of a concentrated salt solution (II.4.1). 
10 ml of glucose, 155 mM (II.5), 20 ml of HEPES buffer solution, 
58.5 mM (I1.6), and 90 ml of water were mixed daily for experiments. 
The final composition of HSS was therefore 136.9 mM Na l- , 6.0 mM 
- K+ , 1.2 mM Mg+2 , 2.4 mM Ca+2 , 150.1 mM CI , 11.9 mM glucose and 
9.0 mM HEPES, with a pH of 7.4. 
Ca+2 and kg+2 free physiological saline solution (CKFH)  
CMFH was also prepared as described previously (Dewar 
et al, 1976). That is, 10 ml of a concentrated salt solution 
+2 minus Ca+2 and Mg 	(11.4.2), 10 ml of glucose, 155 mM (I1.5), 
20 ml of HEPES buffer solution, 58.5 mM (II.6), and 90 ml of water 
were mixed daily for experiments. The final composition of CMFH 
- was therefore 142.9 mM Na + , 6.0 mM K+ , 148.9 mM Cl , 11.9 mM 
glucose and 9.0 mM HEPES, with a final pH of 7.4. 
Ca+2 free physiological saline solution (CFH)  
CFH was prepared by mixing 10 ml of a Ca +2 free 
concentrated salt solution (11.4.3), 10 ml of glucose, 155 mM 
(I1.5), 20 ml of HEPES buffer solution, 58.5 mM (II.6), and 90 
ml of water daily for experiments. The final composition of 
CFH was therefore 140.6 mM Na+ , 6.0 mM K+ , 1.2 mM Mg+2 , 149.1 
- mM Cl , 11.9 mM glucose, and 9.0 mM HEPES, with a pH of 7.4. 
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11.4 
	Concentrated salt solutions  
The following concentrated salt solutions were prepared 
every 2-3 weeks and stored at 4°C in Nalgene containers in between use. 
11.4.1 	Concentrated salt solution for HSS  
NaC1 	52.0 g 
KC1 2.89 g 
MgC1 2x 6H20 	1.57 g 
CaC1 2 x 2H20 2.58 g 
- made up to a volume of 500 ml with water. 
11.4.2 	Concentrated salt solution for CMFH 
NaC1 	54.3 g 
KC1 2.89 g 
- made up to a volume of 500 ml with water. 
11.4.3 	Concentrated salt solution for CFH  
NaC1 	53.4 g 
KC1 2.89 g 
MgC12 x 6H2 0 	1.57 g 
- made up to a volume of 500 ml with water. 
11.5 	Glucose, 155 mM  
This solution was prepared fresh daily for experiments 
and contained 2.79 g of d-glucose (dextrose) per 100 ml of water. 
11.6 	HEPES buffer solution, 58.5 mM  
This solution was prepared by dissolving 13.94 g HEPES 
in approximately 700 ml water, adjusting the pH to 7.4 with 1 M-
Na0H, and then adding sufficient water to make one litre. The 
buffer was prepared every 2-3 weeks and stored at 4 °C in a Nalgene 
container in between use. 
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The experiments on the variation in NBT reduction 
rate with the concentration of NBT (section 3.2.4.3) were 
analysed by using an enzyme kinetics approach. It was felt that 
such an analysis of the data was necessary to determine if the 
assay of the initial rate of NBT reduction was reproducible with 
granulocytes isolated from different donors. For this analysis, 
the principles of kinetic theory were reviewed by consulting 
the detailed discussion of enzyme kinetics presented by Mahler 
and Cordes (1966). These principles will be briefly outlined at 
this point. 
If the reduction of NBT to diformazan is thought of 
as a simple chemical reaction, such as 
k1 
02 + 0; + NBT
+2 
 
NET 	+ 	202 	(III.1) k-1 
then the reaction can be characterised by describing how fast 
NBT+2  is reduced to diformazan, that is, by the kinetics of the 
reaction. The law of mass action specifies that the rate of a 
reaction is proportional to the concentration of the participat-
ing reactants (or substrates), and thus 
rate (or velocity) 	= k1 	[reactants] 
where k 1 is a proportionality constant. For the reaction 
presented above, the rate of formation of diformazan from 
-  NBT+2 = k1 f02 ]
2  • [NBT+2 ]. The rate of this reaction is 
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dependent upon the concentration of three reactants (2 molecules 
- of 02 and one of NBT
+2 ), and therefore the reaction is third order. 
However, reactions with 3 participants usually proceed by a series 
of bimolecular and/or monomolecular steps (Mahler and Cordes, 
1966). It seems reasonable to assume that the rate limiting, 
or slowest step of the reaction would be the half reduction of 
NBT+2 (by one molecule of 02 ) to form the monoformazan (Eadie 
et al, 1970). The reaction could be shown as 
02 + NBT
+2 
 
k1 
k-1 
NBT+1  + 02 
 
The rate of the overall reaction (III.1) would thus be second 
order, with the rate (or velocity) = k l [0:] [NBT+2]. If 
however, we consider the reduction of NBT to formazan as an 
enzyme catalyzed rather than a simple chemical reaction, we can 
study the reaction by using an equation which was devised by 
Michaelis and Menten (1913). They showed that for most enzyme 
catalyzed reactions performed under carefully controlled 
conditions, the variation of rate (velocity) with substrate 
concentration can be described by the following equation:- 
V 	[S] velocity = 	max 
Km + [S] 
where V max = the maximal velocity of the reaction 
[S] = the concentration of the substrate 
(in this case, NBT+2 ) 
and Km 	= the concentration of substrate at which 
the reaction proceeds half-maximally. 
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If the concentration of substrate is large with 
respect to the Km then the equation can be rewritten in such a 
way as to reduce the kinetic order of the reaction (by one) to 
zero order. Thus, 
V 	[S] 	VmaX [S] 	V velocity = max max 
Km + [S] [S] 
That is, the velocity approaches Vmax when [5] is 
very high, and therefore the velocity becomes independent of the 
substrate concentration. In the laboratory this is an important 
consideration because most studies are done on initial velocity 
(or initial rate), and in such studies the substrate concentration 
at any point during the reaction does essentially stay equal to 
the substrate concentration at zero time (i.e. these reactions 
are apparently zero order). 
The shape of the plot of Michaelis-Menten data 
(variation of rate with substrate concentration) is a rectangular 
hyperbola (Fig. III.1). Such a graph is completely defined by 
the two kinetic parameters, V x and K. These two parameters 
are both necessary and sufficient to define the kinetics of 
most reactions, provided the following criteria have been met:- 
(i) only a single substrate is involved (or if more than 
one is involved, the concentrations of all the other 
substrates are held constant). 
(ii) true initial rates (or initial velocities) of the 
reaction are measured by using different starting 
concentrations of the substrate. 
(iii) the concentration of the substrate at zero time is 
much greater than the concentration of the enzyme 
at zero time, and the same constant concentration 
of the enzyme at zero time is used in all measure-
ments. 
(iv) all other variables (temperature, buffer, etc.) are 
held constant in all measurements. 
Determining the Km and Vmax from the hyperbolic 
curve is very difficult as it involves determination of an asymptote 
as the substrate concentration approaches infinity. Therefore 
the data from the Michaelis-Menten plot is usually replotted as 
a straight line (Lineweaver and Burk, 1934), as described by the 
following equation:- 
1 
	
1 	 1 	 (II1.4) 
velocity 	Vmax 	ES) 
	Vmax 
The straight line from such plots (Fig. 111.2) of 
1/velocity versus 1/concentration can be used to determine the 
Km and Vmax values. 
With the foregoing as a guideline, the granulocytes 
from 16 normal donors were used for 16 experiments on the 
variation in NBT reduction with the concentration of NBT. 
Five concentrations of NBT were tested in each experiment. The 
data from these experiments gave the rectangular hyperbolae 
described by the Michaelis-Menten equation. Two of the 16 
plots are illustrated in Fig. 111.3. These graphs were 
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transformed to straight lines (Lineweaver-Burk plots) by plotting 
the data as 1/velocity versus 1/NBT concentration. The two 
curvilinear plots of Fig. 111.3 are shown as linear plots in 
Fig. 111.4. 
The data was fitted to these straight lines by the 
linear regression method using a Hewlett Packard calculator 
(HP 27). From the calculator, the values for the y-intercept 
(= 1/Vmax value), slope (= Km/Vmax value) and 'r' (correlation 
coefficient) 1 were obtained. By dividing the y-intercept 
value by the slope, the x-intercept (= 1/Km value) was obtained, 
and the line could then be drawn through the two intercepts, 
as shown in Fig. 111.4. The 'apparent Km ', 
2 Vmax , and r 
values for the plots from these 16 donors are given in Table 
111.1. There was very good agreement in these values, suggesting 
that the initial rate assay was reproducible with granulocytes 
obtained from different normal donors. 
1 Correlation coefficients are used to guage the 'goodness 
of fit' of the data to a straight line, perfect fit 
being a correlation coefficient of +1.00 for these lines. 
2 The term 'apparent Km' rather than Km is preferable when 
the experiments have been conducted with an impure enzyme, 
for example, with intact granulocytes. 
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FIG. 111.1. The plot of velocity with respect to substrate 
concentration, according to the Michaelis-Menten 
equation (top). The graph is completely defined 
by the two kinetic parameters, K and V m 	max . 
FIG. 111.2. Lineweaver-Burk plot of 1  /velocity versus 
1/substrate concentration (bottom). As shown, the 
y-intercept = 1 / max , v 	the x-intercept = - 1/Km • -  
and the slope is K_/V 
-m max' 
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FIG. 111.3. The data from 2 experiments (2 of 16 donors) on 
the rate of NBT reduction as a function of the 
concentration of NBT dye. Each point is the 
± SEM of 3 determinations. 
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FIG. 111.4. The data from FIG. 111.3 replotted as a Lineweaver-
Burk plot. For line 'A' the x and y-intercepts 
were 18.68 and 11.58, giving an apparent Km and Vmax 
of 0.054 mM and 0.086 0D 515 units/1.3 x 10 6 
granulocytes/5 min, respectively. For line 'B' the 
x and y-intercepts were 10.61 and 15.81, giving an 
apparent Km and Vmax of 0.094 and 0.063 0D515 
units/1.3 x 106 cells/5 min, respectively (see also 
the data collected in Table III.1). 
TABLE 111.1 Kinetic parameters for the reductionof  
NBT by intact granulocytes  
Sample 
Km
a) b) V max 
1 .083 .078 .99 
2 .054 .075 .99 
3
c) .094 .063 	. .99 
4 .068 .052 .93 
5 .071 .075 .91 
6 .050 .085 .90 
7 .118 .093 .94 
8
d) .054 .086 .99 
9 .103 .083 .94 
10 .185 .102 .99 
11 .105 .087 .92 
12 .192 .069 .91 
13 .102 .081 .95 
14 .146 .093 .93 
15 .127 .089 .92 
16 .087 .090 .81 
± SEM 	.102±.011 	.081±.003 	.94±.01 
a) apparent Km for NBT, in mM concentration units 
b) V
max 
in units of 0D515/1.3 x 106 granulocytes/5 min 
c) corresponds to line B in Fig. 111.4 
d) corresponds to line A in Fig. 111.4 
r = correlation coefficient 
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Cytoplasmic microtubules 1 are straight hollow cylinders 
with an external diameter of 25 nm, a wall thickness of 5 nm and a 
variable length (Ledbetter and Porter, 1963; Slautterback, 1963). 
These structures were first seen in cilia by Fawcett and Porter 
(1954) but they had been postulated to exist by many scientists 
in the late 1800's, who believed that 'fibrils' would explain 
the elastic, tensile and architectural properties of cytoplasm 
(reviewed by Burnside, 1975). By advocating the use of glutaral-
dehyde as a fixative for electron microscopy, Sabatini et al 
(1963) greatly assisted the study of microtubules. With this 
fixative microtubules have been found in every eukaryotic cell 
which has been examined closely by electron microscopy (Burnside, 
1975; Snyder and McIntosh, 1976). 
Microtubules are probably most familiar as the 
mitotic apparatus of dividing cells and the fibrils of cilia, 
flagella, centrioles and basal bodies. They have been classed 
as stable (the microtubules in cilia and flagella) or labile 
(those in the cytoplasm of plant and animal cells and comprising 
the mitotic apparatus) by Wilson (1974). Stable mdcrotubules can 
be isolated as intact organelles and are not dissociated by 
chemical agents which bind to and destroy labile microtubules 
(discussed in section IV.1.1). In addition, stable microtubules 
do not appear to be in equilibrium with a subunit pool. In 
1 The name 'microtubule' was first used in 1963 by 
Slautterback. 
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contrast, labile microtubules are considered to be in a state 
of 'dynamic equilibrium' with subunits (Inoue' and Sato, 1967), 
are easily disrupted by 'spindle poisons' (discussed in section 
IV.1.1), and cannot be easily isolated intact from cells because 
of their lability (Wilson, 1974). 
In cross section the wall of the microtubule is 
almost invariably composed of 13 subunits (Snyder and McIntosh, 
1976), as illustrated in Fig. IV.1. When viewed longitudinally, 
13 helically-wound protofilaments can be seen running parallel 
to the long axis of the microtubule (Fig. IV.1). Ledbetter and 
Porter (1964) were the first to demonstrate the existence of the 
13 subunits. The unique class of proteins making up microtubules 
were called tubulins by Mohri (1968). They are dimeric molecules 
with molecular weights of 115,000 daltons, known as 6S tubulin. 
With protein denaturation, two similar subunits calleda and a 
tubulin (3 - 4S) are formed. The amino acid composition of these 
subunits is remarkably similar (Snyder and McIntosh, 1976). 
In vivo the labile or cytoplasmic microtubules appear 
to exist in a state of dynamic equilibrium between the polymerized 
form (the microtubule) and a soluble subunit pool (Inoue, 1964; 
Inoud'and Sato, 1967; Stephens, 1973; Borisy et al, 1974). The 
mechanism whereby the cell is able to assemble and disassemble the 
microtubules is not completely understood, but nucleotides, calcium, 
magnesium, microtubule-associated proteins, and microtubule-
organizing centres appear to play a role in the regulation of the 
process (reviewed by Snyder and McIntosh, 1976; Stephens and Edds, 
1976). The redox state of the cell and in particular the 
sulfhydryl groups may be involved as well, because microtubule 
172 
function can be impaired by oxidized glutathione (Kuriyama and 
Sakai, 1974). 
IV.1.1 Microtubule disrupting agents  
Microtubule-disrupting agents, or microtubule 
inhibitors, are used as pharmacological tools in studying 
microtubule-mediated cellular phenomena. These agents have long 
been called 'spindle poisons' (Wilson et a/, 1974) because they 
inhibit mitosis by impairing microtubule (spindle) function. 
Colchicine, vinblastine and vincristine are the most widely used 
microtubule-disrupting agents. Their chemical structures are 
shown in Figs. IV.2, IV.3 and IV.4, respectively. These drugs 
bind specifically to tubulin 2 and thereby shift the dynamic 
equilibrium towards depolymerization of the microtubules (Taylor, 
1965; Borisy and Taylor, 1967; Deysson, 1968; Dustin, 1972; 
Margulis, 1973; Wilson et a4 1974). 
Colchicine binds to the tubulin which is in soluble 
pools (Wilson and Meza, 1973; Wilson and Bryan, 1974) and thus 
blocks microtubule polyermization. The colchicine binding sites 
are masked on assembled (polymerized) microtubules. One mole 
of colchicine binds tightly and very specifically to one mole of 
tubulin (Wilson and Bryan, 1974) in a non-covalent, slow and 
irreversible fashion (Wilson and Meza, 1973; Wilson and Bryan, 
1974; Wilson et al, 1974). Colchicine binding is strongly 
temperature-dependent - at 00C the binding is extremely slow 
i while at 37 °C t s optimal (Wilson et a/, 1974). 
2 Most studies have used isolated brain tubulin (Snyder and 
McIntosh, 1976). 
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Irradiation of colchicine with ultraviolet light 
converts colchicine (by first-order kinetics) into a mixture of 
B and y lumicolchicines 3 (Wilson et al, 1974), as illustrated 
in Fig. IV.2. The change in colchicine is at the seven-membered 
C ring, which is altered to form two smaller rings. As the C 
ring is crucial for colchicine's binding to tubulin, lumicolchicine 
is inactive as an anti-mitotic agent (Wilson and Bryan, 1974). 
Lumicolchicine does not prevent colchicine's binding to tubulin 
however (Wilson and Friedkin, 1967). Lumicolchicine is extremely 
useful as a control for studies of microtubule-mediated cellular 
functions. It can be assumed that a response is not dependent 
upon microtubule integrity if both colchicine and lumicolchicine 
treatments produce the same result. 
The vinca alkaloids (vinblastine, vincristine and 
desacetylvinblastine) also disrupt microtubules by binding to 
tubulin. Of these, the most studied agent is vinblastine. 
Bensch and Malawista (1969) were the first to observe that the 
interaction of vinblastine with tubulin results in the formation 
of highly regular crystals. These crystals contain one mole of 
bound vinblastine per mole of tubulin (Bryan, 1972). The binding 
of vinblastine to tubulin is strong and rapid, with two binding 
sites per tubulin dimer (Wilson, 1975; Wilson, Creswell and Chin, 
1975). However, the vinblastine-tubulin complex is not very 
stable (Wilson, Creswell and Chin, 1975). The binding sites for 
3 In the literature the photoproduct is usually referred to 
as lumicolchicine, rather than B and y lumicolchicines. 
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the vinca alkaloids, like colchicine's binding sites, are masked 
on polymerized tubulin, and like colchicine, the binding of the 
vinca alkaloids to soluble tubulin will block microtubule poly-
merization (Wilson, Creswell and Chin, 1975). Unlike colchicine 
binding, however, vinblastine binding in vitro is relatively 
insensitive to temperatures between 0 and 37°C. Vincristine and 
desacetyl-vinblastine completely inhibit the binding of vinblastine 
to tubulin because the vinca alkaloids all share the same binding 
site (Wilson, Creswell and Chin, 1975). This site is distinct 
from the binding site for colchicine, and in fact the binding 
of vinblastine can stabilize the more labile colchicine-binding 
site on tubulin (Wilson, 1970). 
Microtubules also have two guanine nucleotide binding 
sites per dimer (which are separate from the vinca alkaloid-binding 
site, according to Wilson, Creswell and Chin, 1975), and the vinca 
alkaloids can competitively inhibit GTP from binding (Snyder and 
McIntosh, 1976). Studies on hog brain tubulin have shown that 
GTP and magnesium in equimolar amounts are required for maximal 
assembly of microtubules in vitro (Olmsted and Borisy, 1975). 
Vinblastine in high concentrations will precipitate 
tubulin in vitro, but this is probably a non-specific effect, 
as vinblastine can also precipitate a large number of other 
acidic proteins, as well as double-stranded DNA (Wilson et al, 
1970). For this reason (discussed by Wilson et al, 1974; 
Wilson, Creswell and Chin, 1975) it is very likely that there are 
two classes of binding sites for vinblastine on tubulin: a high 
affinity, biologically important class and a low affinity, 
biologically unimportant class. The doses of the vinca 
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alkaloids which result in microtubule disruption (that is, the 
doses which are biologically important) in mammalian cells are 
- 7 - 8 x 10-8 M (Wilson, Creswell and Chin, 1975). As one would 
expect, plasma concentrations of this magnitude are achieved 
in vivo during cancer chemotherapy with the vinca alkaloids 
(Owellen et al, 1976). 
Podophyllotoxin and griseofulvin also disrupt 
microtubules by inhibiting microtubule polymerization (Wilson 
et al, 1974; Snyder and McIntosh, 1976), but these drugs are not 
routinely used as experimental tools. Their chemical structures 
are shown in Figs. IV.5 and IV.6, respectively. Podophyllotoxin 
binds to tubulin, competing with colchicine for the colchicine-
binding sites. The binding is reversible, rapid, and not 
temperature-dependent. Griseofulvin, on the other hand, is 
thought to inhibit microtubule assembly by binding to proteins 
associated with microtubules, and not to the tubulin dimer itself 
(Roobol et al, 1977). 
IV.1.2 	Microtubule-mediated cellular functions  
By using the anti-mitotic agents (discussed above) as 
experimental tools, investigators have shown that microtubules 
play a role in many cellular functions. Among the cellular 
phenomena which have been shown to depend upon microtubules 
are 
(i) 	the function of the mitotic apparatus or spindle 
during cell division (Rebhun and Sander, 1967; 
Sato, 1969). 
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(ii) the maintenance of cell shape (reviewed by Porter, 
1966). 
(iii) cell movement (Olmsted and Borisy, 1973). 
(iv) feeding in ciliates (Tucker, 1972) and ingestion 
in phagocytes (reviewed by Stossel, 1975). 
(v) humoral secretion, for example the release of 
insulin from pancreatic B-cells (Malaisse et al, 1975), 
and lysosomal enzyme release in granulocytes (Malawista, 
1975; Weissmann et al, 1975a,b). 
(vi) the translocation of materials in nerve fibres by a 
process known as axonal transport (Ochs, 1974). 
(vii) intracellular movement of organelles such as chromo-
somes, lysosomes, phagosomes and pigment granules 
(reviewed by Burnside, 1975), and finally 
(viii)the control of cell surface topography (reviewed by 
Berlin et al, 1975). The role of microtubules in the 
control of cell membrane organization has been 
discussed in the introduction to this thesis, and in 
section 6.4. 
IV.1.3 	Models depicting a contractile activity of microtubules  
Many of the above-mentioned roles imply motion or 
movement, and as microtubules themselves are not contractile, 
models have been proposed to allow for such a contractile 
activity. The models have usually attempted to depict a 
contractile-like capability of microtubules during mitosis, 
and include:- 
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(i) the 'dynamic equilibrium' model of Inoue and Sato (1967), 
where an increase or decrease in length (through polymeri-
zation or depolymerization) can provide the necessary force 
for a contractile event, for example, to move the 
chromosomes poleward during mitosis. 
(ii) a sliding filament theory, where adjacent microtubules 
slide against each other in a fashion akin to the sliding 
of myosin upon actin in striated muscle (McIntosh et al, 
1969; Warren, 1974; Murphy and Tilney, 1974; Murphy, 
1975). In this model a dynamic equilibrium between sol-
uble subunits and polymerized microtubules [as proposed 
in model (i) above] is thought to be involved initially 
in establishing and then later disassembling microtubules. 
In contrast to model (i) however, cross-bridges between 
adjacent microtubules rather than changes in microtubule 
length are thought to facilitate the motion. 
(iii)A zipper hypothesis, where chromosomes are moved by a 
cyclical lateral interaction between parallel spindle 
fibres and non-parallel sets of microtubules (Bajer, 
1973), and 
(iv) a model where microtubules act as guiding tracks for 
the transport of materials or organelles along their 
length, and where the actual propelling along of these 
materials or organelles is carried out by other linear 
elements, such as microfilaments (Ochs, 1972; Rebhun, 
1972; Forer, 1974; Burnside, 1975). Since this 
particular model was proposed, many investigators have 
shown that microfilaments are indeed often found closely 
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associated with microtubules in the cell cytoplasm (reviewed by 
Nicolson, 1976). 
IV.2 	MICROFILAMENTS  
When viewed by electron microscopy microfilaments 
appear as a randomly oriented meshwork of - 5 - 8 nm diameter 
filaments with a variable length up to several pm (Pollard and 
Weihing, 1974; Nicolson, 1976). These filaments are composed 
of two helically wound polymers of actin (reviewed by Pollard 
and Weihing, 1974; Schreiner and Unanue, 1976; Nicolson, , 1976). 
The monomers which make up cytoplasmic or non-muscle actin are 
single polypeptide proteins of - 43,000 molecular weight which 
contain calcium or magnesium and ATP (reviewed by Nicolson, 1976). 
Microfilaments are often seen in the cortical 
cytoplasm, closely apposed to the plasma membranes of a variety 
of cell types (reviewed by Nicolson, 1976). Microfilaments can 
also be found in the cytoplasm in regions of cellular extension, 
such as pseudopodia (Wessell.s- et al, 1971). Like microtubules, 
the microfilaments are apparently labile - able to assemble into 
helical microfilaments (F-actin) and disassemble into soluble 
globular subunits (G-actin) without requiring protein synthesis 
(Godman et al, 1975). 
Applying the classical technique of heavy meromyosin 
binding to chick embryo cells, Ishikawa et a/ (1969) were the 
first to demonstrate the existence of actin in non-muscle cells. 
Since their discovery, actin has been found in a variety of 
cell types (reviewed by Pollard and Weihing, 1974), including 
phagocytes (Allison et al, 1971; Senda et al, (1975). It was noted 
by early investigators that this actin had the same cellular 
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distribution as the cytoplasmic microfilaments (reviewed by 
Pollard and Weihing, 1974). Using a fluorescent antibody 
technique, Lazarides and Weber (1974) and Goldman et al (1975) 
were able to demonstrate conclusively that the non-muscle actin 
was indeed located in the microfilamentous regions. Further 
characterization has shown that the cytoplasmic actins purified 
from several types of phagocytic cells show strikingly homologous 
structural and functional properties with respect to each other and 
to striated muscle actin (reviewed by Pollard and Weihing, 1974). 
In addition to actin, another protein which bears a remarkable 
similarity to striated muscle myosin has been found in a variety 
of non-muscle cell types, including brain cells, fibroblasts, 
platelets and granulocytes (Pollard and Weihing, 1974). Like 
muscle myosin this protein possesses ATPase activity and is able 
to bind actin. 
The myosin in these various cell types differs from 
the actin however, in that it appears to be heterogeneous 
(Miranda et a/,1974a,b; Pollandand Weihing, 1974). Myosin has 
been found in association with microfilaments (Pollard and 
Weihing, 1974) but is also localized elsewhere in the cytoplasm 
and on the cell surface (reviewed by Nicolson, 1976). The myosin 
is composed of heavy (- 200,000 molecular weight) protein chains 
and two classes of light chains (- 16,000 and 19,000 M.Wt.) 
according to Adelstein, Conti and Anderson (1973). 
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IV.2.1 	Microfilaments as contractile structures  
The discovery of intracellular actin and myosin similar 
in structure and function to muscle actin and myosin led some 
workers to propose a role for these contractile proteins in cellu-
lar phenomena of a contractile nature (Allison, 1973; Heaven and 
Axline, 1973; Pollard and Weihing, 1974). These workers also 
suggested that the contractile events (such as phagocytosis, 
movement, and adherence of cells to substrate) might be controlled 
in a manner analogous to the regulation of muscle contraction. To 
briefly review, striated muscle contraction is regulated by cyto-
plasmic calcium concentrations and the proteins troponin and 
tropomyosin, These proteins bind to muscle actin, and dissociate 
in the presence of calcium. This process allows actin (in the 
presence of magnesium) to facilitate the hydrolysis of ATP by 
myosin. ATP then provides the chemical energy required for myosin 
filaments to slide upon actin to produce contractile force (Huxley, 
1969). Unfortunately a role for calcium in activating actin- 
myosin interaction in non-muscle cells has not been clearly 
established, although several observations indicate that there are 
similarities in non-muscle and muscle contraction. As in muscle, 
cytoplasmic myosin can hydrolyze ATP, and filaments of actin-myosin 
are able to contract in the presence of ATP and magnesium (Pollard 
and Weihing, 1974). Furthermore, one of the regulatory proteins 
(tropomyosin) has been found in platelets (Cohen and Cohen, 1972). 
More recent investigations have shown that cytoplasmic 
actin binds to a protein called a-actinin (Hartwig and Stossel, 1975; 
also Boxer et al, 1976), which may control the formation and 
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binding of microfilaments to each other (Mooseker and Tilney, 
1975). 
IV.2.2 	Microfilament-disrupting agents  
Microfilament organization can be disrupted by a 
related group of fungal metabolites, whose structure is shown in 
Fig. IV.7 (reviewed by Nicolson, 1976). Therefore these agents, 
known as cytochalasins4  , have been used in micromolar doses as 
pharmacological tools to study the role of microfilaments in 
cellular phenomena. Cytochalasins A and B have been isolated from 
Helminthosporium dematioideum, and C and D from Metarrhizium 
anisopliae (Aldridge et al, 1967). Of the four cytochalasins 
only B and D have received widespread use in the laboratory. 
Cytochalasin B is the more useful of the two experimentally 
because of its reversibility of action and low cellular toxicity 
(Carter, 1967; Wessells et al, 1971). 
It is thought that the cytochalasins disrupt the 
architecture of microfilaments by inducing the clumping together 
of dysfunctional actin (Wessells et al, 1971). These drugs 
apparently have no effect on cytoplasmic microtubules (Schroeder, 
1970; Wessells et al, 1971; Bhisey and Freed, 1975; Weissmann 
et a1, 1975a,b). Miranda et al (1974a, b) have put forth an 
alternative mode of action of the cytochalasins. From experiments 
with cytochalasin D (which they found to be - 10 times as potent 
as cytochalasin B) these authors suggest that the cytochalasins 
4 The name 'cytochalasins' comes from cytos (meaning cell), and 
chalasis (meaning relaxation) and was first used by Aldridge 
et al (1967). 
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cause an initial hyper-contraction of the filaments followed by 
clumping and dysfunction as a result of the unrestricted contrac-
tion. The further suggest that with low doses of the cytochalasins 
disassembly of the filaments does not occur, but there is enough 
contraction to produce a response. Studies by others have shown 
that the cytochalasins do not appear, to act on isolated F-actin 
(assembled actin) in vitro (Forer et al, 1971) or interfere with 
the binding of myosin to actin in situ (Schroeder, 1973). 
IV.2.3 	Microfilament-mediated cellular functions  
By virtue of their sensitivity to the cytochalasins, 
microfilaments have been implicated in a variety of cellular 
functions. As suspected by the early workers, the cellular 
functions involved are primarily those where the generation of 
contractile force appears to be required, namely:- 
(i) cytoplasmic streaming, membrane ruffling and membrane 
asymmetry, and cell movement (reviewed by Wessells 
et al, 1971; Allison, 1973; Pollard and Weihing, 
1974; Miranda et al, 1974 a,b; and Nicolson, 1976). 
(ii) secretion of lysosomal enzymes from granulocytes 
(Boxer et al, 1974; Sajnani et al, 1976; Becker, 
1976), and insulin release from pancreatic B-cells 
(Orci et al, 1972; Malaisse et al, 1975). It is 
interesting to note that these secretory events 
are stimulated when microfilaments are disrupted by 
the cytochalasins, whereas other types of secretion 
are inhibited under the same circumstances. For 
example, thyroid secretion (Williams and Wolff, 
1971), growth hormone secretion (Schofield, 1971), 
and histamine release from mast cells (Orr et al, 
1972) are inhibited by the cytochalasins. 
(iii) plasma membrane receptor redistribution (reviewed by 
Nicolson, 1976; Schreiner and Unanue, 1976). 
(iv) cell-cell interactions, for example, the binding of 
erythrocytes to human T cells (Cohnen, Fischer and 
Brittinger, 1975). 
An undesirable side-effect of the cytochalasins is 
their inhibition of the transport of glucose, deoxyglucose, 
glucosamines, and nucleosides, which is probably not mediated 
by microfilament disruption (reviewed by Allison, 1973; 
Pollard and Weihing, 1974; and Nicolson, 1976). 
It is not unreasonable to envisage that micro-
filaments would require points of anchorage in order to 
generate the contractile force, as Stossel (1975) and Wilkinson 
(1976) have appreciated. A model wherein microtubules provide 
such an anchoring system for the microfilaments in their con-
tractile role in the movement of plasma membrane proteins has 
been proposed and is widely accepted (Poste, Papahadjopoulos 
and Nicolson, 1975; Nicolson and Poste, 1976; Nicolson, 1977). 
This model for the role of cytoplasmic microtubules and micro-
filaments in the control of plasma membrane phenomena has been 
presented in the introduction to this thesis (section 1.7). 
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FIG. IV.1. Cross-sectional diagram of a microtubule having 13 
subunits (top). A longitudinal view (bottom) depicts 
the 13 helically-wound protofilaments of a-tubulin 
(a) and f3-tubulin (b), running parallel to the long 
• axis of the microtubule [from Fujiwara K and Tilney 
LG (1975). Ann. NY. Acad. Sci. 253: 27]. 
FIG. IV.2. The structures of colchicine and lumicolchicine, taken 
from Paulson JC and McClure WO (1975). Ann. NY. 
Acad. Sci. 253: 517. 
FIGS. IV.3 and IV.4. The structures of vinblastine and vincristine, 
differing only in the group attached to nitrogen 
(arrows). From Wilson (1975). 
FIGS. IV.5 and IV.6. The structures of podophyllotoxin and 
griseofulvin, taken from Paulson and McClure (as 
above). 
FIG. IV.7. The structure of the cytochalasins, as shown by 
Aldridge et al, 1967: 
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